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ABSTRACT
The elucidation of the complexity underlying diseases such as cancer, has gained a vast
surge with the rapid advances in high-throughput data technologies that resulted in
the generation of a multitude of data. With the increased data availability, bioinform-
aticians are presented with the strenuous task of developing improved methodologies
to deliver biological insights. In the context of predicting the disease outcome, multi-
layered data hold the potential to provide complementary information and improve the
disease prognosis. Data integration is increasingly becoming essential in this context,
to address a wide range of problems such as increasing the power of studies, address-
ing inconsistencies between studies, obtaining more reliable biomarkers and gaining
a broader understanding of the disease. In this setting, the development of statistical
methods faces many challenges. This thesis focuses on addressing these challenges
while contributing to the methodological advancements in the field.
Prior to the integration of multiple data sources, it is imperative to address the stat-
istical problems associated with the analysis of individual data types. To this end, we
propose a clinical data analysis framework to obtain a model with good prediction ac-
curacy, addressing the common issues such as missing data and model instability. This
proposed framework demonstrated the highest prediction accuracy when evaluated on
real biological data, in a comparison study. A detailed pre-processing pipeline is pro-
posed for miRNA data that removes unwanted noise, variations and offers improved
concordance with qRT-PCR data. Furthermore, platform specific models are developed
to uncover biomarkers that are predictive of the survival outcome using mRNA, pro-
tein and miRNA data, to identify the data source with the most important prognostic
information.
This thesis deals with two types of data integration: horizontal data integration,
which is the integration of multiple datasets of the same type, and vertical data in-
tegration, which is the integration of datasets from different platforms for the same
set of patients. In exploring the horizontal data integration, we use miRNA datasets
from multiple sources to develop a comprehensive meta-analysis framework. The pro-
posed novel framework aids in identifying the inconsistencies among studies, while
identifying a reproducible and robust set of biomarkers. The comprehensive analysis
framework addresses the many challenges in horizontal data integration, such as the
differences in study aims and designs, and the heterogeneity of patient cohorts in each
study, favourably through a multi-step validation protocol.
Exploiting the availability of multi-layered data on the same set of patients, clinical,
mRNA, miRNA and protein, we develop novel frameworks in the vertical data integra-
tion paradigm. This type of data integration also faces many challenges such as having
more variables than observations in the omics data and the imbalance of variables in
the integration setting, that are addressed in our frameworks. The first is the integra-
tion of clinical and high-throughput data extending the pre-validation principle. The
proposed integration framework allows variable selection from among platforms and
identifies dominant sources of prognostic information. Next, we derived platform de-
pendent weights to develop a data integration framework with the weighted Lasso. The
v
comparison of integration at various levels using the proposed frameworks revealed
that integration of multi-layered data is instrumental in improving the prediction ac-
curacy and to obtain more biologically relevant biomarkers. Using the proposed data
integration frameworks we devise a visualisation technique to look at prediction ac-
curacy at the patient level. This graphical device revealed important findings with
translational impact to aid in personalised medicine.
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Statistics in medical research gained a vast surge with the development of high-
throughput biotechnologies, which provided thousands of measurements for each pa-
tient. Over the years, high-throughput data generating technologies have evolved im-
mensely from the initially developed microarrays to the next-generation sequencing
(NGS) technologies (Su et al., 2011; Git et al., 2010; Willenbrock et al., 2009). The cost
associated with the sequencing of DNA has been markedly reduced, allowing more
and more data to be generated (Grada and Weinbrecht, 2013; Metzker, 2010; Hurd and
Nelson, 2009). This increased amount of data naturally required the assistance of stat-
isticians and computer scientists to develop advanced methods in analysing data with
mathematical, statistical, and algorithmic methods, hence the development of the field
‘bioinformatics’ (Luscombe et al., 2001). Throughout the years efforts were made to
make these data more publicly available (Hubble et al., 2009; Barrett et al., 2007; Parkin-
son et al., 2007), which allowed the researchers in multiple fields to access them freely.
This in turn facilitated the investigation of different biological questions that impacted
on translational medicine (Robinson, 2014).
Predictive modelling is an important area in bioinformatics that focuses on the bio-
logically relevant question of predicting the outcome (e.g., survival outcome, cancer
sub-type) of a set of patients. With the availability of the massive amount of data, the
interest of researchers has been increasingly focused on constructing better predictive
models to enhance the biomarker discovery. A biomarker is a set of features or vari-
ables that is objectively measured as an indicator of a biological or medical state such
as the presence of some disease state (Strimbu and Tavel, 2010; Biomarkers-Definitions-
Working-Group, 2001). Traditionally, clinical data alone has been used for the identi-
fication of biomarkers. However, in the vicinity of high-throughput data, also known
as omics data, the current clinical management of critical diseases like cancer has clear
potential to be improved (Jayawardana et al., 2015a; Kim et al., 2014; Chin and Gray,
2008; Hanash, 2004). Much work has been done, and is still ongoing in this context,
using single data platforms (clinical and omics data) (Schramm et al., 2012; Segura
et al., 2012; Tremante et al., 2012; Caramuta et al., 2010) and multiple data platforms
(Kim et al., 2014; Mann et al., 2013; Daemen et al., 2009; Boulesteix et al., 2008; Gevaert
et al., 2006). Despite the gravity and the urgency of biomarker discovery and validation
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in a medical context, there are many statistical challenges that need to be addressed
in the development of predictive methods. This thesis aims to address some of these
challenges in clinical data and omics data, as well as in integrating these components.
In the following sections of this chapter we outline the different components of this
thesis. In Section 1.1, we discuss the motivation behind this work and outline the flow
of the remainder of the thesis. This chapter continues in Section 1.2 with describing
the different types of data used to explore and develop the statistical methods in this
thesis, followed by a discussion on data integration. In particular, we explore two types
of data integration, horizontal integration and vertical integration. The methods, stat-
istical challenges and advantages of the data integration will be outlined in Section 1.3.
We conclude the chapter by providing a background on melanoma in Section 1.4, on
which the datasets of this thesis will be based, setting the context for the biological
implications of our findings in the subsequent chapters.
1.1 motivation and outline
In many critical diseases like cancer, it has been observed that the conventional clini-
copathologic parameters and the standard staging procedures are insufficient in assign-
ing prognosis at individual patient level (Weigelt et al., 2010; van’t Veer and Bernards,
2008; John et al., 2008; Rosenwald et al., 2002; Watanabe et al., 2001; Alizadeh et al.,
2000). Specifically in melanoma, the standard clinical factors have limited prognostic
power at an individual level, as patients with tumours of similar morphology can have
markedly different survival outcomes (Table 1.1) (Schramm, 2014; John et al., 2008;
Winnepenninckx et al., 2006; Bittner et al., 2000).
This thesis has been motivated by the need for new improved prognostic biomarkers
to assist in personalised medicine, where the availability of multiple data types (clinical
and omics data) holds the potential to significantly improve upon the current stand-
ards (van’t Veer and Bernards, 2008; John et al., 2008). Such a discovery of improved
biomarkers is vital in assigning treatment therapies reliably at the patient level. The
investigation in this thesis is strengthened by the availability of a complex dataset of
melanoma patients (described in detail in Chapter 2), which enables to examine both
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molecular and clinical information across patients. Furthermore, there is prospect in
improving upon the current methods used in the field using recent methodological
advances such as the weighted Lasso (Bergersen et al., 2011; Zou, 2006), to uncover
improved prognostic markers with the use of the multiple datasets available.
With this motivation in mind, we proceed to develop statistical methods and frame-
works in this thesis using single data platforms (clinical and omics data) and integ-
rating multiple data platforms, in the context of predictive model building. Chapter
2 outlines the datasets used in this thesis. It aims to give a clear description on the
types of data used, on the preliminary analysis performed including pre-processing
and quality control, as well as on the performance evaluation procedures adapted in
subsequent chapters.
Appropriate and sensible low-level analysis is critical in removing unwanted noise
for downstream analysis and further complex methodological development. Therefore,
in this thesis we propose platform specific methods, prior to developing data integ-
ration frameworks. In this context, Chapter 3 develops a framework for clinical data,
mBMI (modified bootstrap multiple imputation framework), modifying and extending
the bootstrap multiple imputation (B-MI) framework proposed by (Campain, 2012).
The proposed framework, while addressing the common problems in clinical data as
missing data and instability in final models, aims to construct a model with good
predictive capabilities.
Chapters 4 and 5 proceed on to the timely concept of data integration, developing
novel statistical frameworks for integrating multiple data sets to discover improved
biomarkers. In particular, Chapter 4 explores horizontal data integration, outlining a
comprehensive meta-analysis procedure to identify a robust set of biomarkers. This
includes some of the work presented in (Jayawardana et al., 2015b).
Chapter 5 proposes novel frameworks for vertical data integration using multiple
types of data (clinical and omics). It makes conceptual advances in statistical bioin-
formatics with regard to personalised medicine, uncovering subsets of patients for
which more dynamic and complex translational models (using both clinical and omics
data) are needed. Some of the work in Chapter 5 is published in (Jayawardana et al.,
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2013) and (Jayawardana et al., 2015a). The thesis concludes with a general discussion
and future research directions in Chapter 6.
1.2 background
1.2.1 Clinical data
Traditionally clinical data has been used and is still used in assigning prognosis to pa-
tients with critical diseases like cancer. Even with the advancement of high-throughput
data technologies and the generation of a myriad of data, the importance of clinical
data is not reduced (Jayawardana et al., 2015a). The wide range of information con-
tained within the clinical data, from clinical variables such as age, sex, to pathological
and mutation information, might be one of the reasons behind this. Hence it is of ut-
most importance that this vital source of data is analysed accurately, addressing the
challenges in statistical clinical research. Although clinical information from multiple
data sources will be used throughout this thesis, the Mann clinical data (Mann et al.,
2013) will be used primarily to investigate multiple aspects of clinical data (Chapter 3).
In the analysis of clinical data to uncover important predictive variables, regression
models are used to study the relationship between p explanatory/predictor variables
(collected in the design matrix X 2 R(p+1)⇥n, the first row of X is a row of 1’s to
model the intercept) and the response variable (y 2 Rn). The generalised linear model
(GLM) (Nelder and Wedderburn, 1972) extends the linear regression model to address
a wider range of data. In general, in a GLM the expectation of the response (E(yj) = µj)
is modelled as
g(µj) = xTj  , j = 1, 2, . . . ,n,
where g(µj) is a monotone function called the link function that connects the expec-
ted value of the response variable (the random component) to a linear combination of
explanatory variables (the systematic component), xTj   =  0 +  1x1j +  2x2j + . . .+
 pxpj, where   is the vector of regression parameters. In this thesis, the logistic regres-
sion model will be used, as the response variable (y) is binary, which is coded as 1 and
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0 respectively, to represent good prognosis and poor prognosis groups. Here, the link
function is logit, given as
g(µj) = ln
  µj
1-µj
 
.
More details are given in Chapter 3.
Despite the wide use and importance of clinical data, many apparent issues need to
be dealt with in order to obtain a stable predictive model. Missing data is one such
problem that is unavoidable in many clinical studies, and hence there is a substantial
amount of literature that discusses missing data in clinical research, including (Little
and Rubin, 2002; Schafer, 1999; Rubin, 1987). Most statistical methods require complete
datasets and this has hindered their use in the presence of missing data. The data could
be missing completely at random (MCAR) where missingness is unrelated to variables
in the dataset, missing at random (MAR) where missingness is completely random
when conditioned on data available and missing not at random (MNAR) where miss-
ingness is related to missing data (Little and Rubin, 2002). Over the years, statisticians
have used many approaches in handling missing data. Complete case analysis is one
such approach that can be used if data are MCAR. However, considering only the
complete cases increases the loss of precision and power and can introduce bias. Im-
putation has become a more commonly used method in handling missing data, as it
allows the construction of a complete dataset and continuation with the commonly
used complete data methods, while having more power and potentially less bias than
the complete case methods (Rubin, 1987).
In recent years dealing with missing data has become less problematic when meth-
ods such as multiple imputation (MI) became available in standard statistical software.
Although there are many other techniques to handle missing data (Barnes et al., 2008;
Carpenter and Kenward, 2008; Ibrahim et al., 2005; Robins et al., 1994; Little, 1986), this
thesis will use multiple imputation, as it is one of the most widely used methods in
dealing with missing data in clinical studies. There is a vast array of literature that
discusses various aspects of multiple imputation including (Sterne et al., 2009) that ad-
dresses potential and pitfalls, (Harel and Zhou, 2007) that reviews theory behind MI
and compares software available and (Campain, 2012) that compares different imputa-
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tion algorithms. The use of MI algorithms depends on the structure of the missingness
within the data. Most MI algorithms such as Amelia II (King et al., 2001) assumes that
the missingness is MAR, whereas there are other algorithms such as MICE (van Buuren
and Groothuis-Oudshoorn, 2011) that can handle both MAR and MNAR. In this thesis
we use AMELIA II and MICE to handle missingness in our clinical data. A detailed
investigation of MI and MI algorithms is beyond the scope of this thesis.
Another problem in analysing clinical data is model instability. In the variable se-
lection procedure, in selecting the most important variables to describe the response,
a small perturbation in the original data set can potentially incur large changes in
the final model in many instances (Steyerberg et al., 2000; Breiman, 1996), hence the
model instability. This can be explored by perturbing the data, taking sub-samples
or re-samples via methods such as the bootstrap (Efron and Tibshirani, 1986; Efron,
1979) and considering multiple sets of predictors or variables in the selection of the
final model. There are many reasons behind the model instability, including highly
correlated predictors (Curto and Pinto, 2007; Kiers and Smilde, 2007) that lead to unre-
liable regression coefficients and hence erroneous conclusions. Several methods have
been proposed to deal with model instability, such as methods that address multicol-
linearity in the predictors (Kiers and Smilde, 2007) and model averaging techniques
that address the variability in the models developed from re-samples (Schomaker and
Heumann, 2014; Campain, 2012; Heymans et al., 2007).
Chapter 3 develops ‘mBMI’, modified bootstrap multiple imputation framework, to
build a stable model for clinical data addressing missing data through multiple imputa-
tion and instability through bootstrap sampling. The mBMI introduces a new measure
for selecting a sparse subset of variables depending on their predictive capability to be
assessed for the final model, rather than considering the whole set of variables.
1.2.2 High-throughput biomedical data
Over the past decade layers of complexity in the cell has been uncovered, resulting in
the generation of more data sources at different levels. DNA (deoxyribonucleic acid),
the basic component of a chromosome, is the heredity material or the information car-
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rier in all living organisms. It is made up of molecules called nucleotides assembled
as a chain consisting of four chemical bases called adenine (A), thymine (T), cytosine
(C) and guanine (G). A DNA molecule consists of two complementary strands of nuc-
leotides arranged in a double helix. A hydrogen bond will be formed between comple-
mentary base pairs binding adenine with thymine (A to T) and cytosine with guanine
(C to G) (Chargaff, 1951). The DNA molecules are packed into thread-like structures
called chromosomes (23 pairs for humans) in the nucleus of each cell.
The process by which the inherent information embedded within the DNA, known
as genes, are synthesised into physical or biological outcomes is called gene expression
and this constitutes one of the central tenets of molecular biology (Crick, 1970). The
central dogma of molecular biology (Crick, 1970) explains the flow of genetic informa-
tion in a biological system and is often beneficial in understanding cell biology (Figure
1.1): the information coded in DNA is passed on to a type of RNA (ribonucleic acid)
called messenger RNA (mRNA) and the mRNA can travel outside the nucleus into the
cytoplasm to create functional proteins.
mRNA
Messenger RNA (mRNA) is created by a process called transcription, where the in-
formation of a gene is copied onto a complementary single stranded RNA molecule.
This is governed by complementary base pairing between the DNA and RNA, where
A in the DNA is transcribed to U (uracil) in the RNA, T to A, G to C and vice versa.
After this process mRNA has the capacity to travel through the cell, undergoing post-
transcriptional modifications to be translated into amino acids or proteins (Watson
et al., 2013).
In this thesis we primarily use mRNA data measured via microarray technology.
Microarrays allow to measure the activity level or the expression level for thousands
of genes in a single sample simultaneously. To achieve this purpose, microarrays make
use of the hybridisation of DNA, the process by which a single stranded DNA obtains
a correct complementary strand, by measuring the concentration of the gene’s mRNA
transcript in the cell’s total RNA (Karakach et al., 2010). To determine this, DNA probes
are immobilised onto a slide, printed as spots or coded onto beads. Fluorescent labelled
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Figure 1.1: Central dogma of molecular biology (Crick, 1970) and the generation of
multiple datasets at different levels of the information flow: DNA is cre-
ated by self replication and the information is transcribed into messenger
RNA which can be translated into proteins. At different levels of this pro-
cess multiple omics data are obtained using high-throughput data technolo-
gies, that can obtain measurement of thousands of objects in one experiment
in a limited time frame.
or pre-determined complementary DNA (cDNA) strands generated from mRNAs in
samples are then placed onto the microarray slide. The labelled cDNAs that represent
mRNAs in the cell will then hybridise (bind) to any complementary probes on the
microarray slide, leaving its fluorescent tag, which can be measured by scanners to
give the relative quantities of mRNA on the sample. The levels of intensity or the
colors of the resulting slide are used to determine which genes are more expressed in
normal tissues vs. which are more expressed in disease tissues such as cancer, which
leads to a vast area of research uncovering disease causing genes.
Different types of microarrays have been designed since the first spotted array (Schena
et al., 1995). Among the many approaches used are spotted arrays, where the cDNA
probes or long oligonucleotides are printed onto the slide (Diehl et al., 2001), ‘on-chip’
arrays, where the probes are built directly onto the surface of the slide (Auer et al.,
2009), and bead arrays, where complementary oligonucleotide sequences are attached
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to microscopic beads (about 20-30 beads with the same probe sequence) combined and
spread over the slide (Fan et al., 2006). Microarray platforms can be identified by the
company that constructed them such as Illumina, Affymetrix and Agilent.
Some of the other technologies used to measure gene expression are quantitative
real time polymerase chain reaction (qRT-PCR) and next generation sequencing tech-
nologies (NGS). qRT-PCR is considered to be a gold standard for measuring gene ex-
pression as it is known to generate robust, quantitative expression data for single genes
and offers rapid and reproducible results (Klein, 2002). High-throughput data gener-
ating technologies had a major breakthrough when next generation sequencing (NGS)
technologies emerged in recent years. NGS technologies allowed the investigation of
multiple genomes and transcriptomes at much lower costs in an extremely efficient
way, producing much higher resolution and coverage than what was previously avail-
able, and an incredible volume of data (discussed in detail in (Patrick, 2014)).
Protein
Proteins are made of chains of amino acids. In the process of translation, mRNA leaves
the nucleus, interacts with a complex called ribosome, and code for amino acids by
reading the sequence of mRNA bases by codons (sequence of three bases in mRNA).
Many amino acids are coded by more than one codon, such that the information stored
in one gene could be translated to make many different proteins (Alberts et al., 2002).
In this thesis we use protein data obtained via quantitative iTRAQ (isobaric Tags
for Relative and Absolute Quantification), which is a chemical labelling method that
can be used to quantify proteins and liquid chromatography coupled to tandem mass
spectrometry (LC-MS/MS). The proteins are sequenced using tandem mass spectro-
metry (MS/MS or MS2), where the sequences are cut into smaller segments and ion-
ised whereby the molecules separate based on mass. When sufficient hits are detected
at the detector, these are picked for fragmentation and a spectrum based on the mass
is created. The peptide sequence in the mass spectra is identified via methods such as
database search and De-novo sequencing (Hughes et al., 2010). The identified peptides
are quantified via methods such as iTRAQ, where labels are add onto peptides that
are broken apart in MS/MS. Often the relative abundance of a peptide is measured as
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the ratio of intensities of a peptide across conditions investigated. A review describing
the technologies can be found in (Rauniyar and Yates, 2014).
MicroRNA
Despite the availability of genes or DNA segments that code for proteins, it has been
found that there are many other parts on the genome that play a vital regulatory role,
but are not involved in protein production (Lee et al., 1993). MicroRNAs (miRNAs) are
one such class of non-coding RNAs that are central in the regulation of gene expres-
sion (Kong and Han, 2005; Bartel, 2004). MiRNAs usually induce gene silencing, caus-
ing down regulation of gene expression. Through pairing, miRNAs prevent protein
production by suppressing protein synthesis and/or by promoting the degradation
of their target mRNAs. MiRNAs are known to be involved in a wide range of bio-
logical processes such as cell cycle control, apoptosis and several developmental and
physiological processes as cardiac and skeletal muscle development, ageing and im-
mune responses (Mo, 2012; Git et al., 2010). Due to this regulatory role of the miRNAs,
they have been implicated in a variety of human diseases like cancers, heart disease
and neurological disorders (Mo, 2012). Because of this, miRNAs are intensely studied
as potential candidates for diagnostic and prognostic biomarkers and predictors of
drug response.
With the increasing interest in miRNAs, the technologies for measuring gene expres-
sion have been successfully transferred to measure miRNA expression. The three prin-
cipal methods used in this context are microarrays (Yin et al., 2008), qRT-PCR (Chen
et al., 2005) and NGS technologies (Hafner et al., 2008). A comparison of these three
technologies can be found in (Git et al., 2010).
1.3 integration of data
Data integration has become a popular field of research among scientists, as it holds
the potential to use multiple datasets (both clinical and omics data) to decipher the
biological information they contain more effectively, rather than only using a single
data source. The increasing availability of this multitude of data enables the researchers
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to perform analysis on diverse topics to yield a depth of valuable information. The
overarching aims of data integration are to achieve improved precision, accuracy and
statistical power over that from an individual data source (Hamid et al., 2009; Hong
and Breitling, 2008; Choi et al., 2003; Normand, 1999). The information uncovered from
multiple data sources are more likely to be robust and reliable than from a single data
source, therefore integration is very useful in comparing and validating results from
multiple studies as well (Hamid et al., 2009; Hong et al., 2006).
1.3.1 Horizontal data integration
In horizontal data integration, a set of statistical tools is used to combine multiple
studies or data sources of the same type that answer related hypotheses for conclusive
inference. In the more traditional sense, horizontal data integration deals with two
levels of integration: ‘mega-analysis’, where the datasets are combined prior to analysis
making a single ‘mega’ dataset which will then be analysed to investigate a biological
question; and ‘meta-analysis’, where statistics from different studies are combined to
make common conclusions.
Mega-analysis especially focuses on normalisation of the merged dataset using meth-
ods including null correction, quantile normalisation, ComBat (Johnson et al., 2007) and
RUV-2 (Gagnon-Bartsch and Speed, 2011) discussed in detail in (Campain, 2012). Com-
prehensive reviews on meta-analysis using microarrays and genome-wide association
studies (GWAS) are provided in (Begum et al., 2012) and (Tseng et al., 2012).
Microarray meta-analysis studies answer a wide range of questions, where a majority
deal with detection of differentially expressed (DE) genes (Tseng et al., 2012). Examples
of different methods used for DE genes detection are Fisher’s method (Rhodes et al.,
2002; Fisher, 1950) for combining p-values, fixed and random effect models for combin-
ing effect sizes (Choi et al., 2003), methods for combining ranks such as the RankProd
algorithm (Hong et al., 2006) and latent variable approaches such as the probability of
expression (POE) (Parmigiani et al., 2002).
Meta-analysis has also been widely used for inter-study prediction/classification
analysis (Tseng et al., 2012). Validation of biomarkers on external data (Simon, 2011;
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Diamandis, 2010; Subramanian and Simon, 2010; Dupuy and Simon, 2007; Ransohoff,
2007) and inter-study prediction (Shen et al., 2008; Beer et al., 2002) belong to this
external validation category. Validation on external data in the form of a meta-analysis
is important in the sense that it provides confidence for the biomarkers to be used
in clinical practise as it is based on multiple studies rather than a single study. This
class of meta-analysis has been reviewed and used in many studies (Jayawardana et al.,
2015b; Waldron et al., 2014; Schramm et al., 2012; Schramm and Mann, 2011). Other
purposes for which meta-analysis has been carried out include pathway analysis (Shen
and Tseng, 2010; Setlur et al., 2007; Manoli et al., 2006), network and co-expression
analysis (Wang et al., 2009, 2006; Zhou et al., 2005; Segal et al., 2004) and reproducibility
and bias analysis across multiple studies (Yang and Sun, 2007; Parmigiani et al., 2004;
Kuo et al., 2002).
Horizontal data integration has a range of benefits including the added power to the
analysis via increased sample size, ‘integration-driven discovery’ (Choi et al., 2003), im-
proved reproducibility and reliability (Hong et al., 2006) and investigation of conflicting
conclusions in multiple studies (Hong and Breitling, 2008; Normand, 1999). However,
there are many challenges and difficulties, especially in inter-study prediction analysis.
These difficulties include the differences in study aims, designs, experimental proto-
cols, platforms and heterogeneous patient cohorts, causing discrepancies in popula-
tions of interest in multiple studies being considered (Tseng et al., 2012; Campain and
Yang, 2010). Different approaches have been used in the literature to overcome these
obstacles, including directly merging studies of the same platform before construct-
ing a prediction signature and developing sophisticated normalisation techniques to
normalise data across studies to enable the application of the prediction model across
studies (Tseng et al., 2012). Chapter 4 directly deals with some of these challenges,
where a comprehensive meta-analysis of melanoma miRNA signatures/biomarkers is
performed using five miRNA signatures from four data sources (Tembe et al., 2014;
Segura et al., 2010; Caramuta et al., 2010).
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1.3.2 Vertical data integration
In contrast to horizontal integration, the notion of ‘vertical data integration’ refers to
the integration of information for a common set of subjects/patients from multiple
sources of data. These data could be measured from a number of distinct platforms
or different molecular events such as DNA, mRNA, miRNA, protein and clinical. This
type of integration is often more challenging in the sense that data are obtained from
very distinct platforms where the number of variables may differ extensively. For ex-
ample, clinical data typically has about 100 variables and omics data has thousands
of variables. Care is required such that variables from one platform do not overpower
the other so that variables in one platform are ignored or not selected. For complex
diseases, vertical integration could be tremendously advantageous. For example, un-
derstanding the complicated cancer genome requires investigating its dysregulation at
multiple levels such as the genome, transcriptome and proteome (Kim et al., 2014; Chin
and Gray, 2008; Hanash, 2004).
Over the past decade many methods have been developed for vertical data integra-
tion in biological studies. However, most of them focus on pairs of molecular events,
such as clinical and microarray data (Gevaert et al., 2006; Tibshirani and Efron, 2002),
microarray and proteomics data (Daemen et al., 2009), gene expression and copy num-
ber data (Bergersen et al., 2011), transcriptomics and proteomics data (Matheis et al.,
2011).
Vertical data integration has been used in many studies to answer a multitude of bio-
logical questions. Many of these studies use different sources of omics data for clinical
decision support, such as survival outcome prediction or disease subgroup prediction.
Some studies focus on combined predictive power of clinical and omics data. One of
the earlier methods is ‘pre-validation’ (Tibshirani et al., 2002), where a microarray pre-
dictor is constructed and included as one extra variable alongside clinical variables
to predict survival outcome. A kernel-based approach is used in (Daemen et al., 2009)
for clinical decision support, integrating multiple genome-wide data sources. More re-
cently, (Kim et al., 2014) used a graph-based framework that integrates multiple omics
data sources, using an intermediate integration approach to predict cancer clinical out-
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come. Bayesian approaches, such as those using Bayesian networks (Gevaert et al., 2006)
and ‘iBAG’ (Wang et al., 2013), have also been used for integrative analysis to study the
association with patient survival outcome. Vertical data integration has also been used
in contexts other than clinical decision support. For instance (van Iterson et al., 2013)
integrated miRNA and mRNA expression data to improve miRNA target predictions.
Broadly, vertical data integration studies can be grouped into three categories based
on the primary focus of the study (Wang et al., 2013; Daemen et al., 2009). In the first
category, ‘sequential integration’, data from different sources/platforms are analysed
sequentially. One type of data is analysed first and another type is used to confirm
or clarify the findings, for understanding the biology underlying a disease (Qin, 2008;
Tomioka et al., 2008; Fridlyand et al., 2006).
The second group is ‘biological integration’ (Wang et al., 2013), where the datasets are
often merged at database level by cross-referencing the identifiers for common analysis.
Some examples are biological pathway analysis, studying regulatory mechanisms and
studying inter-relationships and associations (van Wieringen et al., 2012; Karpenko
and D., 2010; Goble and Stevens, 2008; Waters et al., 2006). This type of analysis is
often hindered by mismatching issues between samples and the inconsistencies of the
biological annotation databases.
The third group of integration, ‘model-based integration studies’ (Wang et al., 2013),
integrates the data from multiple layers of data sources in a mathematical/statistical
model to answer common questions such as predicting clinical outcome. Data from
multiple platforms are treated equally and the the most relevant features from all avail-
able data sources are selected (Daemen et al., 2009; Lanckriet et al., 2004). Most of the
studies in this category ignored the inter-relationships among platforms, which was
later solved by the introduction of canonical correlation based methods (Waaijenborg
and Zwinderman, 2009; Witten and Tibshirani, 2009; Parkhomenko et al., 2007). Super-
vised sparse canonical correlation analysis was introduced by (Witten and Tibshirani,
2009) to identify linear combinations of two sets of variables that are correlated with
each other and associated with the outcome as well. The recently introduced weighted
Lasso (Bergersen et al., 2011; Shimamura et al., 2007; Zou, 2006) also falls into this cat-
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egory, as it focuses on using additional data as variable weights to guide the variable
selection procedure.
Despite the many advantages of vertical integration, there are many challenges and
difficulties associated with this type of integration owing to the heterogeneous data
sources it accommodates. This includes the processing of distinct platforms to ob-
tain the optimum signal provided by each data source, imbalance of the number of
variables such as that between clinical and high-throughput data, ‘large p, small n’
framework in which the integration is to be performed that limits the statistical meth-
odologies available for such an integration and the mismatch between the samples
which further reduces the sample size (n). Furthermore, performance evaluation is
challenging in this multi-platform setting. The evaluation can be done at various levels
of the process and which of these is most accurate is an open question. Chapter 5 of
this thesis addresses some of these critical challenges and offers several solutions and
possibilities for dealing with vertical data integration, which includes work published
in collaborative research (Jayawardana et al., 2015a, 2013).
1.4 melanoma
This section aims to give a brief overview of melanoma, which is the studied complex
disease in our motivational dataset (elaborated in detail in Chapter 2).
Melanoma, the deadliest form of skin cancer, is a significant health problem caus-
ing approximately 50,000 deaths annually world-wide (Slipicevic and Herlyn, 2012),
accounting for 0.1% of total global mortality (Lucas et al., 2006). Moreover, both incid-
ence and mortality continue to rise in many Western countries (Howlader et al., 2012;
Garbe and Leiter, 2009; Thompson et al., 2005; Marrett et al., 2001). It is also one of
the most common cancers in young adults, exacting a disproportionate social and eco-
nomic toll compared to other cancers (de Vries and Coebergh, 2004). Melanoma is one
of the most common types of cancers diagnosed in Australia, the country with the
world’s highest incidence rate for this disease (http://www.melanoma.org.au).
Despite the gravity of melanoma there has been minimal success regarding new
treatment therapies, the development of which has been hindered by the difficulty
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in identifying patients who could benefit from targeted and potentially aggressive
systemic therapies (Mann et al., 2013; Jönsson et al., 2010). The treatment options are
primarily based on the various stages of melanoma, which are defined by the Amer-
ican Joint Committee on Cancer (AJCC) (Balch et al., 2009, 2001) and include four stages
(Table 1.1). The survival outcome of melanoma is significantly variable, rendering the
clinical management rather challenging. This problem is particularly apparent for pa-
tients with nodal metastatic disease (AJCC Stage III) where 5-year survival estimates
range from 29% to 81.5% (Gershenwald et al., 2010). The dominant prognostic factors
and the five year survival estimates for various stages of the disease are detailed in
Table 1.1.
Table 1.1: AJCC staging of melanoma – This table describes the AJCC staging sys-
tem of melanoma, the dominant prognostic factors associated with various
stages and the 5 year survival estimates.
AJCC stage Dominant prognostic factors 5 year survivalestimate
Stage I and II (Primary
melanoma: clinically
localised disease)
Tumour thickness, Ulcerative
state, Mitotic rate 85% to 99%
Stage III (Nodal
metastatic disease)
No. of metastatic nodes,
Ulceration of primary,
Tumour burden
29% to 81.5%
Stage IV (Distant
metastatic disease)
Site of distant metastases,
Serum LDH (lactate
dehydrogenase) level
15%
Given this markedly different survival outcome between the four stages of melan-
oma and more specifically within Stage III melanoma (illustrated in Table 1.1), there is
an urgent need to identify and validate accurate prognostic biomarkers that will assist
rational treatment planning. The limited set of current prognostic factors (Table 1.1) is
useful in assigning broad probabilities of relapse. However, these factors remain insuf-
ficient for personalising melanoma management, which aims to enable the provision
of the most appropriate treatment to different subsets of patients to ensure optimal
benefit.
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In this thesis, we aim to address this biologically significant problem of uncovering
improved prognostic biomarkers, via the analysis of data from different platforms indi-
vidually and integratively. For this purpose, we use the motivational melanoma dataset
and other external melanoma datasets available publicly (discussed in Chapter 2). The
challenges investigated and the solutions offered in this thesis are generalisable to any
similar dataset of complex diseases other than melanoma.
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This chapter describes the datasets used in this thesis to illustrate our statistical
frameworks. These datasets are summarised in Table 2.1. The structure of the chapter
is as follows. In Section 2.1 we outline the main melanoma dataset used in this thesis.
The details associated with quality control and pre-processing of the data are also
presented. Section 2.2 outlines the three external melanoma datasets, that were ob-
tained from public repositories and from published manuscripts. These datasets are
used primarily in Chapter 4 and for validation purposes in Chapter 5. In Section 2.3
we outline different cross-validation procedures used and perform a comparison study
between them in Section 2.4.
Table 2.1: Summary of the datasets used. This table shows the summary of the data-
sets used in this thesis: Mann (data from Melanoma Institute Australia (MIA)),
TCGA (The Cancer Genome Atlas (http:// cancergenome.nih.gov)), Segura (Se-
gura et al., 2010) and Caramuta (Caramuta et al., 2010). The sample sizes in the
complete datasets are also included. Abbreviations: ntotal, Total sample size;
nStageIII, The no. of Stage III melanoma patients; nwithCPM, The no.of patients
with matched clinical information; n, The sample size used for the analysis; nPP,
The no. of patients in Poor Prognosis group; nGP, The no. of patients in Good
Prognosis group.
Data type Mann TCGA Segura Caramuta
Clinical ntotal = 105
nStageIII = 84
n = 48
(nPP = 22,
nGP = 26)
mRNA ntotal = 99
nwithCPM = 79 nStageIII = 43
n = 47 n = 27
(nPP = 22, (nPP = 11,
nGP = 25) nGP = 16)
miRNA ntotal = 95
nwithCPM = 75 nStageIII = 41
n = 45 n = 23 n = 59 n = 15
(nPP = 22, (nPP = 12, (nPP = 23, (nPP = 7,
nGP = 23) nGP = 11) nGP = 36) nGP = 8)
Protein ntotal = 41
n = 33
(nPP = 14,
nGP = 19)
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2.1 mann data
This dataset has been provided by Professor Graham Mann’s group, and will be re-
ferred to as ‘Mann data’. The Mann data contains clinical data, mRNA (gene expres-
sion) data, miRNA data and protein data, with a common set of samples (matched
samples) between them (Table 2.1). Tumour samples were obtained from the Melan-
oma Institute Australia (MIA) Biospecimen Bank, a prospectively collected reposit-
ory of fresh-frozen tumours accrued with written informed patient consent and In-
stitutional Review Board approval (Sydney South West Area Health Service institu-
tional ethics review committee (Royal Prince Alfred Hospital Zone) Protocol No. X08-
0155/HREC 08/RPAH/262, No. X11-0023/HREC 11/RPAH/32, and No. X07-0202/
HREC/07/RPAH/30). These samples were collected since 1996 through MIA, formerly
the Sydney Melanoma Unit (Mann et al., 2013). We use this dataset with the primary
purpose of developing improved predictive models for Stage III patients, utilising the
molecular and phenotype information.
2.1.1 Details and pre-processing of the multiple datasets
Clinical data
The clinical data component of the Mann data includes 84 Stage III melanoma patients
(Table 2.1). A multitude of variables were observed for each patient, which included
clinical variables, pathological variables and mutation variables (Table 2.2). The data
from somatic mutation profiling (BRAF and NRAS mutation status) were identified via
the Sequenom OncoCarta v1.0, MelaCarta v1.0 platform followed by MassARRAY25
mass spectroscopy (Mann et al., 2013).
Initial pre-processing of the clinical data included removing variables that contained
more than 50% missing data and removing the categorical variables with too small
frequencies among categories. This resulted in 21 variables that are used in the clinical
data analysis in Chapter 3. Table 2.2 summarises these selected variables along with
the percentages and number of missing data for each variable. Table 2.3 shows the
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number of missing variables per sample. The average overall missingness is 10% for
the clinical data.
From the survival data for the 84 Stage III patient samples, two extreme survival
groups were identified (Mann et al., 2013):
1. Group 1: Poor Prognosis (PP), survival <1 year after surgical resection and died
due to melanoma.
2. Group 2: Good Prognosis (GP), survival >4 years after surgery with no sign of
relapse.
This resulted in 48 samples for the clinical data with sample sizes of nPP = 22
and nGP = 26 in the two survival groups respectively (Table 2.1). Chapter 3 presents
the details of the complete analysis conducted using these clinical data, where we
propose a framework integrating multiple imputation, bootstrap sampling and logistic
regression to build a stable model for determinants of survival outcome.
mRNA data
We use the gene expression microarray data (mRNA data) generated as described
below. Total RNA was extracted from fresh-frozen Stage III melanoma tissues and
assayed using Sentrix Human-6 v3 Expression BeadChips (Illumina, San Diego, CA).
Quality control and data normalisation were performed using variance-stabilising trans-
formation (VST) (Lin et al., 2008) and quantile normalisation as implemented in the R
package ‘lumi’ (Du et al., 2008). The number of probes analysed was reduced from
48,802 to 26,085 after removing the unexpressed probes with a detection p-value less
than 0.01. More details are provided in (Mann et al., 2013) and the data are publicly
available in GEO1 (GSE54467). The total number of Stage III melanoma samples was
79 and this was reduced to the two extreme survival groups (GP and PP) producing
nPP = 22 and nGP = 25 (Table 2.1). The difference in the sample sizes between the clin-
ical data (n = 48) and the gene expression data (n = 47) was due to the unavailability
of gene expression microarray data for one, otherwise eligible, sample (Jayawardana
et al., 2015a).
1 Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo)
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Table 2.3: Missing datum per sample in the Mann clinical data – This table shows the number
of missing datum per each sample for the complete set of 84 Stage III patients and
the 48 patients from the two survival groups.
Number of missing datum 0 1 2 3 4 5 6 7 8 9
Number of samples (n = 48) 28 4 2 2 4 0 0 0 1 7
Number of samples (n = 84) 51 7 3 3 6 0 0 1 1 12
miRNA data
The profiling of the miRNA expression data was conducted as follows. Total RNA was
extracted from the fresh frozen Stage III melanoma tissues (Roche High Pure miRNA
isolation kit Cat. no. 05080576001, Roche Diagnostic, Indianapolis, IN, USA). RNA
extract quality and quantity was assessed using an Agilent 2100 Bioanalyzer (Agi-
lent Technologies, Santa Clara, CA). miRNA expression profiling was performed using
Agilent Technologies’ miRNA platform (version 16, Agilent Technologies, Santa Clara,
CA). More details are provided in (Tembe et al., 2014). This miRNA dataset is publicly
available in GEO (GSE59334). The patient groups were compared for 45 samples with
nPP = 22 and nGP = 23 (Table 2.1). The sample size differences are due to insuffi-
cient tissue and unavailability of miRNA expression data at the time of the analysis
(Jayawardana et al., 2015a).
We provide some basic biological background on the structure of miRNA data in
Section 4.1, where a systematic pre-processing pipeline is elaborated. For the analysis
in Chapter 5, the miRNA data were normalised using quantile normalisation (as imple-
mented in the R package ‘limma’ (Smyth, 2005)), adjusted for the difference in overall
mean and probe level mean, and aggregated at the miRNA level, producing 390 unique
miRNAs eligible for the analysis.
Protein data
Protein data were obtained via quantitative iTRAQ and liquid chromatography coupled
to tandemmass spectrometry (LC-MS/MS). More details are provided in (Mactier et al.,
2014). All protein expression ratios were log-transformed. In comparing the two sur-
vival groups only 24 patients fell within these two groups. Due to the insufficient
sample size, 9 samples from the original prospective collection that were initially ruled
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ineligible (due to falling outside the survival groups), were included in the analysis
to constitute 33 samples in total (Jayawardana et al., 2015a). This gives nPP = 14 and
nGP = 19.
2.2 external melanoma datasets
In addition to the four datasets from the Mann data described in Section 2.1, three
other external datasets are used in the subsequent chapters. These include two miRNA
datasets from published studies (Segura et al., 2010; Caramuta et al., 2010) and mRNA
and miRNA data from TCGA (Table 2.1). We use these datasets to develop and explore
the statistical frameworks constructed in Chapter 4 and Chapter 5. The external miRNA
datasets and the Mann miRNA data will be used in the meta-analysis in Chapter 4.
More details of the data platforms and the survival classes compared are given in
Appendix C (Table C.2). The TCGA mRNA and miRNA data will be used exclusively
for the biological validation, illustrating the implications of our vertical data integration
in Chapter 5. The cohort sizes are summarised in Table 2.1.
2.2.1 Segura miRNA dataset
miRNA data from (Segura et al., 2010) involving assay of formalin-fixed paraffin-
embedded melanoma metastases, were generously provided directly by Associate Pro-
fessor Eva M Hernando-Monge, Ph.D. (Department of Pathology, NYU Langone Med-
ical Center, New York, NY.). We obtained the raw data and pre-processed as described
in (Segura et al., 2010). Briefly, the steps followed are:
• The dataset was log-transformed (log2 scale) and quantile normalised, the latter
implemented via the ‘limma’ R package (Smyth, 2005).
• Data were filtered to exclude miRNAs with low variance across samples (i.e.,
having a coefficient of variation <1%) and miRNAs with row names equal to
‘null’.
This pre-processing resulted in 614 miRNAs for the analysis.
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2.2.2 Caramuta miRNA dataset
Data for the study by (Caramuta et al., 2010), involving human fresh frozen regional
lymph node metastases of patients with cutaneous melanoma, were available in Gene
Expression Omnibus (GEO), Accession Number: GSE19387 and downloaded on 23/09/
2013 containing 167 miRNA samples. We obtained the processed and normalised
miRNA data. The original sample size was 16, with one patient considered as cen-
sored in the original survival analysis (Caramuta et al., 2010). This patient with short
survival (‘M-4’) had disease unrelated death and due to the inability to allocate this
sample clearly to a survival class, this sample was removed from our analysis. There-
fore, for the present analysis only 15 melanoma samples were considered (Table 2.1).
Since the dataset contained missing data 2% overall missingness, the missing values
were imputed using the k-Nearest Neighbours (KNN) imputation algorithm, imple-
mented in R via the ‘impute’ package (Hastie et al., 2015) with k = 10.
2.2.3 Data from TCGA
The publicly available mRNA and miRNA data for Skin Cutaneous Melanoma (SKCM)
from TCGA were downloaded and are detailed below. Relatable protein information
was not available from TCGA and could not be tested. TCGA case count of SKCM is
very large (> 400 as at September 2014). However, the cohort is a heterogeneous mix
of sample types and stages, among other factors. In this thesis, only the AJCC Stage
III melanomas from the TCGA data were considered. The patient stage at the time of
tumour banking was only available for samples from the Melanoma Institute Australia
tissue bank, therefore these patients were filtered. The cases where the sample was not
from melanoma lymph node metastases and where patient stage at the time of tumour
banking was not Stage III were removed.
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mRNA data
The normalised mRNA (UNC IlluminaHiSeq_RNASeqV2) expression information along
with the corresponding clinicopathological annotations for the subset (n = 43) of AJCC
Stage III samples available were used to validate findings in Chapter 5. The cohort with
similar classes to that of the Mann data (i.e., survival > 4yrs with no sign of relapse
or survival < 1yr after resection of metastatic disease) was initially sought. However,
partitioning the data in this way resulted in an untenable sample size. Therefore, the cri-
teria for good and poor prognosis were adjusted as follows, which retained 27 samples
(Table 2.1):
1. Group1: Poor Prognosis (PP), survival <4 years after surgical resection and dead
(nPP = 11, the range of survival times 0.4-3.9 years), and;
2. Group 2: Good Prognosis (GP), survival > 4 years after surgery (nGP = 16, the
range of survival times 4.6-20.7 years).
Variance stabilised transformation (VST) was applied to the normalised dataset using
the R package ‘DESeq’ (Anders and Huber, 2010).
miRNA data
miRNA (BSGSC IlluminaHiSeq_mRNASeq) data for SKCM were used in both Chapter
4 and 5. The sample cohort available at the time of the analysis in Chapter 5 was
different from the cohort used in Chapter 4.
For the analysis in Chapter 5 we used the cohort of 43 samples (explained above
in Section 2.2.3: mRNA data). The miRNA data was normalised using the trimmed
mean of M-values method (TMM) (Robinson and Oshlack, 2010) and variance stabil-
ised transformation was applied.
For the analysis in Chapter 4 we used the miRNA data downloaded on 23/10/2013,
resulting in 41 samples eligible for inclusion in the analysis. We carried out a de-
tailed pre-processing procedure on this miRNA data and the procedure is included
in Chapter 4. Detailed consideration of the sample sizes in each survival group (more
details are given in Appendix A) and the guidance from Professor Mann for the results
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to be of clinical relevance, resulted in choosing the following survival groups with a
total of 23 samples (Table 2.1) for the analysis:
1. Group1: Poor Prognosis (PP), survival 6 2 years after surgical resection and died
due to melanoma (nPP = 12), and;
2. Group 2: Good Prognosis (GP), survival > 3 years after surgery with no sign of
relapse (nGP = 11).
2.3 evaluation of prognostic outcome : cross-validation
This thesis focuses on the predictive capability of the models/frameworks developed
or compared. Therefore, in the majority of this work we use the prediction error rate or
misclassification error to assess the performance. In this section we outline the different
CV procedures used in this thesis to enhance the clarity.
As discussed in Chapter 1, performance evaluation is one of the key challenges
in data integration, or more generally in bioinformatics method development. Only
through repeated application in real world independent datasets that have similar char-
acteristics to the training data, can a statistician be confident of the methods developed.
Such an exposure to real data ensures that the statistical methods developed will yield
meaningful results with impact in medical research.
A major challenge in performance evaluation is the unavailability of independent
data that are similar to the data at hand, to validate the models. Such situations gave
rise to a variety of methods for performance evaluation. The holdout method, where
the data are partitioned into two mutually exclusive subsets (a training set and a test
set), is one such method. However, the holdout method is known as a pessimistic es-
timator as it makes inefficient use of the data, because only a portion of data is used
for training (Kohavi, 1995). The holdout method is also hindered by the limited avail-
ability of samples, especially in molecular data context. Bootstrap estimation (Efron,
1979), where a bootstrap sample is created by sampling with replacement from the
data, addresses this limited sample availability issue. However, the bootstrap is known
to have large bias and low variance (Kohavi, 1995; Bailey and Elkan, 1993).
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The finite amount of sample availability demands the re-use of samples through
repeated partitioning of the data into training and testing samples. Cross-validation
(CV) is such a method that makes efficient use of the available samples while offering a
straightforward way of performance evaluation. This is achieved by randomly splitting
the available samples repeatedly into training sets to train models and testing sets to
validate the model. There are many variations of the CV:
• k-fold CV: The total sample size (n) is split into k subsets, where in each of the k
iterations, a subset is used as the test set and the remaining (n-n/k) samples are
used as the training/learning set. By ensuring that this split is done randomly,
one could eliminate or minimise the possible biases of samples of similar type
grouping together. However, even though the sampling is done randomly, k-fold
CV could still be biased if a seed is chosen to split the samples. The most com-
monly used k’s include choosing k = 5 and k = 10.
The repeated application of k-fold CV is shown to be a better approach than
performing k-fold CV once, in dealing with bias and variance of the estimations
(Efron et al., 2004; Kohavi, 1995; Burman, 1989).
• Leave-one-out CV (LOOCV): LOOCV, also known as complete CV, is a special
case of k-fold CV with k = n. LOOCV removes the possibility of samples cluster-
ing, however this is more computationally expensive. LOOCV also has low bias
and high variability in estimation (Bailey and Elkan, 1993; Efron, 1983).
• Stratified CV: Similar to k-fold CV. However, the folds are stratified so that they
contain the same proportions of labels as the outcome variable. This method is
known to be better, both in terms of bias and variance in estimations than k-fold
CV (Kohavi, 1995; Weiss and Indurkhya, 1994).
Apart from the different variations of the CV discussed above, a mixture of various
CV procedures are used in the literature (van Vliet et al., 2012; Varma and Simon, 2006;
Wessels et al., 2005; Michiels et al., 2005). Direct comparison between the CV error rates
from these procedures is difficult and sometimes invalid due to the differences in their
layouts. Therefore, it is imperative to understand the differences in the procedures and
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adapt a CV procedure consistently throughout an analysis, when the aim is to com-
pare between methods or models. It is clear that when developing a prediction model
or a prediction framework, each aspect, such as the feature selection, classification al-
gorithm or parameter selection for the classification algorithm, should be inside the
CV loop. This ensures that the estimation has low estimation bias. However, this is not
always feasible in the vicinity of complex data structures, the complexity in the frame-
work as well as time constraints. Therefore, in most instances when dealing with real
life data, one is limited to the validation of the most important aspects of the process.
As already pointed out in the literature, ‘to choose a classifier or to combine classifiers,
the absolute accuracies are less important and we are willing to trade off bias for low
variance, assuming the bias affects all classifiers similarly’ (Kohavi, 1995).
To improve the clarity and readability of the remaining of the thesis, in the following
we discuss and compare the different CV layouts used. The main focus is given to
variable/feature selection and classification components of the frameworks. A detailed
comparison of different tuning parameters within the classifiers is out of the scope
of this thesis. In this thesis, whenever k-fold CV is used for performance evaluation,
we use the repeated application of the CV (100 runs), which is shown to be a better
approach as discussed above. The repeated CV also allows us to assess the variability
of the error estimates, giving a better sense of the prediction accuracies compared in
the subsequent chapters.
2.3.1 CV procedure A: FullCV
This procedure (Figure 2.1) involves the cross-validation of both feature selection and
classification. An additional layer (or loop) of CV is introduced to obtain the optimum
number of features to be included in the classification algorithm. Therefore, instead of
having a fixed classifier, it includes a fixed classifier training algorithm (Varma and Si-
mon, 2006). The FullCV method avoids the bias introduced by using all of the training
data to choose the features (Reunanen, 2003; Simon et al., 2003; Ambroise and McLach-
lan, 2002). This method is similar to the pre-validation approach (Jayawardana2014,
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Vliet2012, Tibshirani2002). FullCV can be used for the process of identifying novel bio-
markers/prognostic signatures, and works as follows:
1. The data are randomly split into k folds (k = 5) with one part retained as the test
set and the remaining k- 1 parts used as the training set in each fold.
2. For each training set, an internal CV is performed to select the optimum number
of features (i.e., the biomarker/signature) - using the training set, multiple sets
of features are selected (e.g. 5, 10, 15, . . . , 100 number of features) and a CV is
performed within the training set to select the optimum number of features out
of these sets giving the lowest error rate.
3. This optimum set of features is then selected using the complete training set
using the same feature selection method employed in the previous step.
4. A classifier is constructed on the training set, using the selected features.
5. The performance of the classifier is then evaluated on the test set, producing the
predicted values for each observation in the test set.
6. Steps 2-5 are repeated for all allocations of the k folds into the training and test
set, producing a complete prediction vector with one prediction for each sample.
7. Steps 1-6 are repeated for S runs (S = 100), where in each repetition the dataset
is newly split into k folds, producing 100 predicted vectors.
8. Finally, these predicted vectors are compared against the actual classes (e.g. sur-
vival outcome: good and poor prognosis) to produce S prediction error rates.
Despite the optimal nature of the FullCV procedure, one cannot ignore the other
possible methods of CV which could be comparably efficient in terms of computational
time. Moreover, when a comparison between a set of procedures or models is made, if
the scientist uses the same validation protocol, it will still be a valid comparison.
2.3 evaluation of prognostic outcome : cross-validation 32
LS1$
Split$
Select$
Features$
Build$
classiﬁers$
Select$op4mal$
no.$features$
Re
pe
at
$fo
r$a
ll$
k$
fo
ld
s$
LS2$ TS2$
Classiﬁer$
Predict$
10$ 20$ 500$…
Data$$
Feature3selec4on$
Op4mal3no.3of3features3in3LS$
Classiﬁer$
Predict$
LS1$
TS1$
Re
pe
at
$fo
r$a
ll$
k$
fo
ld
s$
Figure 2.1: CV procedure A: FullCV
2.3.2 CV procedure B: ClassifierCV
In ‘ClassifierCV’, the CV is performed to evaluate the classifier only, but not the feature
selection (Figure 2.2). This method is similar to pre-specifying the number of features
to be selected, outside the CV loop. Hence, ClassifierCV is biased towards feature
selection, possibly under-estimating the errors, as the test set takes part in the training
process. The procedure is as follows;
1. The data are randomly split into k folds (k = 5) with one part retained as the test
set and the remaining k- 1 parts used as the training set in each fold.
2. For each training set, multiple sets of features are selected (e.g. top10, 20, . . .), and
classifiers are trained for each of the feature sets.
3. The performance of the classifiers are then evaluated on the test set, producing
the predicted values for each observation in the test set.
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4. Steps 1-3 are repeated for all allocations of the k folds into the training and test
set, producing complete prediction vectors with one prediction for each sample
for each feature set.
5. These predicted vectors are compared against the actual classes (e.g. survival
outcome: good and poor prognosis) to produce prediction error rates.
6. Optimal number of features is then selected as the feature set that produced the
lowest error rate.
7. Steps 1-6 are repeated for S runs (S = 100), where in each repetition the dataset
is newly split into k folds, producing 100 prediction error rates.
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Figure 2.2: CV procedure B: ClassifierCV
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2.3.3 CV procedure C: ResubCV
In this procedure (‘ResubCV’), feature selection is performed by comparing re-substitution
error rates (Figure 2.3). The procedure is as follows:
1. The data are randomly split into k folds (k = 5) with one part retained as the test
set and the remaining k- 1 parts used as the training set in each fold.
2. For each training set, multiple sets of features are selected (e.g. top10, 20, . . .) are
selected, and classifiers are trained for each of the feature sets.
3. The performance of the classifiers are then evaluated on the same training set,
producing the re-substitution error rates.
4. The optimal number of features is selected using the lowest re-substitution error
rate, a classifier is trained using this number of features on the training set, and
the performance is evaluated using the test set.
5. Steps 1-4 are repeated for all allocations of the k folds into the training and test
set, producing a complete prediction vector with one prediction for each sample.
6. Steps 1-5 are repeated for S runs (S = 100), where in each repetition the dataset
is newly split into k folds, producing 100 predicted vectors, which in turn will be
compared against the actual classes to produce S prediction error rates.
2.3.4 CV procedure D: FixedCV
In this procedure (‘FixedCV’) a pre-determined number of features (e.g. top 20) is used
(Figure 2.4). One could use some other procedure to determine the optimal number
of features or use prior knowledge to determine this optimal number. This procedure
violates the assumption that all training is done within the CV procedure, thus incur-
ring a bias (Varma and Simon, 2006). Briefly, the dataset is split into learning and test
sets as explained previously. The fixed number of features (pre-determined) is selec-
ted using the learning set and a classifier is trained on this set of features, which will
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Figure 2.3: CV procedure C: ResubCV
then be tested on the test set. Repeating the procedure for all k iterations will produce
a complete prediction vector. Repeated S runs of the procedure result in S predicted
vectors and thus, S prediction error rates.
2.3.5 CV procedure E: FinalCV
This procedure is often used for validating final models (Figure 2.5). The ‘FinalCV’
procedure is often useful when comparing the prediction accuracy of previously con-
structed biomarkers/signatures in an independent dataset. The procedure is similar
to Fixed features CV and follows the same steps. However, in FinalCV the exact set
of features/variables is also known apart from the number of features. Therefore, the
exact features are selected using the learning set in each fold.
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Figure 2.4: CV procedure D: FixedCV
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Figure 2.5: CV procedure E: FinalCV
In the next section, we carry out a comparison study of the CV layouts/procedures
discussed above.
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2.4 comparison study of the cv procedures
We compare the CV procedures in terms of their prediction capabilities, efficiency and
the selected features. For this purpose we use the Mann mRNA data to illustrate the
procedures in real data. Features are selected by ranking them using the differences
in median expression values of the two groups (GP and PP) which is referred to as
the ‘median robust method’ (Jayawardana et al., 2015a; Campain, 2012) and the clas-
sification algorithm employed is support vector machines (SVM) as implemented in
‘e1071’ R package (Meyer et al., 2014). We use the 5-fold CV repeatedly in S = 100
runs of the complete CV protocols, allowing to account for the variability in error rates.
For the ‘FixedCV’ the fixed number of features selected from learning set was set to
be 20 and this is an arbitrary choice. The features in the ‘FinalCV’ procedure were
pre-selected using the median robust method (selected the top 20 features) using the
complete dataset.
Table 2.4: Comparison of CV procedures – This table shows the results from the
comparison study of the five CV procedures discussed above.
CV procedure
Mean
5-fold
CV error
rate
Percentage
change
from full
CV
Total
time
Features
included in more
than 50% of
models
A: FullCV 34% - 3.27hrs 55
B: ClassifierCV 26% 24% 43min 53
C: ResubCV 35% 3% 38min 31
D: FixedCV 33% 3% 28min 13
E: FinalCV 23% 29% 1min 20
We observed that the ClassifierCV and FinalCV procedures produced relatively low
mean error rates of 26% and 24% respectively (Table 2.4, Figure 2.6). As discussed
above, this could be an under-estimation of the true error rate (which is unknown),
attributed to the lack of cross-validating the feature selection properly. The percent-
age change in CV error rates from the FullCV, which can be assumed to be a closer
approximation to the true error rate, are 24% and 29%, respectively, for the two meth-
ods. The FullCV, resubCV and FixedCV procedures produced similar CV error rates
(34%, 35% and 33% ) with percentage changes in mean CV errors from FullCV being
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Figure 2.6: Comparison of CV procedures: Final 5-fold CV error rates
quite negligible (3%). When comparing the computation time, the FullCV procedure
is significantly computationally expensive (3.27 hours) owing to its comprehensive CV
procedure, while the others showed similar efficiency levels (43 minutes, 38 minutes
and 28 minutes respectively for B, C and D procedures) with one exception, the Fi-
nalCV procedure (1 minute).
The final set of features were determined by taking the most frequently included
variables (in more than 50% of the models) and these were 55, 53, 31, 13 and 20 (fixed)
respectively (Table 2.4). The higher number of stable variables in FullCV (55) and Clas-
sifierCV (53) compared to ResubCV (31), indicates that the FullCV and ClassifierCV
are better at producing more stable variables. However, the numbers in FixedCV (13)
and FinalCV (20) are limited by the arbitrary choice of fixed number of variables we
allowed to be selected in each run (p = 20).
The variable inclusion frequencies of the procedures A–D showed a similar pattern
(Appendix A). When considering the intersection between the final selected genes (Fig-
ure 2.7) we observed that all the genes intersected, with the only difference being the
extra genes selected in each procedure. There were 13 such common genes among all
procedures A–D, 7 genes common to all procedures except FixedCV, 11 genes common
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Figure 2.7: Comparison of CV procedures: Intersection of the genes selected
to procedures A–C, 22 genes common between A and B and 2 genes for A only (Figure
2.7). As discussed above, the selection of the CV procedure to be used in the evaluation
of a process should be based on the most important element to be cross-validated as
well as based on a cost-benefit analysis. This comparison also highlights the fact that
when we are comparing published papers, we cannot simply compare the published
error rates directly, because of the possible differences between the CV procedures.
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Clinical data is widely used for decision making in many critical diseases. In diseases
like cancer it is still considered to be the primary data source to determine the survival
of patients and in allocating patients to various treatments (Balch et al., 2009). Typically,
clinical data consists of a combination of nominal, categorical and continuous variables
pertaining to different characteristics of a patient.
Statistical research encounters many challenges when analysing clinical data, includ-
ing missing data and unstable final models. In Chapter 3 of (Campain, 2012), the author
proposed the B-MI, a procedure that incorporates bootstrap sampling and multiple
imputation to address these challenges. However, the direct application of the B-MI
procedure to our primary dataset, Mann data (introduced in Chapter 2), rendered un-
stable models with high prediction errors. This might be due to the different structure
of the Mann data to the data that was used to develop B-MI. For example the sample
size in (Campain, 2012) was n = 416 in contrast to n = 48 in the Mann data.
In this chapter, we extend B-MI to address the issues of model instability and high
prediction errors. Our proposed approach, the mBMI (modified bootstrap multiple
imputation) framework involves the following modifications and novel features:
1. Selection of the best performing subset of models.
We select the best performing models that have a small prediction error rate
(a pre-specified proportion from all of the constructed models on bootstrapped
samples) to derive the final model. This step will ensure an informative pro-
gnostic model. In B-MI no such thresholding was used to obtain the final model,
instead all of the selected models (using the BIC (Schwarz, 1978)) were considered
to obtain the final model. In our data we found that the B-MI procedure did not
possess good predictive power.
2. Selection of the stable variables from the best performing models.
In (Campain, 2012) stability was ensured using an inclusion threshold; if the
proportion of models that included a particular variable (inclusion frequency)
exceeded this threshold, then that variable was used in the final model. In the
mBMI a similar concept of thresholding is used. However, we use the above
selected subset of the top models to calculate the inclusion frequency of variables.
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This step ensures the stability of the final model, while warranting the predictive
capability.
3. Cross-validation (CV) error rate to evaluate the models.
To be consistent with the remainder of the thesis, we use the CV error rate to
evaluate the prediction error of the models. This is in contrast to the area under
the receiver operating characteristic curve (AUC) that was used in (Campain,
2012). Furthermore, we used CV to evaluate the mBMI procedure in contrast to
the hold-out method in (Campain, 2012), which is known to make inefficient use
of data (discussed in Chapter 2).
Although the proposed framework could be applied to any real clinical data set,
we were in particular motivated by the detailed series of clinical information in the
Mann data. The characteristics in the Mann data pose many additional challenges in
constructing models. These include; (i) the smaller sample size (n = 48), this makes
the missing data problem more prominent, contributing to the instability of the mod-
els, and (ii) the large number of variables (p = 21) relative to the sample size, that
includes both categorical and numerical variables. The clinical variables considered
herein are detailed in Chapter 2 (Section 2.1.1). In summary, the Mann data contains
10% missing data overall, and only approximately half of the samples are complete
(ncomplete = 28). Two extreme survival groups were identified from the survival times;
the good prognosis group (GP) and the poor prognosis group (PP). Therefore, the de-
pendent variable is essentially a binary variable, which is coded as 1 and 0 respectively
to represent GP and PP groups in constructing models.
The analysis of the Mann data is carried out in a prognostic setting, the interest being
to predict the survival outcome accurately. Therefore, logistic regression is utilised for
constructing models as discussed in Section 1.2.1. The probability of an ’event’ (e.g.
death) occurring is µj, where µj = P(yj = 0) and we model µj through
ln(
µj
1-µj
) = xTj  , j = 1, 2, . . . ,n,
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for xj = (x0j, x1j, . . . , xpj); the vector of p explanatory/predictor variables, and   =
( 0, 1, . . . , p); the vector of regression parameters.
This chapter elaborates the mBMI framework in Section 3.1, where the exploration
of the framework constitutes of two parts, a comparison study and a simulation study.
It is our primary focus to develop frameworks that work on real data. Therefore, the
mBMI framework is applied to the Mann data in Section 3.2 to evaluate its effect-
iveness on real data. In order to compare the predictive capabilities of the proposed
framework with a collection of other methods, a comparison study is performed in Sec-
tion 3.2. However, a major drawback in using real data to evaluate the framework is
that the stability of the variables cannot be assessed, as the true variables are unknown.
Therefore, in Section 3.3 the performance of the mBMI framework is investigated using
a simulation study, where the stability of the variables are explored to select optimum
parameters for the mBMI framework.
3.1 the mbmi framework
The novel framework developed in this chapter mainly addresses the common chal-
lenges when using clinical data for model building: missing data, stability of models
and their ability to predict. These challenges are discussed next.
Missing data and multiple imputation
Missing data poses analysis challenges in a wide range of studies. Because of this, there
exists a substantial amount of literature discussing missing data including (Little and
Rubin, 2002), (Schafer, 1999) and (Rubin, 1987). Despite the presence of many advanced
and efficient methods of dealing with missing data, multiple imputation (MI) has been
widely accepted as a tool with good properties that can be readily applied in a wide
range of datasets (Schafer, 1999). Complete case analysis greatly reduces the statistical
efficiency of the analysis by the reduced sample sizes and also removes the underlying
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structure from the data. In contrast, imputation, where the missing data are filled-in,
allows to use complete data analysis approaches while maintaining the original data
structure, including the sample size. Furthermore, MI allows to take into account the
variability associated with the missing values by imputing these multiple times. The
estimated parameters can be aggregated using the average as per Rubin’s rule (Rubin,
1987), where the overall estimate is;
 ¯q =
Pm
r=1  ˆrq
m ,
where  ˆrq is the estimated value of the qth parameter from the rth imputed data-
set. The variance is calculated by combining the between-imputation variance B =
(1-m)-1
Pm
r=1( ˆrq-  ¯q)
2, and the within-imputation variance U¯ = m-1
Pm
r=1 SE
2
rq,
where SErq is the standard error of the qth estimated parameter. The estimated total
variance is Tq = (1+ 1m)B+ U¯.
When the interest is on the selection of variables, an inclusion frequency (how of-
ten the variable is selected out of the multiple models constructed) can be involved in
aggregating the parameter estimates. If a particular variable is prevalent in more mod-
els than a pre-determined inclusion threshold (Heymans et al., 2007; Austin and Tu,
2004), the variable is included in the final model. The multiple imputation inclusion
frequency (⌧MI) can be incorporated into the overall parameter estimate through
 ¯q =
Pm
r=1  ˆrq
m I(⇢ˆq > ⌧MI),
where ⇢ˆq is the estimated inclusion frequency of variable q. In this thesis, ⌧MI was set
to 50% as a good balance between an overly sparse model and a model with coefficient
estimates that incorporate a large number of zero estimates. We did not explore the
sensitivity of this choice in detail.
MI algorithms are readily available in statistical software such as R. In this thesis,
Amelia II (King et al., 2001) and MICE (van Buuren and Groothuis-Oudshoorn, 2011)
are used for imputing clinical data, as these algorithms can handle both continuous and
categorical data (for more details on the imputation algorithms we refer to (Honaker
et al., 2011) and (van Buuren and Groothuis-Oudshoorn, 2011)). These are popular pro-
cedures and we refer for a comparison of various MI algorithms in our context to
(Campain, 2012). Amelia II (King et al., 2001) assumes that the variables are jointly
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multivariate normal and that the data structure is missing at random (MAR; see also
Chapter 1). The missing data are imputed using a bootstrap and expectation maxim-
isation (EM) approach. For our analysis we use the R package ‘Amelia’ (Honaker et al.,
2011). Multiple imputation by chained equations (MICE) (van Buuren and Groothuis-
Oudshoorn, 2011) is an iterative procedure using the Gibbs sampler, where random
variables are generated from a marginal distribution directly without calculating the
density (Casella and George, 1992). MICE is available in the R package ‘mice’ (van
Buuren and Groothuis-Oudshoorn, 2011).
Instability of regression models
We call the regression models unstable when a small perturbation in the original data-
set results in large changes in the final model. Instability occurs due to many reas-
ons including highly correlated variables (Kiers and Smilde, 2007; Curto and Pinto,
2007), instability of parameter estimates or imbalanced class distributions. This chapter
mainly focuses on the instability of parameter estimates that is more common when
the sample size is small as in the Mann data. Since this thesis investigates the construc-
tion of predictive models, the stability of the model is of utmost importance as unstable
models that are not reproducible could cause high prediction errors on independent
data.
Predictive modelling
In order to achieve high prediction accuracy, it is imperative to select a stable set of
features that are reproducible and perform well on independent data. Therefore, the
predictive modelling and the construction of stable models are highly related. In med-
ical research, special interest focuses on building a parsimonious model that is inter-
pretable and applicable in a clinical sense to determine patient prognosis. Therefore,
we aim to select a subset of variables that is stable and achieves high prediction accur-
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acy through developing our mBMI framework.
The mBMI framework combines bootstrap sampling and multiple imputation, where
multiple subsets of variables with high predictive capability are used to obtain a stable
model with high prediction accuracy. The framework is graphically represented in Fig-
ure 3.1, and detailed below.
The data set Z = (X,y), where X = [x0, x1, . . . , xp]T , a (p+ 1)⇥ n matrix of explan-
atory variables, where n is the sample size, p is the number of predictors, and y is the
binary response vector of length n with classes coded as 0 (PP) and 1 (GP).
1. Stage 1: Multiple Imputation
The data set undergoes m multiple imputations producing m complete datasets
denoted by Z1,Z2, . . . ,Zm.
2. Stage 2: Bootstrapping
The bth bootstrap sample is drawn, where b = 1, 2, . . . ,B. Zrb denotes the boot-
strapped imputed data for the bth bootstrap sample and the rth imputation. The
bootstrap sample index vector is fixed over the m datasets. That is Zrb has the
same sampled columns for all r = 1, 2, . . . ,m. These datasets are paired in that
they share the same observed values but have different imputed values. Stratified
bootstrap samples are drawn such that the class distribution is consistent and the
proportion of complete and imputed samples are maintained in each bootstrap
sample drawn. This approach is consistent with (Campain, 2012).
3. Stage 3: Feature selection
A logistic regression is applied to each of the imputed and bootstrapped datasets,
where variable selection is performed using a selection criterion such as Akaike’s
information criterion (AIC) (Akaike, 1974) or the Bayesian information criterion
(BIC) (Schwarz, 1978). This gives for each of the m datasets the estimated boot-
strap parameters vector,
 ˆrb = ( ˆ
r
0,b,  ˆ
r
1,b, . . . ,  ˆ
r
p,b),
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where those components not retained by the variable selection procedure have
zero estimates. Any other variable selection criterion could be employed here
and the procedure is flexible enough to incorporate feature selection methods
as stepwise procedures or regularisation methods such as the Lasso (Tibshirani,
1996) and Elastic net (Zou and Hastie, 2005).
4. Stage 4: Aggregate over MI data sets
Variables are aggregated across the m data sets using an inclusion frequency,
where the variables that are included in more than a certain percentage (here
50%) of the m models are selected and aggregated by averaging the m estimates,
thus producing one model.
The inclusion frequency of the bth bootstrap sample for the qth variable (the
proportion of times variable q is retained in the bootstrap sample for m datasets)
is
⇢ˆq,b =
1
m
Pm
r=1 1{ ˆ
r
q,b 6= 0}.
The aggregated coefficient for the qth variable is
 ¯q,b =
Pm
r=1  ˆ
r
q,b
m 1{⇢ˆq,b > ⌧MI},
where ⌧MI is the multiple imputation inclusion frequency threshold.
5. Stage 5: Repeat the procedure
Repeat for b = 1, 2, . . . ,B bootstrap samples and obtain a (p + 1) ⇥ B matrix
of parameter estimates  ¯, where in each column the variables selected in one
bootstrap run will have a non-zero estimate, thus producing B models.
6. Stage 6: Identify models with good prediction accuracy
For each of the B models, the prediction error rate is calculated, using the CV
error rate (‘FinalCV’ is used; see Section 2.3). The best performing feature com-
binations (models) are then chosen based on a prediction error threshold (⌧CV ),
resulting in s models. The best performing models can be chosen in two ways:
• Setting a prediction error cut-off
Prediction error cut-off = ⌧CV .
Best performing models = Models with CV error rate 6 ⌧CV .
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• Selecting the top performing models
Prediction error threshold = ⌧CV .
Best performing models = Top ⌧CV ⇥ 100% of the models ranked according to the
prediction error rate.
7. Stage 7: Identify best performing variables
Considering the best performing feature combinations (the s models from Stage
6), the features/variables are then ranked based on their inclusion frequency, ⇢ˆq,
where
⇢ˆq =
1
s
Ps
i=1 1{ ˆq,i 6= 0}, q = 1, 2, . . . ,p.
8. Stage 8: Final model fitting
The ranked variable list is then considered in a logistic regression model based
on a final inclusion frequency threshold (⌧FM). A variable is included in the
final model if ⇢ˆq > ⌧FM, and the final model is obtained by applying a logistic
regression model and model aggregation on this set of variables.
 ¯⇤q =
Pm
r=1  ˆ
⇤r
q
m ,
where  ˆ⇤rq is the parameter estimate of the final model for the qth variable in the
rth imputed dataset.
This mBMI procedure focuses on the stability of the variables that are included
among the best prognostic models to devise a final model. This produces a stable
model with good prognostic capabilities. Similar procedures were developed in (Hey-
mans et al., 2007), (Campain, 2012) and (Schomaker and Heumann, 2014), but without
focusing on top performing models.
3.2 comparison study
There are numerous procedures and methods for clinical data analysis in the medical
statistics literature. It was of interest to assess a selection of these methods relative to
our mBMI approach in terms of the prediction error, as predictive modelling is the
main focus in this thesis.
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Figure 3.1: The schematic of the mBMI framework.
Despite the merits of the mBMI procedure in building stable predictive models for
any clinical dataset with missing values, our procedure was primarily constructed to
answer biological questions underpinning the Mann dataset. Hence our comparison is
based on the evaluation of the final models from each procedure from the Mann data.
3.2.1 Mann data: The mBMI
The mBMI framework was applied to the Mann clinical dataset. As discussed in Section
2.1.1, the Mann dataset has clinical, pathological and mutation variables (p = 21 after
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pre-processing) with a relatively low sample size of n = 48, when the two survival
groups (GP vs. PP) are considered.
We applied the mBMI framework with the following parameters held fixed after
discussion with biologists and clinicians in the melanoma research group according to
the accuracy levels they require.
• Number of multiple imputations: m = 25 using Amelia II.
• Variable selection: stepwise selection with BIC as the selection criteria.
• Number of bootstrap samples: B = 500.
• MI inclusion threshold: ⌧MI = 0.50. This value is maintained in the remainder of
the thesis.
• Prediction error threshold (cut-off): ⌧CV = 0.30. This value was set after dis-
cussion with the biologists as they required the final model to have prediction
accuracy of at least 70%.
• Final inclusion frequency threshold (⌧FM). Instead of setting a fixed value for the
inclusion frequency in the selection of the variables to be used in the final model,
we further expanded this step as follows:
Step 7 of the mBMI determines the ranked list (according to their inclusion fre-
quency) of best performing variables. The ranked variables are then included
in a logistic regression model in a forward algorithm, where in the first model
the highest ranked (most frequently appearing) variable is included, and in the
second model the top two highest ranked variables are included and so on, until
the full set of variables are included into the model. These models are then val-
idated using CV. The final model was selected to be the top set of variables that
gave the lowest prediction error.
Results: The final clinical model is the model with the 10 top performing variables
(Table 3.1). The error rate for predicting patient outcome (final model fitting step) ini-
tially increased as the number of variables included in the final model changes from
1 to 2, and then steadily decreased until it reached its minimum of 20% (Figure 3.2)
incorporating 10 variables, before increasing again.
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Figure 3.2: Final variable selection in mBMI. The application of the mBMI proced-
ure to the Mann data. The fluctuation of the 5-fold CV error rate with the
number of variables in the final model in the last stage of the mBMI.
In addition to earlier disease stage (Stage I cf. Stages II/III) at initial presentation, the
following clinico-pathologic and mutation factors were associated with improved out-
come: intermittent sun exposure of the primary site (cf. chronic), decreased size of the
metastatic tumour, younger age, the presence of a nodular component in the primary
melanoma, tumour cell type ovoid, elongated or spindle (cf. round), and higher mitotic
rate of the preceding primary tumour primary, absence of BRAF mutation or absence
of NRAS mutation, and, absence of naevus in association with the primary tumour
(Table 3.1). In most cases the sign of the mean coefficient value was as expected and in
some cases is supported by prior literature, e.g., lower stage (Mann et al., 2013; Balch
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Table 3.1: Final model from mBMI. Coefficients for top-ranking clinical vari-
ables chosen as the final model via the mBMI framework.
Variable MeanCoefficient
Standard
Error
1 Tum_NRASmut (Yes/No) -5.18 2.60
2 Prim_Site_SunExp(Intermittent/Chronic) 4.30 2.48
3 Prim_Stage (Stage II/Stage I) -8.70 4.27
4 Prim_Stage III -7.04 3.90
5 Age_Analysis -0.17 0.09
6 Tum_MetSize -0.05 0.04
7 NM_variable (1/0) 3.80 2.37
8 Prim_Mitos 0.32 0.18
9 Tum_CellType (1/0) 2.76 1.93
10 Tum_BRAFmut (Yes/No) -2.11 1.83
11 Prim_Naevus (Present/Absent) -1.78 2.44
et al., 2009), cell shape not round (Shaw et al., 2006), smaller sized regional node meta-
stases (Balch et al., 2009), absence of naevus in association with the primary melanoma
(Kakavand et al., 2014), and absence of BRAF or absences NRAS mutation (Mann et al.,
2013). More details are shown in (Jayawardana et al., 2015a).
3.2.2 Mann data: Other modelling procedures
The modelling methods compared to mBMI are briefly outlined below. Throughout the
comparison study m = 25 multiple imputations were used with ⌧MI = 0.50 for model
aggregation.
1. Multiple imputation and logistic regression.
• Stepwise model selection:
Variable selection was carried out using a stepwise selection procedure us-
ing BIC as the selection criterion. A final logistic regression model is fitted
to the data using the selected variables.
• Lasso and Elastic net model selection:
For Lasso based model selection the R package ‘glmnet’ was used (Friedman
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et al., 2010). Here a generalised linear model is fitted via penalised maximum
likelihood. The objective function for the penalised logistic regression uses
the negative binomial log-likelihood, and is minimised:
min ✏Rp+1
⇣
-
h
1
n
Pn
j=1 yj(xTj  )- log(1+ e
xTj  )
i
+  
⇥ 
1-↵
2
 
|| ||22 +↵|| ||1
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.
The regularisation path is computed for the Elastic net penalty ((1-↵)/2|| ||22+
↵|| ||1) at a grid of values for the regularisation parameter  . The Elastic net
mixing parameter ↵ is between 0 and 1, and when ↵ = 1 the Elastic net
penalty is the Lasso penalty and when ↵ = 0 it is the Ridge penalty.
We use the misclassification error as the criterion to select  , and ↵ = 1
(Lasso model selection) and ↵ = 0.5 (Elastic net model selection).
2. Random Forest:
Variable selection was carried out using the package ‘varSelRF’ (Diaz-Uriarte,
2010). It uses the Out-Of-Bag (OOB) error as minimisation criterion and elimin-
ates the least important variables successively using variable importance scores
from Random Forest.
3. Clustering:
Hierarchical clustering was performed on the variables using the R package ‘Clus-
tOfVar’ (Chavent et al., 2013). One imputed dataset was used to select the number
of clusters and then it is applied over the m datasets. The CV error rate for in-
clusion of each variable in the cluster was computed after the optimum number
of clusters was determined. The variable that results in the lowest error rate is
selected from each cluster to be included in the final model.
4. Principal Components Analysis:
For each imputed dataset, the principal components (PCs) were retained such
that the cumulative proportion of variation explained by the PCs was at least
75%. CV was carried out on this new dataset of PC scores.
5. B-MI:
The B-MI (Campain, 2012) was used to select the variables.
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6. Weighted BMI:
The B-MI procedure was modified such that a rank is associated with each model.
The modification is as follows;
• In Stage 6 of the mBMI framework, the CV error of all of the B models are
calculated.
• Rank the B models based on their CV error such that the highest CV error
model has rank 1 and we denote the rank from the bootstrap model b by rb.
• Give a score to all the variables based on these ranks.
For the qth variable,
cq =
PB
b=1
rb⇥1{ ¯q,b 6=0}
B(B+1)/2 .
• Rank the variables based on this score (higher score for variables included
in models with low CV error).
• The ranked variables are then included in a logistic regression model in a
forward algorithm, where in the first model the highest ranked variable is
included, and in the second model the top two highest ranked variables are
included and so on, until the full set of variables are included into the model.
The final set of variables is the set that gives the lowest CV error.
Results: Comparison of methods onMann data. The CV error rates of the final models
were compared and the results are summarised in Table 3.2. The mBMI method gave
the lowest prediction error rate with a parsimonious model (24% with 10 variables). A
comparative error rate could be achieved by weighted BMI with Lasso selection (26%)
with 11 variables. All the other methods had a CV error between 34% to 50%. LOOCV
error rates were used in this comparison study as required by the biologists for the
error rates to be comparable with a previous study (Mann et al., 2013) using the Mann
data.
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Table 3.2: Comparison of modelling procedures for clinical data.
The number of variables selected are given in square
brackets
Method Variableselection
Prediction error
rate
Logistic
Regression
Stepwise
selection 38% [12]
Lasso 39% [19]
Elastic net 42% [18]
Ridge 41% [21-all]
Random forest 45%
Clustering 35% [7]
Principal Components Regression 50%
BMI Elastic net (best) 35%[13]
Weighted BMI Stepwise 34% [6]
Weighted BMI Lasso 26% [11]
mBMI Stepwise 24% [10]
3.3 evaluation of the mbmi framework : simulation study
To explore additional features of the mBMI framework, a simulation study was carried
out where optimal parameters are investigated for the mBMI framework. Through this
simulation study, we attempt to give a clearer picture of the utility of the mBMI frame-
work, where the parameters within the mBMI could be optimised according to the
dataset used. Simulating data for a logistic regression is often more challenging than
for a linear regression model, hence a much larger dataset is used than the Mann data
with a simpler data structure. A total of 20 explanatory variables were generated inde-
pendently from a uniform distribution (U(-1,1)) and standardised to have zero mean
and unit variance. The response variable was randomly generated from the binomial
distribution, where the probability of success vector (⇡) was obtained using the pre-
determined parameter vector ( ) and simulated regression data (X),
⇡j =
1
1+e
-xTj  
.
Since the outcome classes were relatively balanced in the Mann data, we attempted
to have similar class structure in the simulated data. The simulated response variable
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Table 3.3: The regression coefficients for the simulated
variables. The true parameter vector ( ), and
the 90% confidence intervals of the parameter
estimates using a logistic regression model are
given in the table. The confidence intervals in
bold contain zero.
Variable True beta
90% Confidence interval
5% 95%
A* 1.0 0.65 1.06
B* 1.0 0.29 0.68
C* 1.0 0.37 0.76
D* 1.0 0.36 0.76
E* 1.0 0.34 0.73
F* -1.0 -0.52 -0.14
G* -1.0 -0.69 -0.30
H* -1.0 -0.51 -0.13
I* -1.0 -0.75 -0.37
J* -1.0 -0.76 -0.37
K 0.0 -0.34 0.04
L 0.0 -0.21 0.17
M 0.0 -0.25 0.12
N 0.0 -0.33 0.04
O 0.0 -0.28 0.10
P 0.0 -0.42 -0.05
Q 0.0 -0.12 0.26
R 0.0 -0.35 0.02
S 0.0 0.01 0.38
T 0.0 -0.29 0.09
had 259 one’s (i.e. good prognosis) and 241 zero’s (i.e. poor prognosis), where the total
sample size was 500.
A logistic regression model is applied to the simulated data. Table 3.3 shows the
90% confidence interval obtained for the parameter estimates. It is apparent from the
results that model instability is present even when we use the complete dataset, as two
of the variables with zero coefficients produce confidence intervals without including
zero.
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Selection of the parameters
Within the mBMI, we can vary the following parameters as explained in Section 3.1;
• Prediction error threshold (⌧CV ).
In the mBMI after ranking the B models by their prediction error rate, the best
performing models are selected (Stage 6 of the mBMI) using the prediction error
threshold. That is, the models showing the highest prediction accuracy are selec-
ted for the next steps of the analysis. In this simulation study, ⌧CV was varied to
consider top 2.5%, 5%, 10-50% models (⌧CV = 0.025, 0.05, 0.10, 0.20, . . . , 0.50).
• Final inclusion frequency threshold (⌧FM).
The inclusion frequency of the variables in the best performing models are con-
sidered (Stage 8 of the mBMI) in selecting the final model. We varied ⌧FM from
0 to 1. That is if ⌧FM = 0, then all the variables that are included in at least one
of the models are used in the final model. If ⌧FM = 1, then the variables that are
included in all of the models are used in the final model.
Results: The results are summarised in Figure 3.3 and 3.4. The patterns of prediction
error rates are similar for all ⌧CV (see Appendix B). To select the ⌧FM, the inclusion
frequencies of variables for all ⌧CV are considered. One instance is illustrated in Figure
3.3, where the prediction error threshold, ⌧CV is 0.025 (i.e., top 2.5% models). The
separation between the variables in the true model and the variables that are not in
the true model can be clearly seen after ⌧FM = 0.65. Therefore in this instance the
final inclusion frequency threshold was selected to be 0.65. Similarly the best ⌧FM was
selected for each ⌧CV (see Appendix B). To select the best ⌧CV and ⌧FM combination
the prediction error rates of the models with selected ⌧FM were considered (Figure 3.4).
The error rate from ⌧CV = 0.025 was slightly lower than the others. Therefore, from
this simulation study, the parameters selected were,
• ⌧CV = 0.025 (prediction error threshold: consider the top 2.5% models).
• ⌧FM = 0.65 (final inclusion frequency threshold: the variables that are included
in at least 65% of the top models).
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Figure 3.3: Stability of the variables. The stability measures of the variables when
⌧CV = 0.025. The rows represent the variables and the columns represent
different ⌧FM values. A variable is considered to be stable if they are in-
cluded in the majority of the fitted models. In this figure the color indicates
the stability, where darkness is proportional to the inclusion frequency. The
scale varies from 0 (the variable is not included in any of the fitted models)
to 1 (the variable is included in all of the fitted models, hence highly stable).
3.4 discussion and conclusions
Missing data, instability of final models and predictive modelling are some of the key
challenges when model building for clinical data. This chapter focused on develop-
ing a framework that addresses all of the above mentioned challenges via the mBMI
framework.
To construct a stable model for the purpose of achieving high prediction accuracy,
the stabilising steps in the mBMI were proposed. For a model to be stable, the same
set of variables should be consistently chosen even with perturbations in the data.
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Figure 3.4: The prediction error rates of the selected models. The 5-fold CV error rate
for ⌧FM selected for each ⌧CV .
These perturbations in the data were created by taking bootstrap samples and selecting
variables over the many re-samples of the data. Our framework facilitated the selection
of best performing subsets of variables, focussing on those models with small CV
error rate. To ensure that the final model is stable, the variables that had an inclusion
frequency above a pre-specified threshold were considered.
The tuning of the parameters, prediction error threshold and final inclusion fre-
quency threshold can be regarded as data dependent steps. The simulation of data
that clearly demonstrates the features of the mBMI procedure proved to be rather chal-
lenging, however the main features of the mBMI have been demonstrated via the sim-
ulation study conducted in this chapter. Due to the complexity of the Mann data, sim-
ulating data that possess similar characteristics was much harder. Furthermore, with
smaller sample sizes similar to that of the Mann data, it was rather difficult to illustrate
the components of the mBMI. Therefore, although such datasets were simulated and
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explored using the mBMI, to give a clearer picture, a much simpler simulation study
was presented in Section 3.3. Choosing ⌧CV = 0.025 and ⌧FM = 0.65 proved to produce
better results for this particular simulation set-up, also because of its ability to distin-
guish between the true variables and other variables clearly as the stability of the true
variables were significantly higher. These parameters also produced comparable CV
error rates for the final models constructed. No significant distinction between the CV
error rates were noticed, which might be due to the simple structure of the simulation
set-up.
The application of the mBMI in the Mann data enabled us to assess its validity in
real clinical data. The results produced an interpretable model in the clinical context
with a good prediction error rate. A comparison study of the mBMI method with a
collection of other methods popular in clinical data modelling was carried out using
the Mann data. Stability could not be assessed due to the data being a real dataset.
We conjecture that the stability measures in the mBMI produced a final model that is
stable as well. The CV error rates of the final model indicate that the mBMI framework
produced the best model in terms of its prediction capability.
Overall, the mBMI framework can be regarded as a very useful and effective method
that addresses missing data, unstable models and predictive model construction. Our
parrallel implementation of the mBMI in a multi-core architecture made the explora-
tion of the features within the mBMI much easier and less time consuming.
4
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Biomarker discovery and the evaluation of its accuracy in a prognostic setting has
been one of the key questions in the field of bioinformatics over the years. Traditionally,
a single data source, either clinical or high-throughput omics data, has been used to
address this. The availability of multiple datasets through public repositories such as
GEO (Barrett et al., 2007)1, ArrayExpress (Parkinson et al., 2007)2 and TCGA3 provides
unprecedented opportunities: to use the many available data sources effectively in
the biomarker discovery process to identify more effective biomarkers, to improve the
power of current studies via the availability of more data samples and/or variables,
and to validate the current biomarkers. One such field that emerged utilising the avail-
ability of multiple data sources is ‘horizontal data integration’, where multiple datasets
of the same type are used in an integrative analysis (Tseng et al., 2012). As discussed
in Chapter 1, horizontal integration can be broadly categorised into meta-analysis; the
integration of statistics from different studies, and mega-analysis; combining the data-
sets prior to the analysis. In this chapter, we examine methods and approaches in
horizontal data integration in a meta-analysis setting, using multiple datasets of the
same type (e.g., same disease).
Classically, meta-analysis has been used to combine datasets to provide more power
to the analysis. This is done by combining statistics to detect a common set of important
features and effect sizes, where usually all the studies share a common null hypothesis.
In contrast, we use the meta-analysis in a prognostic context in this chapter, to better
estimate the prediction accuracy of biomarkers as well as to identify a robust set of bio-
markers from multiple studies. In biomedical applications this class of meta-analysis
often includes studies with different aims and designs. However, integrating data in
such a meta-analysis is still imperative to gain new information. This meta-analysis
allows to evaluate the biomarkers using independent data, in the light of increasing
the confidence on these biomarkers in clinical use. The conclusions are more robust
as they are based on multiple studies rather than a single data source. In Chapter 1
we discussed a number of challenges and issues associated with meta-analysis. Two
of the challenges encountered are: (i) the differences in study aims and designs that
1 Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo).
2 http://www.ebi.ac.uk/arrayexpress/
3 The cancer genome atlas (http://cancergenome.nih.gov).
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hinder the comparison of different biomarkers, as all variables being considered are
not assayed in each of the multiple studies, and (ii) the heterogeneous patient cohorts
in each study.
In this chapter, we use the miRNA datasets from multiple studies (discussed in
Section 2.2) in developing a comprehensive meta-analysis procedure, while addressing
the above challenges. The miRNA biomarkers are of particular interest here, as they
are a new type of biomarkers that emerged recently. In melanoma, there are only a
handful of studies (Segura et al., 2010; Caramuta et al., 2010) that investigate this class
of markers. As such, these datasets highlight the challenges associated with horizontal
data integration and lend themselves to illustrate the advantages in meta-analysis to
comprehensively evaluate the efficacy of signatures in a biologically relevant context.
Section 4.1 describes pre-processing of the datasets, as careful analysis at this stage
is essential to obtain optimal signal from each data source. In Section 4.2, novel bio-
markers are identified for the studies where no published prognostic biomarkers are
available. In Section 4.3 we utilise all tissue-based miRNA prognostic signatures in
metastatic melanomas proposed in the literature to date (Jayawardana et al., 2015b;
Segura et al., 2010; Caramuta et al., 2010) in a systematic cross-validation (CV) of the
biomarkers. The aim of the above analysis is to assess the prognostic utility of the
biomarkers in independent datasets, thereby highlighting a robust set of biomarkers.
Furthermore, the C-index (Uno et al., 2011) will be used as an alternative method to
the CV error rate to evaluate the signatures. The use of the C-index allows to assess
the signatures for the actual event times (survival times), rather than for the prediction
of binary outcome (GP vs. PP) as in CV. The signatures are then evaluated relative
to equivalent but random variable sets to assess whether they have better predictive
power. In Section 4.4, a robust and reproducible set of miRNAs are evaluated in the
validation datasets. The meta-analysis procedure explored in this chapter (Figure 4.1)
yields insights into the translational potential of this class of markers.
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Figure 4.1: Schematic of the meta-analysis procedure. The figure outlines our compre-
hensive meta-analysis procedure. The shaded cells in the table denote the
instances where the signatures are validated on their own training data.
4.1 pre-processing and normalisation of the datasets
In this chapter, we use four miRNA datasets for meta-analysis. The first dataset is the
Mann miRNA data (Section 2.1), for simplicity we refer to it as ‘Mann data’ in this
chapter. Apart from this in-house miRNA data, three other external miRNA datasets
are used in the analysis. These are the datasets from TCGA, the Segura data (Segura
et al., 2010) and the Caramuta data (Caramuta et al., 2010). The latter two were identi-
fied after a comprehensive literature search for miRNAmicroarray expression profiling
studies in clinical samples of metastatic melanoma. The details of the Segura and Cara-
muta datasets, pre-processing and low-level analysis were detailed in Section 2.2. The
pre-processing and the normalisation of the Mann data, which includes a comprehens-
ive comparison of normalisation procedures, and the pre-processing of TCGA data are
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detailed in this section. This low-level analysis is imperative in removing unwanted
noise in the data to assist in downstream analysis.
The Mann data
This data is used as the primary miRNA dataset and we use this to develop a pre-
processing approach for miRNA data, which includes a comparison study to determ-
ine the optimal normalisation method. Because of the comprehensive nature of the
pre-processing involved, the details are given in this chapter and were not shown
in Chapter 2. The pipeline developed here involves careful pre-processing, low-level
analysis and normalisation required to ensure a more accurate and clean dataset for
further analysis (Figure 4.2). This procedure can be adopted for any similar miRNA
microarray dataset.
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Figure 4.2: Schematic of the processing and analysis of the Mann data. On the left
hand side of the plot the numbers of miRNAs (probes and technical replic-
ates) at various stages of the process are shown.
This dataset can be downloaded from Gene Expression Omnibus (GEO, GSE59334;
3523 probes and 1347 miRNAs) (Tembe et al., 2014). Actual miRNAs were selected,
where all positive and negative controls were filtered out. The data contained 1347
miRNAs with each miRNA consisting of multiple probes (1-4), and each probe consist-
ing of multiple technical replicates (10-40). A filtering protocol comprising of three key
steps was applied:
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• For each probe, the average expression value over all technical replicates were
taken.
• The probes having a maximum expression value greater than or equal to 7.5
across all the samples (patients) were selected (the probes having low expression
with maximum expression level across samples < 7.5 were filtered out). This
process resulted in a filtered dataset of 734 probes pertaining to 390 miRNAs
(Figure 4.2).
• The filtered data were mapped to the level of technical replicates (13,760 entries).
Typically miRNA data contain much less signal than mRNA data. Therefore, it is
critical to apply a filtering protocol as described to enable successful downstream ana-
lysis. Such a filtering was applied with the intention of improving upon the signal in
the data, as the majority of the miRNAs exhibited low expression values relative to oth-
ers (Figure 4.3). The boxplots of the data before and after filtering (Figure 4.4) show the
effect of filtering. It is apparent that the data before filtering has much lower expression
at the sample level (45 samples) than after filtering. Also, the batch effect is much more
evident in the data before filtering (Figure 4.4a), and this has much less impact in the
filtered data (Figure 4.4b) as the samples are on the same scale with similar variability.
Comparison of normalisation procedures. The normalisation of data is an imperative step
in assuring stronger signal in the data. It aims to remove batch effects and unwanted
noise or variation from external factors, both technical and biological. In this section,
we perform a comparison study of different normalisation procedures to select the
most appropriate normalisation procedure for this data. There exist comparison stud-
ies in the normalisation procedures literature, for example for miRNA microarray data
(Rao et al., 2008; Hua et al., 2008) and for miRNA-Seq data (Garmire and Subramaniam,
2012). However, none of these studies compared the effect of utilising a more recently
developed method of removing unwanted variation, RUV (Gagnon-Bartsch and Speed,
2012) in normalisation. In this thesis we use RUV in combination with the more tra-
ditionally used quantile normalisation, which is considered as a more general ‘global
adjustment’ method (Gagnon-Bartsch and Speed, 2012). Evaluation strategies similar
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Figure 4.3: Heatmap of the probe-level expression values in the Mann data. Many
probes had very low expression values and as a result are not likely to add
value to any subsequent analysis; rather, they would be expected to add
noise to the data.
to those described in (Gagnon-Bartsch and Speed, 2012) were used for this comparison
study as follows:
1. Number of differentially expressed miRNAs
The number of differentially expressed (DE) miRNAs discovered are expected to
increase after proper normalisation, as it is an indication of the increase in dis-
tinction between the groups (e.g. survival groups; GP and PP) being compared.
We used a linear mixed effects model to find the number of DE miRNAs, owing
to the structure of the data (every miRNA in this dataset corresponded to one
or more probes and each probe had one or more technical replicates). This ap-
proach takes into account the variability between conditions (e.g. good vs. poor
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Figure 4.4: Boxplots for the expression values of the samples in the Mann data. a) be-
fore filtering the data, b) after filtering the data. x-axis shows the 45 samples
ordered by the batch number.
prognosis), as well as within probes and samples (more details are given in Ap-
pendix C). The model used was
yijkl = µ+↵i + ⌘k +  ijk + ✏ijkl.
Here, yijkl denotes the normalised log2 expression for the ith condition, jth
sample, kth probe and lth replicate, µ denotes the baseline expression, ↵i denotes
the effect of the ith condition, ⌘k denotes the effect of the kth probe,  ijk de-
notes the variability in the ith condition for the jth sample and the kth probe, and
✏ijkl denotes the measurement error. The fixed effect coefficients of the model
are µ and the ↵’s, and the random terms are the ⌘’s,  ’s and ✏’s. It is assumed
that all random terms are Gaussian as follows: ⌘k ⇠ N(0, 2⌘) independent of
 ijk ⇠ N(0, 2 ) independent of ✏ijkl ⇠ N(0, 2✏). The R package ‘nlme’ (Pinheiro
et al., 2014) is used to fit this mixed model (using the function ‘lme’). A condition
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refers to any comparison of interest. For the purpose of comparing normalisation
methods here: 1) the survival groups (good vs. poor prognosis); and, 2) BRAF
mutation status (BRAF V600E/K mutant vs. wild type) are considered. Candid-
ate DE miRNAs are defined by controlling for 5% false discovery rate (FDR).
2. Distribution of p-values
The distribution of p-values from a DE analysis, when shown through a histo-
gram, is expected to be almost uniform over the interval (0,1) with a spike near
zero (Gagnon-Bartsch and Speed, 2012; Leek and Storey, 2008, 2007). This is be-
cause by definition, the non-DE features (miRNAs here) are uniformly distrib-
uted over the unit interval, as it is assumed that only a fraction of features are
associated with the comparison of interest (condition). The miRNAs associated
with the comparison of interest will ideally have approximately zero p-values. A
dataset that has been processed well, removing unwanted variations, is expected
to exhibit this ideal situation.
3. Correlation with qRT-PCR data
As explained in Chapter 1, qRT-PCR data are considered as the gold standard
for measuring expression and hence are frequently used for validation purposes
(Hua et al., 2008). For this comparison, the qRT-PCR data for a subset of ten
miRNAs described in (Tembe et al., 2014), were obtained and normalised via RUV.
This data is then compared with the same subset of ten miRNAs in the Mann data
normalised via different methods using Pearson’s correlation coefficients.
Different combinations of quantile normalisation (implemented in ‘limma’ package
(Smyth, 2005) and a modified version of RUV (Removing Unwanted Variation (Gagnon-
Bartsch and Speed, 2012); ‘randomRUV’ with nuCoeff being a regularisation factor and
k being the number of unobserved factors (for more details we refer to Appendix C),
were compared with different parameters (k = 2, 10 and nuCoeff = 0.00001, 0.001, 0.1),
before and after filtering the data (filtering explained above). The following normalisa-
tions were compared in this section:
1. Q (Quantile normalisation then filtering)
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2. subQ (Quantile normalisation after filtering)
3. RUV (RUV then filtering; k = 10,nuCoeff = 0.001)
4. subRUV (RUV after filtering; k = 10,nuCoeff = 0.001)
5. subRUV1 (RUV after filtering; k = 10,nuCoeff = 0.1)
6. subRUV5 (RUV after filtering; k = 10,nuCoeff = 0.00001)
7. QRUV (Quantile normalisation then RUV before filtering; k = 2,nuCoeff =
0.001)
8. subQRUV (Quantile normalisation then RUV after filtering; k = 2,nuCoeff =
0.001)
9. subQRUV1 (Quantile normalisation then RUV after filtering; k = 10,nuCoeff =
0.1)
10. subQRUV5 (Quantile normalisation then RUV after filtering; k = 10,nuCoeff =
0.00001).
Results: Filtered data that were quantile normalised followed by RUV under different
parameters showed the best performance overall. Specifically, the subQRUV approach
yielded the highest number of DE miRNAs for survival group distinction (good and
poor prognosis) and a comparably higher number of DE miRNAs for BRAF muta-
tion (mutant and wild type) (Table 4.1). The p-value histograms under both conditions
showed the best distribution (near uniform, with peak at zero) under the subQRUV
normalisation protocol (Figure 4.5). The comparison with the qRT-PCR data using
the correlation coefficients showed high consistency with the QRUV-normalised data,
where the highest absolute value of the correlation coefficient was exhibited for the
majority of the miRNAs (Table C.1). Therefore, the subQRUV normalised data (data
filtered then normalised by quantile normalisation and RUV with nuCoeff=0.001 and
k=2) was used for the subsequent analysis. Finally, the data were aggregated at the
miRNA level by taking the average across all probes and technical replicates for each
miRNA (390 miRNAs) (Figure 4.2).
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Table 4.1: Number of differentially expressed miRNAs from each normalisation method. The
number of DE miRNAs for the separation of two survival groups (good vs. poor pro-
gnosis) and for BRAF mutation (mutant vs. wild type), for some of the normalisation
techniques compared in this study. Option 4 was ultimately used since it gave the
highest number of DE miRNAs for survival groups, as well as comparably higher
number of DE miRNAs for BRAF mutation.
Method
Differentially
expressed miRNAs for
survival groups
Differentially
expressed miRNAs for
BRAF mutation
1 Quantile! filter (Q) 7 5
2 Filter! Quantile (subQ) 7 0
3 Filter! RUV (subRUV) 3 19
4 Filter! Quantile! RUV(subQRUV) 10 19
5 Filter! Quantile! RUV(nuCoeff=0.1) (subQRUV1) 7 4
6
Filter! Quantile! RUV
(nuCoeff=0.0001)
(subQRUV5)
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TCGA miRNA data
In the miRNA expression dataset downloaded from TCGA, there were miRNA-Seq
counts for 1134miRNA regions that were annotated as ‘mature’, ‘star’, ‘stemloop’, ‘un-
annotated’ and ‘precursor’, along with their respective accession number (e.g. mature,
MIMAT0000062). The following filtering steps were applied:
• For direct comparability with the remaining microarray-based expression data-
sets evaluated in this study, all sequences other than those annotated as ‘mature’
or ‘star’ regions were excluded.
• The read counts for each miRNA (e.g., the sum of the read counts for all se-
quences under the unique identifier ‘hsa-let-7a-1_MIMAT0000062’) were aggreg-
ated, this produced 775 miRNAs.
• The data for the ‘expressed’ miRNAs were filtered, i.e. all miRNAs with row
sum of counts equal to zero across the samples were excluded, resulting in 774
miRNAs (Figure 4.6).
4.1 pre-processing and normalisation of the datasets 72
fre
qu
en
cy
fre
qu
en
cy
fre
qu
en
cy
fre
qu
en
cy
Figure 4.5: Histograms of p-values from analysis of differential expression (DE).
The histograms of p-values for the DE analysis on the comparison of in-
terests (conditions) show, a) the survival group comparison between good
and poor prognosis and b) the mutation status comparison between BRAF
mutant and wild type.
This filtered dataset was normalised using TMM, the trimmed mean of M-values
method (Robinson and Oshlack, 2010), to account for differences in library sizes. Data
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were then transformed using ‘variance stabilised transformation’ in the R package
‘DESeq’ (Anders and Huber, 2010) (Figure 4.6).
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Figure 4.6: miRNA-Seq data analysis pipeline for data from TCGA. On the left hand
side of the plot the numbers of miRNAs at various stages of the process are
shown.
4.2 identification of new mirna-based prognostic signatures
From the broadly identified miRNA datasets in melanoma (Mann, TCGA, Segura,
Caramuta), only (Segura et al., 2010) and (Caramuta et al., 2010) contain signatures.
Therefore, we concentrated on identifying prognostic signatures for the Mann and
TCGA data as part of our meta-analysis procedure. For this purpose, the CV proced-
ure ‘A: Full CV’ outlined in Section 2.4.1 was used with the following parameters:
• Feature selection method: ‘Median robust’ (Jayawardana et al., 2015a; Campain,
2012).
In the median robust method, the miRNAs are ranked based on the difference
between the median expression of the two groups (PP and GP). A set of molecular
signatures are devised such that the kth molecular signature contains the k top-
ranked features. The final expression value for miRNA q is
eq = x˜q,GP - x˜q,PP,
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where x˜q,GP and x˜q,PP represent the group median for the qth miRNA for GP
and PP groups, for q = 1, 2, . . . , 390.
• Classification method: Nearest shrunken centroids (NSC) (Tibshirani et al., 2002)
as implemented in ‘pamr’ R package (Hastie et al., 2014).
This procedure was applied to the Mann and TCGA datasets. In the Mann data, the
set of features evaluated (Step 2 of Full CV) was varied over top 5, 10, . . . , 100 and in
TCGA over the top 10, 20, . . . 500, depending on the varying total number of features
in each dataset (390miRNAs and 774miRNAs, respectively). The prognostic signature
comprised of the set of miRNAs included in more than 50% of the models (500models
in total; 5-folds x 100 runs).
Results: The prediction error rates of the identified prognostic biomarkers/signatures
were evaluated via the ‘Final CV’ procedure (CV procedure E, Section 2.4.5) using leave-
one-out cross-validation (LOOCV) to be comparable with the other error rates. The
signatures for the Mann and TCGA data comprised of 12 and 15miRNAs, respectively
(Table C.2) which produced LOOCV error rates of 33% and 39% (Table 4.2).
Abiding by the standards for validation of biomarkers, REMARK (REporting recom-
mendations for tumour MARKer prognostic studies)-criteria (McShane et al., 2005),
the prediction accuracies of these biomarkers were compared with the prediction
accuracy of the four most statistically significant clinico-pathologic prognostic para-
meters in Stage III melanomas. These standard-of-care parameters are the number of
tumour-positive lymph nodes, tumour burden at the time of staging (microscopic v.
macroscopic), presence or absence of primary tumour ulceration, and thickness of the
primary melanoma (Balch et al., 2009). These four variables were used in a logistic re-
gression model to assess their prognostic power and the results are presented in Table
4.2. The results showed an improved predictive performance for the Mann signature
(33% compared with 36% for standard-of-care variables). However, this improvement
was not shown for TCGA signature (39% compared with 37%).
Finally, the performance after the integration of these signatures with the standard-
of-care variables was evaluated. Here, the pre-validated vectors (Tibshirani and Efron,
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2002) from each signature were derived and these were used together with the clin-
ical variables in a logistic regression model (Jayawardana et al., 2015a). The prediction
error rates (Table 4.2) in this integrative framework were very similar (41% and 42%,
respectively) for the two datasets, indicating that integration did not add value in this
instance.
Table 4.2: LOOCV error rates for the prognostic signatures identified using the
Mann and TCGA data.
LOOCV
error rate Method of assessment
Mann
12-miRNA prognostic signature 33% NSC
Standard-of-care variables1 36% Logistic regression
Standard-of-care variables1 and
12-miRNA signature combined 41%
Pre-validated vector in
a logistic regression
framework
TCGA
15-miRNA prognostic signature 39% NSC
Standard-of-care variables1 37% Logistic regression
Standard-of-care variables1 and
15-miRNA signature combined 42%
Pre-validated vector in
a logistic regression
framework
1 Number of tumour-positive lymph nodes, tumour burden at the time of staging (microscopic vs. mac-
roscopic), presence or absence of primary tumour ulceration, and thickness of the primary melanoma
(Balch et al., 2009).
Abbreviations: NSC, nearest shrunken centroids; TCGA, The Cancer Genome Atlas.
4.3 cross-platform meta-analysis
We used two approaches to perform the meta-analysis in this chapter. The primary
method used is CV, where the signatures are assessed for their ability to predict the
survival groups (GP vs. PP) in every validation dataset. The C-index is also used as
an alternative method to CV, because it allows us to compare the performance of the
signatures in predicting the actual survival times. More details of the datasets and their
signatures are given in Appendix C (Table C.2).
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4.3.1 Evaluation using the CV error
Meta-analysis was perfomed via a systematic cross-validation to assess the signature
performance in independent datasets. The five signatures (3 published and 2 identified
in Section 4.2) from the Segura, Caramuta, Mann and TCGA data were used in this
meta-analysis. Similar analysis has been performed in (Schramm et al., 2012; Campain,
2012). This cross-validation meta-analysis is shown in Figure 4.1 and is as follows:
1. For each study a miRNA list (say signature X) was obtained which formed the
feature vector.
2. For each of the four datasets (say dataset A), miRNA expression data were ob-
tained and pre-processed as already described.
3. LOOCV was performed on the expression dataset A, where one sample was
randomly assigned to the test set and the remaining samples were treated as the
training set;
• Using the expression dataset A and the miRNA list from signature X, a NSC
classifier was constructed on the training set.
• The classification rule constructed was then examined for its capacity to
predict patient survival outcome (GP and PP) of the test set (dataset A).
• The procedure was repeated for the assignment of each sample into a test
set, which gave a complete predicted vector, thus producing a LOOCV pre-
diction error rate for signature X on dataset A.
One of the main challenges in horizontal data integration is the differences in the
study aims and designs. Our cross-validation meta-analysis also encounter this issue,
which resulted in not all miRNAs of a given signature being present in the other inde-
pendent datasets. The reasons behind this are that these miRNAs are either not detec-
ted, not measured, or below filtering limits. In these instances assessment proceeded
using the smaller number of miRNAs actually available for analysis.
Another challenge encountered was the heterogeneity of the patient cohorts from
multiple studies, which resulted in untenable sample sizes when filtered according to
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some criteria. To address this, we performed the validation procedure with filtering
according to the biomarkers and also without filtering, using the complete validation
datasets.
Our comprehensive validation protocol constitutes of three parts and these are de-
scribed below:
1. Part 1: Validating the biomarkers and the survival endpoints associated with the
biomarkers
The accuracy of each biomarker in predicting patient clinical outcome was tested
in each of the other expression datasets using equivalent survival endpoints (used
in determining the survival outcome groups: GP and PP) associated with the
signature. The validation datasets were filtered to be comparable to the setting
where each signature was derived originally, including the determination of sur-
vival classes (GP and PP). However, in some instances these survival endpoints
were not strictly identifiable or resulted in too small sample sizes to evaluate
effectively in the validation data.
2. Part 2: Validating the biomarkers only
We evaluated the performance of the biomarkers using the survival classes of the
validation dataset. This allowed the use of the full validation dataset.
3. Part 3: Evaluating the performance of biomarkers relative to random feature sets
This approach is a newly emerging standard for evaluating the performance of
gene expression microarray signatures (Waldron et al., 2014; Beck et al., 2013),
based on (Venet et al., 2011) who found that equivalent random features could
cluster patients into prognostically different subgroups. This challenged the tend-
ency to interpret signatures that are significantly associated with survival, as hav-
ing biological and/or clinical relevance. Therefore, to deal with this issue in this
study we compared the predictive power of each signature with that of random
miRNA sets of the same size obtained from within the same expression dataset.
The comparison entailed:
• The predictive power of the random miRNA sets (mean error rate over the
error rates of 100 random sets of the same size as the signature of interest).
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• Improvement over random signatures (IOR) score.
Assessed by the fold change in the CV error for random signature compared
to that of the signature of interest in each validation dataset. This produced
100 such improvement scores, one for each set of the random signatures.
Improvement over random signature = CV error of the random signatureCV error of the signature of interest .
A score greater than one indicates an improvement in prediction accuracy
for the signature of interest compared to the random gene set. The higher
the score, the greater the improvement and the greater the predictive capab-
ility of the signature with respect to a random set of miRNAs of the same
size. A score below 1 indicates that the random miRNA set performs better
on the respective dataset than the actual signature of interest. Similar scores
have been computed to serve this purpose in the literature (Waldron et al.,
2014).
Results: The predictive power of each of the signature miRNA lists was assessed in the
validation datasets (Table 4.3 and 4.4). The NSC classifier was used for this purpose,
except in the case when only 1 miRNA was being assessed, and the support vector
machine (SVM) classifier was used instead. The prediction accuracy of the final mod-
els was evaluated using LOOCV. The sample limitation in most of the datasets did not
allow to use 5-fold CV.
Part 1 - Validation of each signature and its classes (Table 4.3): The table shows the CV
error rates, the available miRNAs to be assessed in each validation dataset (square
brackets) and the number of samples assessed in each survival class (parentheses;
GP:PP). For example, in the validation of the Mann 12-miRNA signature on the Cara-
muta data, the CV error rate was 54% and out of the 12 miRNAs, only 7 were present
in the Caramuta data (indicated by ‘[7]’). In this instance the total sample size of the
Caramuta data when filtered according to the criteria of the Mann biomarker was 13
with 6 and 7 samples in GP and PP groups respectively (indicated by ‘(6:7)’).
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Table 4.3: Part 1: Validation of the biomarker and their survival classes. Summary of
LOOCV error rates for independent validation of miRNA prognostic signatures
in metastatic melanoma.
Biomarker Mann Segura Caramuta TCGA
Mann (12 miRNAs)
33% [12] Notevaluable1 54% [7] 38% [12]
(23:22) (1:1) (6:7) (5:8)
Segura
(18 miRNAs)
31% [16] 22% [18] 27% [7] 42% [18]
(23:22) (36:23) (8:7) (25:11)
(6 miRNAs)
31% [6] 27% [6] 40% [1] 33% [6]
(23:22) (36:23) (8:7) (25:11)
Caramuta (6 miRNAs)
48% [5] Notevaluable1 13% [6]
Not
evaluable1
(18:22) (1:2) (8:7) (2:8)
TCGA (15 miRNAs)
53% [5] Notevaluable1 62% [3] 39% [15]
(23:22) (1:7) (6:7) (11:12)
1 Insufficient sample size for analysis.
Number of miRNAs able to be assessed in each validation dataset is indicated in square brackets. Number of
samples assessed in each class (longer survival:shorter survival) is given in parentheses.
In four cases the error rate evaluation procedure could not be completed due to small
sample size (shown in parentheses in Table 4.3). This is because in this case we restric-
ted the validation dataset to survival classes of the signatures. The lowest error rate
observed (13% for the Caramuta signature in their own data) did not validate when
examined in the larger, independent sample size of 40 from Mann (5 out of 6 miRNAs
present produced an error rate of 48%). The 18-miRNA and 6-miRNA signatures from
the Segura data achieved estimated error rate s of 22% and 27% via their own data.
Although the error rates were much higher in the independent validation, these signa-
tures showed best independent validation results overall (27% in the Caramuta data for
the 18-miRNA signature and 31% in the Mann data for both signatures). Of the newly
proposed signatures, the Mann signature performed best in its own data (33%), but
did not validate well in the independent datasets (38% in TCGA data being the best
independent validation). TCGA signature did not perform well even in its own data
(39%). However, a critical caveat was that very few of the 15 miRNAs were identifiable
in independent datasets.
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Table 4.4: Part 2: Validation of the signature only. Summary of LOOCV error rates for inde-
pendent validation of miRNA prognostic signatures, using the survival classes of
the validation dataset.
Biomarker Mann (45) Segura (59) Caramuta(15)
TCGA
(23)
Mann (12 miRNAs) 33% [12] 29% [11] 53% [7] 52% [12]
Segura
(18 miRNAs) 31% [16] 22% [18] 27% [7] 43% [18]
(6 miRNAs) 31% [6] 27% [6] 40% [1] 39% [6]
Caramuta (6 miRNAs) 51% [5] 31% [6] 13% [6] 35% [6]
TCGA (15 miRNAs) 53% [5] 39% [10] 53% [3] 39% [15]
Number of miRNAs able to be assessed in each validation dataset is indicated in square brackets. Number of
samples assessed in each validation dataset is given in parentheses.
Part 2 - Validation of the signature only (Table 4.4): This validation process was carried
out because the examination of signatures and their associated classes as in Part 1 val-
idation often lead to ineffectual sample size. The small sample sizes in the filtered data-
sets are due to differences among cohorts in survival distribution, tissue type, and/or
other factors. Therefore, to overcome this challenge, the survival endpoints associated
with the validation expression datasets were used, which resulted in increased sample
sizes (Table 4.4, parentheses) relative to part 1. The prognostic utility of the signa-
ture per se was examined in relatable, although not identical survival class conditions.
Some of the LOOCV errors remained the same due to samples being apportioned to
good and bad survival classes in the same manner, despite the different follow-up
definitions used. Therefore, the 18-miRNA signature from Segura still showed the best
independent validation result (27% in the Caramuta data) with the Mann signature fol-
lowing closely behind (29% in the Segura data). The other signatures also validated in
at least one independent dataset (31% for the 6-miRNA Segura signature in the Mann
data, 31% for the Caramuta signature in the Segura data and 39% for TCGA signature
in the Segura data), although this result could not be observed consistently in every in-
dependent validation dataset. In some cases these higher error rates may be attributed
to the small number of miRNAs that could be evaluated in independent cohorts (e.g.
out of the 15 miRNAs from TCGA signature, only a small number of miRNAs could
be evaluated in other data; 3 in the Caramuta data and 5 in the Mann data).
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Part 3 - Evaluation of prognostic miRNA signatures relative to equivalent random gene
sets: When random signature validation proceeded via the Mann and Caramuta data-
sets, random gene sets produced the expected error rates of approximately 50% (Table
4.5). Notably, the same observation could not be made for signature assessments using
the Segura expression data, where random gene sets predicted accuracy better than
what would be expected by chance (40-41%). When considering the improvement over
random signatures (IOR) scores, all but one signature - the 6-miRNA signature from
Segura - showed the largest gains in accuracy over random equivalent gene sets when
assessed in their own expression data (Figure 4.7, Table 4.6). In contrast, this signature
displayed greater gains in accuracy over random sets when evaluated using the data
from Mann (Figure 4.7). In terms of validation in independent datasets overall, the
two signatures from Segura showed the largest improvement over random sets. The
smallest gains were observed for TCGA signature (Figure 4.7, Table 4.6). It is note-
worthy that the Caramuta signature showed high variability of improvement scores (1
to 7) when assessed via its own expression data. In terms of the validation datasets,
TCGA dataset and the data from Mann showed the largest improvement scores for
independent validations (Table 4.6).
Table 4.5: Part 3: CV error rates from random miRNA sets. The performance of the random
signatures in each validation dataset using mean LOOCV error rates.
Biomaker Mann (45) Segura (59) Caramuta(15)
TCGA
(23)
Mann (12 miRNAs) 53% 41% 51% 62%
Segura
(18 miRNAs) 51% 40% 44% 61%
(6 miRNAs) 59% 40% 58% 66%
Caramuta (6 miRNAs) 59% 40% 58% 66%
TCGA (15 miRNAs) 52% 40% 47% 61%
4.3.2 Evaluation using the concordance index
In this chapter, we used CV as the main approach of meta-analysis, where it is used as
a validation tool for evaluating performance of the signatures in independent data. The
error rates produced used patient clinical outcome groups (good vs. poor prognosis)
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Table 4.6: Part 3: Improvement in the accuracy of signatures over random signature scores. The
table gives the mean scores for the improvement over 100 random gene sets. The average
score for signatures (using independent validation datasets) and the average scores for
datasets are also presented in the table.
Mann
(45)
Segura
(59)
Caramuta
(15)
TCGA
(23)
Average
score for
signatures
Mann (12 miRNAs) 1.62 1.41 0.96 1.20 1.19
Segura
(18 miRNAs) 1.66 1.82 1.64 1.57 1.57
(6 miRNAs) 1.89 1.49 1.45 1.68 1.68
Caramuta (6 miRNAs) 1.15 1.30 4.45 1.88 1.44
TCGA (15 miRNAs) 0.99 1.03 0.88 1.57 0.97
Average score1for dataset 1.42 1.25 1.23 1.55
Average score2for dataset 1.46 1.41 1.88 1.55
1 Average based on independent validation scores (where the dataset was not the training dataset of the respective
signatures).
2 Average across all signatures.
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Figure 4.7: Improvement over random signature scores. The improvement in predic-
tion error of the signatures relative to the prediction errors of equivalently
sized random miRNA sets, for each of the 100 random miRNA sets gener-
ated, ordered by the signature of interest.
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and are essentially estimating the ability of the model to predict the survival group
a patient belongs to. Extending the analysis, we assessed all signatures using Uno’s
concordance index (C-index) (Uno et al., 2011). The C-index is routinely used in the
medical literature to quantify the capacity of a given biomarker to discriminate among
subjects with different event times (Lee et al., 2014; Pennells et al., 2014; van Klaveren
et al., 2014; Waldron et al., 2014). The C-index can be interpreted as ‘the probability
that a patient predicted to be at lower risk than another patient will survive longer
than that patient’ (Waldron et al., 2014). Expected values of the C-index are 0.5 for
random predictions and 1 for perfect risk models (Waldron et al., 2014). This phase of
the analysis comprised of two components:
1. Calculation of the C-index and standard errors.
This proceeded via the ‘survC1’ package (Uno, 2013) in R and used similar para-
meters to previous related work by Waldron and colleagues (Waldron et al., 2014)
in its calculation. tau (truncation time) was the combined median survival time
(21 months in this analysis) and itr (iterations) was 1000.
2. Synthesis of the results (C-indices) of each signature via a meta-analysis.
Following the approach described in (Waldron et al., 2014), this meta-analysis was
implemented using the R package ‘rmeta’ (Lumley, 2012). The meta-analysis pro-
duced a synthesised C-index for each signature as a weighted average of C-index
in each dataset. Weights of each C-index were calculated using the inverse of
the estimated variance, corresponding to a fixed effects meta-analysis. In the syn-
thesis of the C-index, the C-index based on the training dataset of each signature
was excluded, so as to reflect the validation in independent datasets. Signatures
were then ranked by this synthesised estimate of the C-index.
Results: The results revealed that all signatures predicted accuracy better than random
predictions, as shown by C-index>0.5 (Table 4.7). Overall, TCGA signature showed the
best predictive power via its own expression data with a near perfect risk score (C-
index =0.99). However, this predictive power was not retained in independent valida-
tion using the other datasets (0.63-0.67). All other signatures performed well in their
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own training data with the lowest C-index of 0.72 reported in the case of the Mann
signature, however, this signature performed better in independent datasets (C-index:
0.81-0.91). Due to the higher number of miRNAs in the Segura 18-miRNA signature
compared to the sample size in TCGA dataset (n = 23), the Segura 18-miRNA signa-
ture could not be evaluated in TCGA dataset.
The Mann signature and the Segura 18-miRNA signature showed the highest con-
cordance between the predicted and actual patient survival times (synthesised C-index
score = 0.83; Table 4.7). This indicates that these two signatures exhibited the best inde-
pendent validation performance. To remove a source of bias, the training dataset was
excluded in the synthesis of the C-index of the signatures. The remaining three sig-
natures did not yield high synthesised C-indices (0.65-0.68) demonstrating their poor
performance in independent validation datasets.
The validation datasets were ranked by the average C-index across signatures (i.e.,
column-wise ranking). From the average C-index across signatures, TCGA dataset
rendered to be the best validation dataset, closely followed by the Caramuta data-
set. The performance of these two datasets (TCGA and Caramuta) opposed the results
of the evaluation using CV errors (Table 4.3 and Table 4.4). When the CV was used
(Section 4.3.1), these datasets failed to provide good validation results for most of the
signatures, which could be attributed to the relatively small sample sizes in each of the
survival classes.
4.4 robust set of biomarkers
We examined the direct overlap among the independently derived signatures analysed
herein (summarised in Table C.2) to ascertain a more robust set of biomarkers. While
there were no miRNAs common to all biomarkers, 5 miRNAs intersected between
the Mann 12-miRNA and the Segura 18-miRNA signatures and 2 miRNAs intersected
between the Segura 18-miRNA and the Caramuta 6-miRNA signatures (Figure 4.8).
However, the meta-analysis showed that overall, the Segura signature and the Mann
signature performed the best in independent data. Therefore, we consider the intersec-
tion between the Mann and the Segura signatures as a more robust set of biomarkers.
4.4 robust set of biomarkers 85
Table 4.7: Meta-analysis via the C-index. The synthesised C-index to assess the performance of
each signature among independent datasets are given in the table, together with its
95% confidence interval, and the ranking of each signature. The last three rows show
the average score for each validation dataset and the rank of each dataset based on
that value.
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Mann (12 miRNAs) 0.72 0.81 0.83 0.91 0.83 0.71 0.95 1
Segura (18 miRNAs) 0.73 0.85 0.92 N/E 0.83 0.67 0.98 1
Caramuta (6 miRNAs) 0.63 0.69 0.88 0.73 0.68 0.51 0.81 3
Segura (6 miRNAs) 0.66 0.83 0.63 0.70 0.66 0.58 0.78 4
TCGA (18 miRNAs) 0.63 0.66 0.67 0.99 0.65 0.56 0.74 5
Average score for
dataset1 0.66 0.72 0.76 0.78
Average score for
dataset2 0.67 0.77 0.79 0.83
Rank of the datasets 4 3 2 1
1 Average based on independent validation scores (where the dataset was not the training dataset of the respective
signatures).
2 Average across all signatures.
To evaluate the performance of these 5 miRNAs (miR-142-5p, miR-150-5p, miR-342-3p,
miR-155-5p and miR-146b-5p), we generated the prediction error rates for this set in
the four datasets using the CV (similar to Section 4.3.1).
Results: The 5-miRNA signature validated in the Mann and the Segura data (LOOCV
error rates of 31% and 24% respectively) but not on other datasets (Table 4.8). The
mean error rate for the signature was 40%. However, in the Caramuta data only 2 of
the 5 miRNAs were present and the Caramuta and TCGA datasets did not provide
good validation results in previous cases as well (Section 4.3.1). Therefore, further
investigation on these 5 miRNAs using other independent data are required to assess
their validity.
Table 4.8: Validation of the 5-miRNA biomarker. This table shows the LOOCV error rates
for the identified set of miRNAs in every validation dataset.
Data Mann Segura Caramuta TCGA Mean
LOOCV 31% [5] 24% [5] 67% [2] 39% [5] 40%
Number of miRNAs able to be assessed in each validation dataset is indicated in square brackets.
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Figure 4.8: Overlap among the biomarkers evaluated. a) Venn diagram for the over-
lap among the miRNA-based signatures evaluated in this study. Circles
sizes represent the actual relative size of each signature. The 6 miRNA sig-
nature from Segura is shown in bold. b) Scatter plots of the union of all
miRNAs present in at least one of the signatures among the 4 validation
datasets. Expression values are the raw values of the miRNA expression
data in each dataset, transformed for ease of comparison (Table C.3). Col-
ours represent miRNAs common between signatures and the value of -2
was used to represent miRNAs that were not present in the raw data even
before any filtering was done.
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4.5 discussion and biological implications
In this chapter meta-analysis has been explored as a validation tool to evaluate the
performance of biomarkers in independent datasets. Through our comprehensive meta-
analysis procedure we have addressed many challenges associated with this form of
horizontal integration and highlighted the distinct advantages.
In our meta-analysis procedure we developed a pre-processing approach for miRNA
data prior to the data integration. This pre-processing step is imperative to ensure that
there is adequate signal in the data to proceed to any downstream analysis. The signal
in our miRNA data is much less than in the mRNA data, where approximately 50%
signal is found. Therefore, mRNA data analysis methods cannot be applied to miRNA
data directly. To address this issue of low signal, in our pre-processing pipeline we ap-
ply filtering on the data which is critical in enabling successful downstream analysis.
The cut-off we apply (7.5) is arbitrary and depends on the dataset. The structure of the
miRNA data shows that there is much variability between different probes within a
miRNA (Figure C.1). Therefore this variability is accounted for in our analysis using
a mixed effects model (Section 4.1). Currently there is no standard way of performing
normalisation in miRNA data, in contrast to the more established methods in mRNA
data. Our pre-processing pipeline addresses this dearth through a systematic com-
parison of normalisation methods to select the most appropriate method for miRNA
arrays, that leads to perform meta-analysis and obtain meaningful downstream inter-
pretations from the data.
The assessment of the signatures/biomarkers in multiple independent datasets as-
sures robustness in the validation of signatures, allowing for high confidence in the
error rate estimates along with their associated conclusions. This is one of the main
advantages of the meta-analysis performed in this chapter. Such confidence is imper-
ative in medical research, for the proposed and published biomarkers to be of value in
clinical practise. This meta-analysis is also advantageous in identifying inconsistencies
among multiple studies that use similar types of data of the same disease. For instance
in this chapter we used melanoma miRNA data, but the published and proposed sig-
natures from multiple studies did not contain common miRNAs across all signatures.
4.5 discussion and biological implications 88
The low amount of intersection among signatures highlights the inconsistencies among
studies that aim to address similar biological questions. Meta-analysis has been used
frequently in the literature to address such inconsistencies. Some examples are (Qu
et al., 2015; Wei et al., 2014; Wu et al., 2014; Zeng et al., 2014). Furthermore, meta-analysis
is beneficial in highlighting reproducible features across multiple datasets, that would
guide future research and extensive investigations on these features.
Despite the many merits of our meta-analysis we also encountered numerous chal-
lenges and in the following we address these.
One of the main challenges is the differences in the study aims and designs. This
resulted in not all of the miRNAs in the signatures being present in the other validation
datasets. Therefore, the signatures failed to be directly evaluated in other studies. In
these instances the analysis was performed with the available, albeit low number of
features.
To further investigate the possible reasons behind the absence of miRNAs across
datasets, we examined the raw expression data prior to the application of any data
pre-processing filters under each study (Figure 4.8, Appendix Table C.3). This was
to ascertain whether the missing miRNAs were either not detected, not measured or
below filtering thresholds of the pre-processing protocols. This investigation revealed
that a number of missing miRNAs were removed during filtering, while others were
not assayed or detected under each dataset. This detailed breakdown of the expression
information serves to illustrate that while certain miRNAs play a significant role in
their own training data, they might have relatively low impact in other validation
datasets (Figure 4.8b). It also highlights the not insubstantial challenge to validation
presented by among platform differences e.g.,more than half of the sequences captured
via the RNA-seq technology used in TCGA assays were not assessed in the previous
generation platform (Agilent’s Human miRNA Microarray system) used by Caramuta
and colleagues (Caramuta et al., 2010). More details are provided in Appendix C.
Another challenge encountered in our analysis was the heterogeneity of the patient
cohorts across multiple datasets. Because of the differences in the study cohorts, the
validation of signatures together with the signature survival classes, was restricted
(validation part 1). This is due to the untenable sample sizes that resulted after filter-
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ing the samples according to different survival endpoints of the studies. While our
validation proceeded where possible in this restricted setting (validation part 1), to
increase the sample size available for the analysis we instead used the survival end-
points associated with the validation expression dataset (validation part 2). Use of this
approach addressed the challenge in dealing with ineffectual sample sizes while the
prognostic utility of the signature was examined in relatable, although not identical,
survival classes.
In general, although all of the studies were on metastatic melanoma, many biological
differences in the study designs and cohorts were noticed. It could be due to this reason
that none of the biomarkers globally validated in all independent cohorts, and this
also might explain the reasons behind the absence of all miRNAs in each study. For
instance, the Mann study was smaller in terms of sample size (n = 45) when compared
with the Segura study (n = 59). The former was restricted to an analysis of AJCC
Stage III regional lymph node metastases while the latter included both Stage III and
Stage IV samples from among different tissue sites (brain, distant skin, local recurrence,
regional lymph node, visceral, and regional skin). The more restrictive approach used
in the Mann data sought to reduce the potential for confounding effects due to sample
heterogeneity.
In spite of these hurdles, our study revealed many biologically relevant implications.
We identified two new miRNA-based prognostic signatures. For compliance with the
REMARK criteria, we compared the performance of these signatures with the predict-
ive accuracy of standard-of-care clinico-pathologic markers (Balch et al., 2009). It is
interesting that the analysis of recently available data from TCGA did not produce a
signature of high accuracy, nor was that signature validated in the independent data.
Small sample size seems a probable explanation. It is also possible that cohort differ-
ences may have contributed to the result. For example, the survival data from TCGA
were less mature than the data from (Tembe et al., 2014), reflected in differences in the
overall distribution of survival times between them.
We undertook the first systematic meta-analysis of all tissue-based prognostic bio-
markers derived from studies of miRNA expression profiling in metastatic melanoma
reported in the literature so far. The comprehensive nature of our meta-analysis pro-
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cedure enabled the handling of the above discussed challenges while highlighting the
advantages. Therefore, the approach is also prospectively applicable to upcoming sig-
natures of interest and/or new potential validation datasets. Due to these reasons, this
analysis is of high significance in the field of melanoma. Accurate prognostic inform-
ation is essential for clinicians to be able to reliably stratify patients for a comparative
assessment of treatment therapies and to inform patients of their likely future clinical
outcome.
Despite the low intersection between the 5 signatures assessed in our study, the
intersection of 5 miRNAs in Segura and Mann (miR-142-5p, miR-150-5p, miR-342-3p,
miR-155-5p and miR-146b-5p) is encouraging from a reproducibility perspective. These
same miRNAs being observed in independent expression profiling experiments will
direct future research, suggesting that they should be immediately prioritised for fur-
ther biomarker validation and functional analyses. Ongoing issues in the dearth of
independent cohorts available for testing and validation of prognostic biomarkers, of-
ten hinders a meta-analysis. High quality validation data with reduced heterogeneity
is urgently required to validate the prognostic biomarkers to be of clinical use.
Conclusion
In conclusion, our research revealed that the two signatures from (Segura et al., 2010)
and the 12-miRNA signature from the Mann dataset could indeed be validated in inde-
pendent data. Moreover, our comparison of signatures with equivalent random gene
sets showed that not all evaluations produced the expected random set error rate of
50%. In the case of the Segura expression data, where random sets of miRNAs achieved
error rates of 40%, cohort heterogeneity (a mixture of patient with Stage III and IV dis-
ease as well as several tissue types) may have been responsible. Also of note, the large
range of improvement scores observed using the biomarker from Caramuta and col-
leagues (Caramuta et al., 2010), as assessed in its own data, shows that while for some
random sets the signature performance is significantly better, random gene sets with
predictive power similar to the signature itself could be found. Our meta-analysis pro-
cedure, which involves several approaches to validation, offers solutions to the critical
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limitations of this integrative analysis, and highlights the potential translational value
in the biomarkers assessed while guiding future research directions.
5
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In this chapter we examine methods in integrating data vertically and develop integ-
ration frameworks to effectively incorporate information from multiple data sources
(platforms) for the same patient. In contrast to horizontal data integration (Chapter 4),
the focus of vertical data integration is on integrating multiple datasets from different
platforms such as clinical data and multiple high-throughput (omics) data. In a medical
context, it has been observed in many critical diseases that the patients with the same
morphology have significantly different survival outcome (Schramm, 2014). Therefore,
a single data source is unlikely to completely reflect the biology underlying a disease,
and might be limiting in distinguishing patients with different outcomes (Jayawardana
et al., 2015a; Kim et al., 2014; Chin and Gray, 2008; Hanash, 2004). Specifically in cancer,
explaining cancer clinical outcomes remains challenging because of the complexity in
the cancer genome (Kim et al., 2014). Analysis at multiple levels of the biological system
remains a necessity to fully elucidate tumour behaviour (Hanash, 2004). Vertical data
integration has been motivated by these observations and expectations on the inde-
pendent or complementary information different data types may provide. It holds the
potential to significantly improve the prognosis of disease outcome with more insight
into a patient’s innate characteristics.
In the last decade, organised efforts have been made to generate a vast amount of
‘vertical data’; that is, data from multiple levels of the biological systems (Chapter 1)
obtained for the same sample, to facilitate the above investigations. With the advance-
ments of high-throughput data technologies, the generation of data from multiple plat-
forms has become quicker and cheaper (Grada and Weinbrecht, 2013; Metzker, 2010).
The large scale efforts by consortia such as TCGA1 made matched samples across dif-
ferent datasets publicly available. However, the development of improved statistical
methods and frameworks in this paradigm are required to close the gap between the
availability of a vast amount of data and the biological questions that need to be ad-
dressed. In this chapter, we aim to address and close this gap by developing statistical
frameworks with impact in the medical context.
In addition to the majority of the issues in horizontal data integration (Chapter 4)
such as those associated with individual platforms (data types), this chapter deals with
1 The cancer genome atlas (http://cancergenome.nih.gov).
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the new challenges that arise from vertically integrating data from distinct platforms
(different data types). One of the key challenges here is having more variables than
observations in the omics data, the large p small n problem, and therefore we have
to deal with a substantially increased number of variables in the integration. Further-
more, different platforms have significantly different number of variables, such as the
clinical data with p < n and omics data with p  n, causing an imbalance of variables
in the integration setting. Moreover, the mismatch of the samples between different
data types further reduces the effective sample size, which hinders the development
of statistical methods. The integration of different data types to determine which data
source contains more influential prognostic information and to investigate whether
data integration improves upon the current clinical standards, remains a challenge in
the presence of the above concerns. Despite the many issues, the potential advantages
of this class of data integration, such as the complementary information from differ-
ent data types, has inspired many researchers to further explore this area of research.
Furthermore, if the dominant prognostic variables could be identified from each data
type, the cost of data generation could be significantly reduced.
This chapter aims to address these challenges of vertical data integration and ex-
plores its advantages via the development of novel statistical frameworks in a predict-
ive setting. We exploit the availability of multiple data sources; clinical, pathological
and mutation information, mRNA, miRNA and protein information, on the same set
of patients from the Mann data (introduced in Chapter 2). The use of this motivating
dataset facilitates to assess the actual biological relevance of the methods developed.
This chapter begins with the individual platform analysis in Section 5.1, which is an
imperative step before proceeding to data integration. In Section 5.2, the principle of
pre-validation (Tibshirani and Efron, 2002) is extended to develop novel frameworks
in vertical data integration, incorporating the mBMI framework (developed in Chapter
3). Figure 5.1 summarises the data and the procedure followed in Sections 5.1 and 5.2.
In Section 5.3, platform dependent weights are constructed to develop a vertical data
integration framework, utilising the weighted Lasso (Bergersen et al., 2011). The cross-
validation (CV) procedures discussed in Chapter 2 are utilised to generate a novel
form of a visualisation technique, that can be used in the vertical data paradigm, in
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Section 5.4. This leads to the biologically-based discovery of the dominant sources of
prognostic information out of the multiple data sources at the sample level.
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Figure 5.1: Schematic of the data integration procedure using pre-validated vectors.
5.1 individual platform analysis
In this section, we model the different data types (platforms) individually to identify
the most accurate prognostic biomarker through each data platform. This would en-
able the comparison of data platforms and to evaluate whether a single platform was
capable of achieving the desired accuracy or whether the data integration undeniably
adds value. The analysis at individual platform level is also important in understand-
ing the noise level associated with each platform. The clinical, mRNA, protein and
miRNA data from the Mann dataset will be used in this chapter. The details of the
pre-processing steps followed are given in Section 2.1.1.
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5.1.1 Clinico-pathologic and mutation data modelling
The clinical data component of the Mann data comprises of clinical, pathological and
mutation variables. We used the mBMI framework developed in Chapter 3 to model
the clinical data; its modelling procedure is detailed in Section 3.2.1.
5.1.2 High-throughput data modelling
Data from each of the high-throughput (omics) data platforms were analysed using a
two-step procedure. In the first step the optimal number of features (genes, proteins,
miRNAs) is selected based on the CV error rate and then, a prognostic classifier is built
on the selected features. For this purpose, the CV procedure ‘B: Classifier CV’ outlined
in Section 2.3.2 was used. The specific choice of the parameters is detailed below.
Feature selection of high-throughput data
mRNA and miRNA data: The feature selection (devising molecular signatures) in mRNA
and miRNA data was performed using the ‘median robust’ method (Jayawardana et al.,
2015a; Campain, 2012). In the median robust method, the genes/miRNAs are ranked
based on the difference between the median expression of the two groups (PP and GP),
and a set of molecular signatures are devised such that the kth molecular signature
contained the k top-ranked features.
The final expression value for gene/miRNA q is
exprq = x˜q,GP - x˜q,PP,
where x˜q,GP and x˜q,PP represent the group median for the qth gene/miRNA for GP
and PP groups, for q = 1, 2, . . . ,p (p = 26085 in the mRNA data and p = 390 in the
miRNA data).
Protein data: A fixed effects model was used to select features. For each protein, pep-
tides with less than 24 missing values across samples (n = 33) were considered and a
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fixed effects model was applied with the group effect (whether each sample belongs
to group PP or GP) and peptide effect (which takes into account the fact that each
protein contains multiple peptides). The peptides were ranked based on the coefficient
estimates of the group effect from the fixed effects model. A set of molecular signatures
was devised such that the kth molecular signature contained the k top-ranked features.
For each molecular signature, the features (peptides) in that molecular signature were
filtered from the data set, adjusted for the sample means and aggregated on protein
level using the mean.
The final expression value for protein q is;
exprq = groupq = Estimated group effect q from the fixed effects model,
xqjk = groupq + peptidej + eqjk,
where groupq represents the effect of two groups GP and PP and peptidej represents
the peptide effect.
Classification methods
Prior to performing the actual analysis and obtaining final prediction error rates for the
high-throughput data, we compared a number of classification algorithms and the best
performing classification algorithm was chosen to conduct the final modelling. A brief
summary of the classification methods employed in this study is given in the following.
1. Diagonal Linear Discriminant Analysis (DLDA)
DLDA (Hastie et al., 2003) is commonly used in high dimensional data settings
and preferred over LDA (Linear Discriminant Analysis). It is preferred because
DLDA can have more variables (p) than samples (n). DLDA assumes that the
features are independent within each class, that is, the within-class covariance
matrices are diagonal, other than having a common covariance matrix across
classes as in LDA. New samples are classified to the class that gives the largest
value for the discriminant score. DLDA was implemented in this thesis using the
R package ‘supclust’ (Dettling and Maechler, 2011).
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2. Nearest Shrunken Centroids (NSC)
NSC (Tibshirani et al., 2002) identifies subsets of variables that best characterise
each class. This method computes a standardised centroid for each class, which
is the average expression for each variable divided by the within class standard
deviation for that variable and shrinks each of the class centroids towards the
overall centroid using soft thresholding. For a new sample, it takes the expression
profile and compares it to each of the shrunken class centroids, and classifies the
sample into the class whose centroid that it is closest to. The R package ‘pamr’
(Hastie et al., 2014) was used to implement NSC in this section.
3. k-Nearest Neighbours (KNN)
KNN (Ripley, 1996) identifies the k nearest neighbours or observations to a new
sample based on some distance measure (usually the Euclidean distance) and
classifies the new observation using the majority decision rule. In this section
results for k = 5 are shown, as results for k = 1 and k = 10 did not produce
greater accuracy. KNN was implemented using the R package ‘class’ (Venables
and Ripley, 2002) in this section.
4. Support Vector Machine (SVM)
SVMs were originally developed by (Cortes and Vapnik, 1995) for binary clas-
sification. SVM aims to find the optimal separating hyper-plane between two
classes by maximising the margin between the closest points of the classes. The
points on the boundaries are called support vectors. When a linear separator can-
not be found, the data are projected to a higher dimensional space via kernel
techniques, where the data becomes linearly separable. This whole task involves
solving a quadratic optimisation problem. The results using the linear kernel are
shown in this section. Other kernels have also been used and are not detailed
here as they did not produce greater accuracy. SVM was implemented using the
R package ‘e1071’ (Meyer et al., 2014) here.
Results: Comparison of classification methods on high-throughput data. The above
mentioned classification methods were employed in building a classifier and these
classifiers were then compared in a single run of the CV process to select the best
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performing classifier that gives the minimum CV error rate for each data type. Figure
5.2 illustrates this comparison of different classification methods for the three high-
throughput data platforms. As shown, there were no significant differences between
the four classification methods over the range of molecular signatures in each data
type. Through this comparison, the following classification methods were chosen as
the best performing classification methods:
• mRNA data: SVM
• protein data: NSC
• miRNA data: NSC
5.2 integrative prognostic modelling using pre-validated vectors
‘Pre-validation’ was initially developed in (Tibshirani and Efron, 2002), with the aim
of constructing a less biased microarray predictor to be modelled alongside the clin-
ical variables. Many applications and extensions of pre-validation are available in the
literature. For example, (Boulesteix et al., 2008) assessed the additional significance
of microarray data compared to clinical data in breast cancer and colorectal cancer
data, (Segura et al., 2010) compared the prediction accuracy of a miRNA signature for
melanoma patients to that of other predictors on clinical and demographic variables
and (van Vliet et al., 2012) compared three different integration strategies (early, inter-
mediate, and late integration) on breast cancer data containing gene expression data
and clinical parameters.
This chapter makes use of the principle of pre-validation, where a molecular signa-
ture from each omics data platform is used to obtain a single variable (the pre-validated
vector) which is modelled in combination with one another and also with the clinical
variables.
The pre-validation procedure of (Tibshirani and Efron, 2002) is detailed as follows
and it is graphically represented in Figure 5.3.
1. Divide the samples into k equal parts.
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Figure 5.2: Comparison of classification methods in high-throughput data. The x-axis
represents the number of features in the molecular signature, and the y-
axis represents the 5-fold CV error rate. a) Comparison for mRNA data. b)
Comparison for protein data. c) Comparison for miRNA data.
2. Set aside one part as the test set component.
3. A molecular signature (set of features) is obtained using the other k - 1 parts
(learning set) and a classifier is trained on the learning set on the molecular
signature.
4. Use this classifier to predict the survival class of the kth part.
5. Repeat steps 2-4 for all k parts, resulting in a pre-validated vector of estimates
for the omics data. This pre-validated vector (denoted as APV ) is a complete
prediction vector with one prediction for each sample.
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6. This pre-validated vector is used together with other types of variables (e.g., clin-
ical variables) in a logistic regression model to get the final prediction error rate.
When an independent data set is available, pre-validation is not a substitute. If k = n
this would result in a highly variable LOOCV pre-validation vector (Tibshirani and
Efron, 2002).
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Figure 5.3: The pre-validation procedure. The graph illustrates the pre-validation pro-
cedure in Tibshirani and Efron (Tibshirani and Efron, 2002).
In the integrative analysis, when the p clinical variables are integrated with the pre-
validated vector from the omics data (APV ), a logistic regression model can be de-
veloped as follows:
logit(⇡j) =  0 + 1x1,j + 2x2,j + . . .+ pxp,j + p+1APVj
Where ⇡j is the probability of an ‘event’ occurring (⇡j = P(Yj = 1)),  q is the coef-
ficient for the qth variable (q = 0, 1, . . . ,p + 1) in the regression, and xq,j is the jth
sample’s observation for the qth clinical variable. The pre-validation procedure could
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be easily adapted to include multiple pre-validated vectors (e.g. A1,PV ,A2,PV ). In the
integrative settings, this pre-validated vector is treated as a complete variable and can
be coupled with the m imputed clinical data sets as an additional variable for model-
ling purposes leading to m regression models. These models can then be aggregated
using an inclusion frequency (as explained in Chapter 3). Hence this procedure allows
the production of an integrated regression model making use of the pre-validated high-
throughput data vector and the clinical variables.
5.2.1 Data integration framework
To identify the principal sources of prognostic information from among the different
data types - clinical, pathologic, mutation, gene, protein and miRNA information -
we performed an integrative analysis under two settings. Both settings involved the
principle of pre-validation (Tibshirani and Efron, 2002). The two integrative prognostic
modelling procedures developed are detailed below.
• Setting 1: With variable selection (mBMI)
The mBMI method (Chapter 3) was used, where all of the clinical variables
(p = 21) and pre-validated vectors from the high-hroughput data sources were
used as initial variables. The pre-validated vector for each of the omics data
types used was the one that gave the lowest prediction error rate out of the
100 that were obtained in high-throughput data modelling as described above.
The mBMI procedure selected from among these variables (clinical variables and
pre-validated vector/s) to generate a final model focussing on the prognostic
capability of the selected group of variables.
• Setting 2: Without variable selection
Top-performing clinical variables (from Chapter 3, Section 3.2.1) were modelled
together with the pre-validated vectors from the various high-throughput data
types in a logistic regression model. The prognostic capability of these models
was then assessed using 5-fold CV error rates.
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Results: In these integrative settings, the patients were matched across datasets ac-
cording to their identification numbers. The highest number of possible samples were
considered in each integration. To account for the variability, the analysis was repeated
100 times and the mean error rates are reported in Table 5.1. Overall, the data type
associated with the lowest mean CV error rate was the mRNA data (25%). The other
omics data (protein and miRNA) did not show any improvement over the clinical data
(mean error rates 35% and 37% respectively compared to 30% in the clinical data).
The integrative analysis aided in identifying dominant sources of prognostic inform-
ation that could allow for improvements to individualised risk assessment. In integra-
tion setting 1, the lowest error rate of 18% was reported for the combination of clinical
information with a gene expression pre-validated vector, showing that the integrated
platforms could perform better than individual platforms. Relative to this result, pro-
gnostic accuracy was reduced for combinations of protein and clinical information
(32%) as well as miRNA and clinical information (33%). Although the clinical data
alone performed better, this indicated an improvement over using protein and miRNA
data alone in prognosis. Integrating clinical data together with signatures from all three
high-throughput platforms produced an error rate of 29% (Table 5.1, Figure 5.4).
In integration setting 2, the mean 5-fold CV error rates for the multiple permutations
analysed were on average higher compared with those returned under integration
setting 1: clinical and mRNA data (26%), clinical and protein data (33%), clinical and
miRNA data (33%), and clinical data with signatures from all three platforms (33%)
(Table 5.1 and Figure 5.4).
5.2.2 Validation
The validation of the results from individual platform analysis and integrative analysis
consist of 2 components. Firstly to comply with the standards of biomarker validation,
the constructed models were compared with the current standard among the clinicians
for prognosis of Stage III melanoma patients. Due to the unavailability of a similar
independent dataset, the results were validated on the full cohort of the present dataset
itself, prior to any restrictive filtering of the samples. These are detailed below.
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Table 5.1: Five-fold cross-validation error rates for the final models. Error rates in predicting
patient outcome for each of the different data types analysed in this study, as well as
for various combinations thereof, with the model applied.
Mean 5-fold CV error rate Classification
method Details
1 clinical 30% mBMI with LR1
2 mRNA 25% SVM
3 protein 35% NSC
4 miRNA 37% NSC
Individual
platform
analysis
Integration
setting 1
(mBMI)
Integration
setting II
(without
selection)
5 clinical + mRNA 18% 26% Pre-validated LR1
6 clinical + protein 32% 33% Pre-validated LR1
7 clinical + miRNA 33% 33% Pre-validated LR1
8
clinical + mRNA
+ protein +
miRNA
29% 33% Pre-validated LR1
Integrative
analysis
1 LR: logistic regression
1. Comparison with the standard-of-care
To compare the prediction accuracy of the models constructed above with the
existing standard-of-care factors, the four most statistically significant clinico-
pathologic prognostic parameters in patients with Stage III melanomas (i.e., num-
ber of tumour-positive lymph nodes, tumour burden at the time of staging (micro-
scopic v. macroscopic), presence or absence of primary tumour ulceration, and
thickness of primary melanoma) were evaluated in relation to the GP and PP
classes of this study. A logistic regression model constructed using these 4 vari-
ables was used for this purpose and the prediction error rate was assessed by
5-fold CV error rate.
2. Survival analyses
Kaplan-Meier curves were constructed for the prognostic classifiers developed
under the various combinations of data types, based on observed survival times
(in years) and survival status (dead (event) or alive (censored)) using the R pack-
age ‘KMsurv’ (Klein et al., 2012). Because of the limited availability of similar
independent data, the full Stage III cohort (n = 84) from the Mann data was
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Figure 5.4: Prediction error rates for the prognostic models considered in this ana-
lysis. 5-fold CV error rates for the different data types, individually and in
combination with each other, when modelled under two different integra-
tion settings: i.e. with and without variable selection.
used without the samples for which data were unavailable. e.g., for the model
combining clinical and mRNA information, Kaplan-Meier curves were construc-
ted for the subset of patients (n = 79) for whom clinical and mRNA data were
available. A log-rank test was used to examine whether there were significant
(p- value < 0.05) differences between groups (GP and PP) being compared.
Results: The prognostic models built in this study were more accurate than the
existing standard-of-care. This is illustrated by the mean 5-fold CV error rate of
52% via a logistic regression model built on these 4 variables, compared to the
error rates from all the other models (Table 5.1).
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The lowest prediction error (18%) was observed when the clinical and mRNA
data were integrated under integration setting 1 (Section 5.2.1). This resulted
in an improvement over the individual platform modelling of both clinical and
mRNA data. Therefore, the KM curves were constructed for the clinical, mRNA
and the integrated clinical and mRNA classifiers. Figure 5.5 illustrates the KM
curves for these data using all patients in the AJCC Stage III cohort for whom
data were available (n = 79, Figure 5.5A) and for the independent subset of
these patients (n = 32, Figure 5.5B). All Kaplan-Meier plots generated using the
79 AJCC Stage III patient data displayed significant among-group differences
(p- value < 0.001), except for the standard-of-care variables (p- value = 0.157).
Notably, the p-value for the combined clinical and mRNA classifier was much
lower (6.95 ⇥ 10-13) than the p-value from clinical individually (2.43 ⇥ 10-4).
Significance was not retained for the independent subset of 32 patients. However,
the p-value (0.08) for the integrated clinical and mRNA classifier was noticeably
lower than the p-values observed for the two data types evaluated individually,
as well as for the standard-of-care classifier (0.55, 0.38 and 0.16, respectively).
5.3 integration via platform dependent weights
In vertical data integration it is crucial that equal credence is given to all data sources,
such that the modelling procedure is not dominated by the platform size. An important
procedure that we can adapt in this context of vertical data integration is the use of
platform dependent weights to guide the variable selection in a data platform. We
can use one platform (data type) to derive weights, exploiting a particular relationship
with the other data platform, thereby assuring that the final variables selected are
indicative of both data types. This intuitive method of integration avoids the extreme
variable reduction in one platform (for example the pre-validation approach) and also
the risk of one data platform being completely dominated by the other (for example
direct integration of two data types). Rather, the information from multiple data types
is utilised effectively, that is flexible upon the biological context where we perform the
data integration.
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Figure 5.5: Kaplan-Meier curves of the different classifiers. Kaplan-Meier curves
were constructed for good prognosis (GP) and poor prognosis (PP) patient
groups based on predictions using: 1) Standard-of-care variables; 2) Clinical
information; 3) MRNA-based molecular signature; and, 4) The integrated
classifier comprising clinical data and a pre-validated mRNA classifier. The
top panel a) includes all 79 AJCC Stage III patient samples in the cohort,
while the bottom panel b) includes only the subset of the cohort not used to
construct the classifier (i.e., independent subset of samples). P-values reflect
the log-rank test.
This approach is based on the adaptive Lasso proposed by (Zou, 2006), where the
authors proposed the use of weights to guide the variable selection in a standard Lasso
(Tibshirani, 1996) procedure. (Bergersen et al., 2011) adapted this procedure to be used
in a vertical data integration framework, where additional data enters the model in-
directly by acting on the penalty parameter of each variable. This approach naturally
assumes there exists a primary platform and this notion is consistent with many can-
cer prognosis studies (Segura et al., 2010; Bogunovic et al., 2009). The weighted Lasso
approach thus avoids a further increase in the number of variables and holds the prom-
ise to be an innovative method in integrating omics data, as it allows data dependent
weights to be chosen. To date, a number of methods used variations of the weighted
Lasso to introduce variable specific penalisation. This includes (Shimamura et al., 2007)
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in graphical Gaussian models, (Charbonnier et al., 2010) in time course expression data
and (Garcia et al., 2013) in structured variable selection.
In the following, we provide a background on the weighted Lasso procedure, and
detail the data integration framework we develop adapting the weighted Lasso.
5.3.1 The weighted Lasso
In high dimensional omics data settings where there are more variables than samples,
many of the standard statistical methods fail to work. Lasso (Tibshirani, 1996) based
methods became widely used, because they allowed variable selection using fast al-
gorithms in a high dimensional setting. The weighted Lasso is one variation of the
Lasso, where data dependent weights are used in the penalisation such that the pen-
alty parameter varies for each covariate/variable. Suppose y is the response vector,
X = [x1, x2, . . . , xp] is the predictor matrix,   = ( 1, 2, . . . , p) is the parameter vec-
tor,   is a regularisation parameter and wq are data specific weights. The objective
function to be minimised is:
ky-X k2 +  Ppq=1wq| q|.
The weighted Lasso is a generalised version of the standard Lasso (wq = 18q). The
adaptive Lasso (Zou, 2006) is a special case of the weighted Lasso, where the weights
wq =
1
| ˆq|
; and  ˆq,q = 1, 2, . . . ,p are the ordinary least squares estimates after regress-
ing y on X. The R package ‘glmnet’ (Friedman et al., 2010) facilitates the use of variable
specific weights in the Lasso selection.
The use of extra knowledge in inference has been prevalent in the field. Grouping
of the genes in Group Lasso (Yuan and Lin, 2006) and prior structural information on
genes in the Elastic Net Procedure (Slawski et al., 2010) are some examples. Further-
more, recent studies show that more stable results can be generated for the Lasso, when
weights based on relevant external information or prior knowledge of the variables are
used in the penalty parameter (Bergersen et al., 2011; Charbonnier et al., 2010).
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5.3.2 Data integration framework
The data integration framework we develop in this section facilitates the use of mul-
tiple data sources available for the same set of samples, so that the features selected
are more relevant and informative in the prediction of the outcome. We do this by con-
structing weights from one data platform, using the association between the two data
platforms considered. The information across various platforms then enters the model
indirectly as weights, to guide the feature selection procedure of another platform. The
integration framework developed here addresses the omnipresent challenge in the ver-
tical integration setting of more variables than samples (p  n), by avoiding a further
increase in the number of features.
Our data integration framework emulates the CV procedure ‘A: Full CV’, where in
step 2, the weighted Lasso described above (Section 5.3.1) will be used as the feature
selection procedure. To illustrate the framework developed herein, mRNA, protein and
miRNA data from the Mann data (Chapter 2) will be utilised. Furthermore, the mRNA
dataset will be considered as the primary platform as it was observed that gene ex-
pression data have the best prognostic information (Section 5.1). The information from
other datasets will be integrated via weights.
The integration methods compared are:
• Lasso (no weights, feature (gene) selection using only mRNA data)
• WL_GP (weighted Lasso gene selection using weights based on protein data;
integration of mRNA data and protein data).
• WL_GM (weighted Lasso gene selection using weights based on miRNA data;
integration of mRNA data and miRNA data).
• WL_GPM (weighted Lasso gene selection using weights based on protein and
miRNA data; integration of mRNA data, protein and miRNA data).
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5.3.3 Correlation based weights
In the integration framework the weighted Lasso is used to select genes that contain
the information from protein and miRNA data. We investigated the effect of using the
inverse correlation of mRNA data with other data types as weights. The use of this
weighting scheme was associated with the assumption that, genes highly correlated
with selected proteins/miRNAs are more likely to be associated with patient survival.
Therefore, such genes were given less weight to have a higher chance of being selected.
For the integration of two data types (i.e., WL_GP and WL_GM explained above), we
use weights wq, where
wq =
1
⇢q
,
⇢q = median(|cors(Gq,X1)|, |cors(Gq,X2)|, . . . , |cors(Gq,Xp)|).
The ⇢q is the median across absolute values of the Spearman correlation coefficients
(cors) for qth gene (Gq) and the p proteins/miRNAs (X1,X2, . . . ,Xp) (Jayawardana
et al., 2013). Similar correlation based weights have been used by (Bergersen et al.,
2011), where they used the Spearman correlation coefficient to construct weights in
integrating gene expression and copy number data.
We construct a composite weight for the integration of all three omics platforms (WL_GPM),
wq =
1
⇢q
,
⇢q = max (⇢q(GP), ⇢q(GM)),
where ⇢q(GP) and ⇢q(GM) are the median correlation measures obtained as described
above for each gene based on protein and miRNA information respectively. It is con-
jectured that the genes whose expression values are highly correlated with at least one
of the other two platforms are more likely to better explain the outcome.
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5.3.4 Comparison study
Prior to performing the integrative analysis, firstly the three data types were used to in-
vestigate the different parameters that could be optimised within our data integration
framework. The main criterion of evaluation used in this comparison was the CV error
rate produced via the 5-fold CV procedure. The following aspects in the CV procedure
(‘Full CV’) were investigated:
1. The set of variables to be considered
Lasso feature selection facilitates the feature selection in high-throughput data
settings where there are more variables than samples (p   n). Therefore, Lasso
based methods can be used to select features in the mRNA expression data that
has thousands of variables. However, the number of features that is selected will
be approximately 0.2% of the initial number of features (p = 26085 and n = 47
in mRNA dataset). Hence a high degree of variability will likely be observed in
the feature selection. Therefore, in this comparison study different combinations
of variables were considered for the prediction accuracy.
• 1: Using the full set of genes.
The complete set of genes (p = 26085 in mRNA data and p = 200 in pro-
tein/miRNA data) were used in the analysis.
• 2: Using subset of genes.
A subset of genes (p = 200 in mRNA data and p = 200 in protein/miRNA
data) were used in the analysis.
In both cases, subsets (p = 200) of the secondary data platform variables (pro-
tein and miRNA data) were used to ensure that the external information used as
weights to aid in gene selection are indeed ‘relevant external information’.
Subset selection:
The selection of subsets was based on the differentially expressed (DE) features.
The features were ranked according to their adjusted p-value in a DE analysis for
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the separation of two outcome groups, GP and PP, and the top 200 features were
selected. The DE analysis was carried out using the R package ‘limma’ (Smyth,
2005) where a linear model was used to identify DE features between the two
groups. The expression of feature q could be modelled as;
yq = X q + ✏,
where yq is the vector of expression values for feature q, X is the design mat-
rix,  q is a vector of coefficients which included estimable parameters for the
intercept (↵) and the group effect ( ) at two levels with 1 indicating a patient in
GP group and 0 indicating a patient in PP group for our data. ✏ is the vector of
normal errors. In the context of the Mann mRNA dataset this linear model can
be presented as 0BBBBBBB@
y1
y2
...
y47
1CCCCCCCA =
0BBBBBBB@
1 1
1 0
...
...
1 1
1CCCCCCCA
0B@↵
 
1CA+ ✏
2. Different classification algorithms
Once the optimum number of features is determined, a classifier is built on the
selected optimal features. The classifiers compared in this study were: logistic
regression, SVM (support vector machine), diagonal linear discriminant analysis
(DLDA), nearest shrunken centroids (NSC) and k-nearest neighbour (KNN) with
k = 1, 5, 10.
3. Selection criteria of the penalty parameter
In the internal CV loop where the optimum number of features is determined,
a criterion should be utilised to compare the performance of different sets of
features selected by the weighted Lasso. The criteria compared in this study were
misclassification error rate (CV error), AIC (Akaike, 1974) and BIC (Schwarz,
1978).
4. Relative strength of weights
The anti-correlation based weights (weights have an inverse relationship with
correlation measures, such that when the correlation value is high the weights
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tend to be low) utilised in this study were further investigated. The purpose here
was to compare whether the strength of the weights to the penalty parameter
( q = wq⇥  ) in the weighted Lasso feature selection, has any impact on the pre-
diction error rates the models produced. The following functions of correlation
coefficients were compared.
a) Inverse correlation: wq = 1⇢q
b) wq = 11+⇢q
c) wq = 11+p⇢q
d) wq = 11+⇢2q
e) wq = 1- ⇢q
5. Different forms of penalties
Since the introduction of Lasso feature selection, there have been many devel-
opments associated with the penalty function used. Elastic net (Zou and Hastie,
2005) is one such penalty, given by,
(1-↵)/2|| ||22 +↵|| ||1.
Elastic net is known to be particularly useful in p  n situation, or when there are
correlated predictor variables. It is a combination between the Ridge regression
penalty (when ↵ = 0) and the Lasso penalty (when ↵ = 1) (Friedman et al., 2010).
More details are given in Section 3.2.2. In this comparison study, we compared
the effect of different penalty functions on the CV error rate.
Results: It was not feasible to compare all parameters simultaneously, because of the
higher computational time involved due to the high number of combinations. There-
fore, in our comparison study the parameters were selected in a forward manner,
where in each stage a certain parameter was compared while the others remained
fixed. The results are presented here for the integration of mRNA (gene expression)
and protein data (WL_GP integration method). Similar results were obtained for the
other integration methods as well.
1. The comparison of two feature combinations using full set of genes and the sub-
set of genes (comparison 1) suggested that combination 2 with subsets of both
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types of variables performs better in terms of the prediction accuracy (Figure 5.6).
Furthermore, DLDA classifier (comparison 2) performed best (Figure 5.6). These
observations held consistently for all integration set-ups.
glm sv
m
dld
a
ns
c
kn
n.
1
kn
n.
5
kn
n.
10 glm sv
m
dld
a
ns
c
kn
n.
1
kn
n.
5
kn
n.
10
0.10
0.15
0.20
0.25
0.30
0.35
0.40
WL FS_comparison of classification methods_GP
The methods
5−
fo
ld 
CV
 e
rro
r
combination 1 combination 2
Figure 5.6: Comparison of the feature combinations using different classification
methods. The prediction errors for the weighted Lasso gene selection in
the integration of mRNA and protein data.
2. In the internal loop of the CV procedure (‘Final CV’; Chapter 2), CV error, BIC
and AIC were used as the selection criteria of the penalty parameter ( ) to de-
termine the optimum number of features (comparison 3). AIC and CV (the mis-
classification error rate) performed similarly and both produced better prediction
accuracy than BIC (Figure 5.7). Hence, CV was selected.
3. The comparison of different anti-correlation based weights (comparison 4) rendered
that inverse correlation performed better, while the other weights showed much
similar predictive performance (Figure 5.8).
4. The comparison between the Lasso and the Elastic net penalties (comparison 5)
gave similar mean error rates and so the Lasso penalty was used for subsequent
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Figure 5.7: Comparison of different model selection criteria. Misclassification error
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Figure 5.8: Comparison of different forms of anti-correlation based weights. The
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,
e: wq = 1- ⇢q.
analysis.
Selected parameters: The parameters chosen to be used in the subsequent analysis were:
• Feature combination: Use subsets of variables (combination 2).
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• Classification algorithm: DLDA classifier.
• Selection of optimal lambda/penalty parameter: Misclassification error rate (CV).
• Weights: Inverse correlation.
• Penalty in feature selection: Lasso.
5.3.5 Performance evaluation
We assessed the performance of our data integration framework to evaluate the efficacy
of vertical data integration. The parameters selected in the comparison study (Section
5.3.4) was used in the CV procedure.
1. Prognostic capability
It is of interest to see whether the incorporation of weights in the Lasso variable
selection improves the prediction error rate, when compared to the standard
Lasso.
We observed that the prediction accuracy improved (lower 5-fold CV error) in all
3 integration settings (Figure 5.9). The lowest error rate was achieved when all
3 data platforms were integrated (mean 5-fold CV error rate of 17%), indicating
that data integration helps in this setting.
2. Stability of the features
To assess the stability of feature selection, the variables included in majority
(more than 50%) of the models were considered.
All 4 settings being compared consisted of 10 genes each, that had an inclusion
frequency of 50%. However, the inclusion frequencies were slightly higher in all
3 integration set-ups when compared with the Lasso (Figure 5.10). That is, there
were higher number of genes with inclusion frequency in the range 80-100%
when the data were integrated.
3. Biological validation
The melanoma gene cards (Rappaport et al., 2013) consist of scores for genes
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Figure 5.9: Comparison of the Lasso with the weighted Lasso. The evaluation of pre-
diction performance when weights based on relevant external information
(protein and miRNA data) are used to guide the variable selection. Here,
the 3 data integration set-ups are compared with no integration (‘Lasso’)
setting.
known to be related with melanoma progression (from literature and other stud-
ies). Therefore, these scores can be used to assess the biological relevance of the
features selected as the more biologically relevant features will achieve a higher
gene card score. These scores were downloaded from (http://www.malacards.org)
and the cumulative scores for each of the 4 gene lists were calculated. The cumu-
lative scores were used to assess the biological relevance of the genes selected
via the Lasso (no integration, only using mRNA data) and the integration set-
ups (WL_GP, WL_GM and WL_GPM). For this evaluation, we ranked the genes
selected under each setting based on their inclusion frequency. The gene with
the highest inclusion frequency was ranked first, and the cumulative gene card
scores at different top number of genes were compared.
We observed that the cumulative score was higher for the 3 integration set-ups
a majority of the time, when compared with no integration (Figure 5.11). The
WL_GP, where mRNA and protein data were integrated, performed best and
achieved higher scores than the Lasso throughout the entire range of gene sets.
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Figure 5.10: Heatmap of inclusion frequencies. The inclusion frequencies of the genes
selected from the 4 set-ups compared. Each gene list consisted of genes
included in more than 50% of the models under each set-up, and the union
of genes from all 4 lists are presented.
This indicated that the genes selected under data integration produced more bio-
logically relevant feature lists.
5.3.6 Network based weights for data integration
The weighted Lasso can be used innovatively in vertical data integration, as any mean-
ingful weight from other data platforms could be adopted into this setting. Intuitive
weights could be applied here from the background knowledge about the data being
integrated or by consultation with biologists and clinicians proficient in the relevant
field.
In this thesis, the main form of weight considered was the inverse correlation, where
it was assumed that genes that are highly correlated with DE proteins/miRNAs are
more likely to be relevant in survival outcome prediction. Hence such genes were
given less weight. We also considered other forms of weights after discussion with the
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Figure 5.11: The melanoma gene card scores.The genes included in atleast one model
(inclusion frequency> 0%) was ranked according to their inclusion fre-
quencies and the gene card scores were considered at different top number
of genes.
biological collaborators. One such weight was the protein expression network based
weights, and the results are presented in this section.
The protein expression network was obtained (Barter et al., 2014) from the inverse
covariance matrix of the protein dataset (using R package ‘QUIC’ (Hsieh et al., 2011)). If
there exists an edge between two proteins in the network, the inverse covariance matrix
has a non zero entry. The degree (dq) of a protein could be defined as the number of
edges a protein has in the network. The proteins could be mapped to genes and hence
a weight could be obtained for each gene.
The weights considered in this section were:
1. wq = dq
2. wq = 1dq
These two weights were computed using all of the proteins in the network (weights
a and b), and using the subset of proteins with at least five edges (weights c and d).
5.4 visualisation of sample level prognostic accuracy 120
We observed (Figure 5.12) that when mRNA and protein data are integrated via weights
based on protein data (from protein expression network), the weight a produced much
lower prediction error rate than when no weights are employed in gene selection. How-
ever, the other weights did not produce better accuracy compared to the no integration
setting.
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Figure 5.12: Protein expression network based weights. The 5-fold CV error rates
when four different weights utilising protein-based information from pro-
tein expression networks are utilised, when compared with the no integ-
ration setting. Error rates are given when all proteins were considered
(weights a and b) and a filtered subset of proteins (with no. of edges > 5)
were considered (weights c and d).
5.4 visualisation of sample level prognostic accuracy
In recent years, increasing attention has been drawn to personalised medicine (Scolyer
and Thompson, 2013; Yu et al., 2013; Sewell et al., 2012; John et al., 2008), where it was
identified that treatments should be allocated with care to individual patients because
of the heterogeneity of sample cohorts. Therefore, it is imperative that the prognostic
capability of clinical and high-throughput data are evaluated at the patient level. To
address this, we investigated the patient level accuracies of the prognostic models
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developed, to obtain a visualisation technique for identifying such heterogeneous sub-
groups of patients. Such a visualisation technique would enable the identification of
most dominant sources of prognostic information for patient subgroups. Our CV pro-
tocol facilitated the evaluation of variability associated with the prediction each sample
(patient) achieved, because it involved 100 runs of the 5-fold CV.
In the following graphical output of the sample level accuracy, the survival out-
come of the patients (GP vs. PP) is shown as a sidebar. Patients are represented in
the columns (tumour ID) and are ordered based on the overall extent to which they
are misclassified (most to least). The different prognostic models under which each
sample is classified are given in rows. The scale varies from 0 (all 100 runs of the
model misclassified this sample) to 100 (all 100 runs of the model correctly classified
this sample).
1. Sample plots for integration via pre-validation
The Sample plots (Figure 5.13 and Figure 5.14) highlighted informative patterns
of classification accuracy, where they illustrated the degree of concordance between
the different prognostic models for the samples common among data types. Fur-
thermore, the sample accuracy was compared with the AJCC standard-of-care
variables as well.
29% of the 24 samples common among all data types appeared more likely to
be classified correctly under integration setting 1 compared to integration set-
ting 2 (Figure 5.13). For other samples, the reverse was true. In addition, the
classification accuracy of one sample (ID: 343) was markedly improved in most
cases where both the protein information and clinical variables were present in
the model. In this instance, almost all other classifiers performed poorly (<25%
accuracy) (Figure 5.13).
In the 45 samples for which clinical, mRNA, and miRNA information were avail-
able, 15%were correctly classified in more than 75% of the runs within any model
(excluding the standard-of-care variables). There were no samples for which
miRNA information alone outperformed other data types or combinations. One
sample, ID: 350, for which there were no protein data available, was incorrectly
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classified more than 75% of the time irrespective of which data, or combination
thereof, were used. Specifically, this sample was rarely identified as being derived
from a patient with a good outcome (GP: survival > 4yr post resection of meta-
static disease with no sign of relapse) despite the patient follow up status being
alive with no sign of relapse at 2948 days (8+ years) post-surgical resection.
This investigation revealed valuable information, especially to clinicians, regard-
ing the differences in prognostic capability of various data sources at patient
level. It indicated that although some data sources such as protein data had poor
predictive performance overall, for certain groups of patients they contain import-
ant information that could assist in their individualised treatments. Hence, the
overall predictive capability does not always make the data sources redundant.
66 69 37 32 17
3
24
9 51 21
7 45 17
2 88 27
7
34
3 93 34
0
11
9
14
2
33
4 61 12
5
36
0 47 23
4
32
2
samples
Clinical+mRNA+protein
+microRNA(2)
Clinical+microRNA(2)
Clinical+protein(2)
Clinical+mRNA(2)
Clinical+mRNA+protein
+microRNA(1)
Clinical+microRNA(1)
Clinical+protein(1)
Clinical+mRNA(1)
microRNA
Protein
mRNA
Clinical
clinical_standard
Outcome_GP
Outcome_PP
Outcome_GP Outome_PP
66 69 37 32 17
3
24
9 51 21
7 45 17
2 88 27
7
34
3 93 34
0
11
9
14
2
33
4 61 12
5
36
0 47 23
4
32
2
samples
CPM+mRNA+protein+microRNA(2)
CPM+microRNA(2)
CPM+protein(2)
CPM+mRNA(2)
CPM+mRNA+protein+microRNA(1)
CPM+microRNA(1)
CPM+protein(1)
CPM+mRNA(1)
microRNA
Protein
mRNA
CPM
clinical_standard
Outcome = GP Outcome = PP
45 17
2 88 27
7
34
3 93 34
0
11
9
14
2
33
4 61 12
5
36
0 47 23
4
32
2
samples
CPM+mRNA+protein+microRNA(2)
CPM+microRNA(2)
CPM+protein(2)
CPM+mRNA(2)
CPM+mRNA+protein+microRNA(1)
CPM+microRNA(1)
CPM+protein(1)
CPM+mRNA(1)
microRNA
Protein
88 27
7
34
3 93 34
0
11
9
14
2
33
4 61 12
5
36
0 47 23
4
32
2
samples
CPM+mRNA+protein+microRNA(2)
CPM+microRNA(2)
CPM+protein(2)
CPM+mRNA(2)
CPM+mRNA+protein+microRNA(1)
CPM+microRNA(1)
CPM+protein(1)
CPM+mRNA(1)
microRNA
Protein
CPM+mRNA+protein+microRNA(2)
CPM+microRNA(2)
CPM+protein(2)
CPM+mRNA(2)
CPM+mRNA+protein+microRNA(1)
CPM+microRNA(1)
CPM+protein(1)
CPM+mRNA+protein+microRNA(2)
CPM+microRNA(2)
CPM+protein(2)
CPM+mRNA(2)
CPM+mRNA+protein+microRNA(1)
CPM+microRNA(1)
CPM+protein(1)
CPM+mRNA+protein+microRNA(2)
CPM+microRNA(2)
CPM+protein(2)
CPM+mRNA(2)
CPM+mRNA+protein+microRNA(1)
CPM+microRNA(1)
CPM+protein(1)
69 37 32 17
3
24
9 51 21
7 45 17
2 88 27
7
34
3 93 34
0
11
9
14
2
33
4 61 12
5
36
0 47 23
4
32
2
samples
CPM+mRNA+protein+microRNA(2)
CPM+microRNA(2)
CPM+protein(2)
CPM+mRNA(2)
CPM+mRNA+protein+microRNA(1)
CPM+microRNA(1)
CPM+protein(1)
CPM+mRNA(1)
microRNA
Protein
mRNA
CPM
clinical_standard
Outcome = GP Outcome = PP
88 27
7
34
3 93 34
0
11
9
14
2
33
4 61 12
5
36
0 47 23
4
32
2
34
3 93 34
0
11
9
14
2
33
4 61 12
5
36
0 47 23
4
32
2
samples
CPM+mRNA+protein+microRNA(2)
CPM+microRNA(2)
CPM+protein(2)
CPM+mRNA(2)
CPM+mRNA+protein+microRNA(1)
CPM+microRNA(1)
CPM+protein(1)
CPM+mRNA(1)
microRNA
Protein
CPM+mRNA+protein+ icroRNA(2)
CPM+microRNA(2)
CPM+protein(2)
CPM+mRNA(2)
CPM+mRNA+protein+ icroRNA(1)
CPM+microRNA(1)
CPM+protein(1)
r t i i r ( )
i r ( )
r t i ( )
( )
r t i i r ( )
i r ( )
r t i ( )
CPM+mRNA+protein+ icroRNA(2)
CPM+mRNA+protein+ icroRNA(1)
14
2
33
4 61 12
5
36
0 47 23
4
32
2
CPM+mRNA+protein+microRNA(2)
CPM+microRNA(2)
CPM+protein(2)
CPM+mRNA(2)
CPM+mRNA+protein+microRNA(1)
CPM+microRNA(1)
CPM+protein(1)
CPM+mRNA(1)
microRNA
Protein
mRNA
11
9
14
2
33
4 61 12
5
36
0 47 23
4
32
2
CPM+mRNA+protein+microRNA(2)
CPM+microRNA(2)
CPM+protein(2)
CPM+mRNA(2)
CPM+mRNA+protein+microRNA(1)
CPM+microRNA(1)
CPM+protein(1)
CPM+mRNA(1)
microRNA
Protein
mRNA
33
4 61 12
5
36
0 47 23
4
32
2
CPM+mRNA+protein+microRNA(2)
CPM+microRNA(2)
CPM+protein(2)
CPM+mRNA(2)
CPM+mRNA+protein+microRNA(1)
CPM+microRNA(1)
CPM+protein(1)
CPM+mRNA(1)
microRNA
Protein
mRNA
 0 25    50 75   100
Figure 5.13: Patterns of sample misclassification for 24 patients. Investigating
whether there was any consistency among the different prognostic models
with respect to the misclassification of the 24 samples common across all
platforms.
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Figure 5.14: Patterns of sample misclassification for 45 patients. Investigating for con-
sistencies among the different prognostic models generated for 45 samples
evaluated in all approaches excluding protein assays.
2. Sample plots for integration via the weighted Lasso
Similar to the sample plots for integration via pre-validation, here we considered
whether integration adds value in predicting the individual patients, who did not
achieve accurate predictions when only individual data sources were considered.
We observed that while for most patients the data platforms performed similarly,
there were some patients for whom the data integration improved the prediction
performance (Tumour IDs: 249, 217, 396, 61, 343, 36) (Figure 5.15). Therefore, this
is a clear indication that from the individual patient perspective, data integration
is useful.
3. Validation in independent data
This validation was performed to affirm the findings from the original study us-
ing the Mann data, that different platforms perform better for different subsets
of patients. Hence, the subset of samples from The Cancer Genome Atlas (TCGA)
with the necessary clinico-pathologic annotation (Section 2.2.3), was used to eval-
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Figure 5.15: Patterns of sample misclassification. The comparison of patient level pre-
diction accuracies for the Lasso (no integration) and the 3 integration set-
tings using the weighted Lasso.
uate the potential benefit of using multiple data sources rather than a single data
source for predicting the survival outcome of individual patients. Prognostic
modelling was performed as described in Section 5.1.2 (high-throughput data
modelling).
Principal observations are supported by validation in an independent cohort; see
Figure 5.16, which illustrates the degree of concordance between the different
prognostic models for the 27 samples evaluated. Consistent with the original
findings, both mRNA and miRNA data perform well for a subset of patients. For
other groups and/or individuals, mRNA is the more accurate prognostic indic-
ator compared to miRNA, and vice versa (Figure 5.16A). There are approximately
9 samples (33%) that fall off the diagonal, which further clarifies that for these
patients one data platform out-performed the other (Figure 5.16B). Although no
data integration was performed on this data, this observation further implicates
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the potential utility of multiple data platforms rather than one, when predicting
the survival outcome of individual patients.
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Figure 5.16: Patterns of sample misclassification among the different prognostic
models generated using TCGA data. a) the heat map of the values. Pa-
tients are represented in the columns and are ordered based on the overall
extent to which they are misclassified (least to most). b) the scatter plot
of the values. The scale varies from 0 (all 100 runs of the model misclassi-
fied this sample) to 100 (all 100 runs of the model correctly classified this
sample).
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5.5 discussion and biological implications
In this chapter we proposed vertical data integration frameworks, extending the prin-
ciple of pre-validation and the weighted Lasso. The proposed frameworks were de-
veloped using multiple sources of data on the same set of patients, to address the
clinically important question of predicting survival outcomes for patients with meta-
static melanoma. The frameworks produced results that highlighted the advantages of
using multiple data types, while dealing with the challenges encountered favourably
in real biological data.
The use of the principle of pre-validation in a data integration framework proved to
be an effective method, as it is capable of addressing the intrinsic structural disparity
of the different data types. It provides a successful way of handling a large number of
variables in high-throughput data sources, by reducing thousands of omics variables
to a single pre-validated vector. This is an extreme variable reduction, however, the
simplicity of the approach and the ease of its adaptability to use more than two data
types makes it an extremely important approach to be used in vertical data integration.
Our framework is capable of handling the integration of multiple omics data types
with clinical data, using two data integration settings (with and without variable se-
lection). Most studies in the literature used the pre-validation principle to integrate
two data sources only (Segura et al., 2010; Höfling and Tibshirani, 2008; Tibshirani and
Efron, 2002) and mostly to compare the prediction accuracy of data sources in separ-
ate settings (van Vliet et al., 2012; Bogunovic et al., 2009) rather than integrating the
information directly as in our framework. Our framework also allows to choose vari-
ables from among platforms inside the integration framework with the mBMI (setting
1). This provides a much more sensible way of variable selection from among clinical
and omics data, because the thousands of omics variables are now reduced to few
variables, and therefore are in a comparative scale with the clinical data.
Many other complex statistical methods are also available in the literature (discussed
in Chapter 1). However, it is of note that complex methods do not automatically yield
better results in real data (Campain, 2012; Dudoit et al., 2002).
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The results from our vertical data integration using pre-validated vectors have many
biological implications, in particular in the present context of metastatic melanoma.
In the modelling of high-throughput data, only the mRNA signature information out-
performed the more expansive model of clinical variables. This observation appears to
suggest that the most valuable prognostic information is contained within the mRNA
transcript component of the tumour. However, another explanation may be that inform-
ation can be extracted more easily via gene (mRNA) expression microarray platforms
than with the less well developed miRNA and proteome-based technologies. Ongo-
ing examinations of the contribution of miRNA and proteome-based work to improv-
ing biomarkers of prognosis in melanoma are essential work (explored in relation to
miRNA data in Chapter 4). Furthermore, the features identified were shown to be biolo-
gically relevant in (Jayawardana et al., 2015a). This integrated analysis of multiple data
types using the same tumour specimens (samples), is the first of its kind in melanoma
and among the earliest in any cancer (Jayawardana et al., 2015a).
One of the main challenges we faced in validating the framework in independent
biological data was the limited availability of high quality specimens with linked, well-
annotated clinical data. Therefore, we chose to use the extended cohort of the Mann
data to provide a comparable, although not completely independent, validation of the
framework. This dearth of independent validation data is an ongoing challenge in
many diseases (including cancers) and systematic efforts to meet this critical require-
ment are underway (Scolyer and Thompson, 2013).
The weighted Lasso approach also proved to be an effective method to be used in a
vertical data integration framework. The ability to integrate secondary data types via
weights provides an excellent opportunity to prevent a further increase in the number
of variables in an already large p small n paradigm. Furthermore, this method allows
to treat one platform as the primary platform and maintain a hierarchical structure in
the data integration process. Our framework assumed that mRNA data is the primary
platform and the protein and miRNA data were integrated indirectly via weights. The
data integration also relied on the assumption that the genes highly correlated with
the proteins and miRNAs are more likely to be relevant in survival outcome prediction,
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and were given less weight. The use of subsets of the secondary data platforms (protein
and miRNA) chosen from a DE analysis, aimed to ensure that the external information
we used were relevant in the prediction of outcome.
A particular advantage of the data integration using weights is that these weights can
be selected by incorporating prior knowledge from biologists. Our choice of correlation
based and network based weights was inspired by such discussions with the biologists,
and hence the results are more inclined to be biologically relevant.
Our framework using the platform dependent weights is flexible enough to integ-
rate clinical information or other variables. We propose a two stage feature selection
approach which focuses on an intermediate variable reduction, so that the mRNA data
and clinical data has an equal standing. In the first stage, we select the genes based on
protein and miRNA information using the proposed data integration framework (Sec-
tion 5.3.2) and in the second stage we integrate the selected genes and clinical variables
to find the final predictive model. More details are shown in (Jayawardana et al., 2013).
In all frameworks of this chapter, the variability associated with the final models was
considered. The mean error rates over 100 runs were used to indicate the prediction
error, instead of a single value for error that ignores the variability in real data. This
CV protocol also enabled us to propose a novel visualisation technique in Section 5.4,
to investigate the prediction accuracy at patient level. This graphical outcome is of
high significance in the recently emerging area of personalised medicine (Scolyer and
Thompson, 2013; Yu et al., 2013; Sewell et al., 2012), which allows to identify dominant
sources of prognostic information for heterogeneous subsets of patients.
Conclusion
In conclusion, all of the proposed data integration frameworks showed that vertical
data integration is beneficial, illustrated through the application in real biological data.
The use of the pre-validation principle in integration showed that the integration of
clinical and mRNA information held the most potential in assisting patient prognosis.
Our framework using the weighted Lasso also resulted in improved prediction error
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rate (17% compared to 24% in no integration setting), indicating the potential value of
the multi-layered omics data. Both frameworks exhibited biological relevance in terms
of the features selected using multi-platform data. Furthermore, the proposed graph-
ical visualisation tool of the patient level accuracies revealed the potential utility of
multiple data sets, rather than a single data source in predicting the survival outcome
of individual patients. Importantly, these observations were supported by validation in
an independent cohort of samples from TCGA. Our investigation at the patient level is
of high relevance in the medical context, as the identification of heterogeneous subsets
of patients and the data sources that are most relevant in predicting their outcome is
imperative in personalised medicine. This identification eventually aids in assigning
the patients to the most appropriate treatment option (John et al., 2008; van’t Veer and
Bernards, 2008).
6
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Developing statistical methodologies that are applicable in real life medical data is a
major challenge in statistical bioinformatics. The surge in the amount of publicly avail-
able high-throughput data has encouraged researchers to integrate these with in-house
experimental data in order to seek answers for a myriad of biological and medical ques-
tions. However, statistical research faces numerous challenges in the high-throughput
data setting, such as having large number of variables than samples, commonly re-
ferred to as large p small n problem, platform differences and inconsistencies among
studies. The development and validation of statistical methods addressing these chal-
lenges remains a necessity to bridge the gap between increased data availability and
possible elucidations to biological queries. This thesis contributed to the development
of such statistical methodologies and frameworks for real biological problems. We
achieved this purpose through detailed analysis at individual platform (data type)
level and through the integration of multiple datasets.
This thesis was motivated by the Mann data, which allowed us to exploit the avail-
ability of a detailed series of clinical data and omics data (mRNA, protein and miRNA
data) with matched samples in metastatic melanoma (Chapter 2). Through this data-
set and other external data of melanoma patients, we explored and extended methods
that have translational impact in melanoma research. Using real data allowed us to
observe and demonstrate the applicability and impact of the developed frameworks
in the medical context. More sophisticated statistical methodologies, although rich in
their theoretical formulation, may not perform well in real data. This observation, that
the complex methods may not necessarily out-perform simple methods in real data
analysis, has been previously perceived in bioinformatics (Dudoit et al., 2002).
The major contributions in this thesis could be broadly categorised into three dis-
tinct areas: the development of statistical methodologies and frameworks, (i) at the
individual platform level, (ii) for horizontal data integration and (iii) for vertical data
integration. In the following we provide further discussions on the chapters of this
thesis, highlighting the contributions and future directions.
One of the key challenges in developing a statistical method in medical research is
the evaluation of methods developed and the demonstration that they have biological
impact. While the datasets are increasingly becoming publicly accessible, the difficulty
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in finding high quality independent data that closely resemble the training data, hinder
such validation that will justify their applicability in a medical context. As a result, in
this thesis we used evaluation approaches based on cross-validation. In the literature
different forms of CV procedures have been used to evaluate the results in the absence
of independent data (Browne, 2000; Burman, 1989). These procedures concentrate on
different aspects of validation, such as the feature selection and/or classification, and
it is important that we use comparable CV approaches, when the aim is to compare
between methods. However, a comparison study is warranted to assess the advantages
and disadvantages. Therefore, in Chapter 2 we conducted a comparison study of the
many forms of CV used in this thesis.
The development of a framework to address missing data, model instability and
predictive capability of constructed models is an important concept in clinical data
analysis. The mBMI framework (Jayawardana et al., 2015a) proposed in Chapter 3 espe-
cially focuses on constructing a predictive model, while addressing the more common
problems of missing data and model instability via the utilisation of multiple imputa-
tion and the bootstrap. We showed that the novel framework proposed is an effective
method in dealing with these obstacles and demonstrated that it results in the best
predictive performance in real data. The simulation study in Chapter 3 exhibited the
parameters within our framework that could be further investigated and optimised.
A more detailed simulation study based on real data, that proved to be challenging,
is warranted for a clearer demonstration. Future work would involve such a simula-
tion study and also disseminating the R package for mBMI, that is currently under
construction.
The integration of information from multiple data sources long held the promise of
improved solutions to biological questions (Kim et al., 2014; Tseng et al., 2012; Hamid
et al., 2009; Hanash, 2004), however is often statistically challenging because of the
large number of variables and the incompatibilities between platforms. In Chapters
4 and 5, we investigated data integration, exploring and addressing the challenges
and highlighting the advantages in the horizontal and the vertical data integration
paradigm.
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In Chapter 4, we proposed a framework to integrate data of the same type in a ho-
rizontal data integration context. In the proposed framework, meta-analysis was used
as a validation tool to validate biomarkers in independent data. Our comprehensive
approach involved three main stages that are imperative in addressing the challenges
encountered and highlighting the importance of such an integrative analysis. Firstly,
careful pre-processing at individual platform level enabled to obtain the optimal sig-
nal, while minimising unwanted sources of variation. In the next step, we identified
novel biomarkers from two publicly available datasets, of which one performed better
than the existing standard-of-care variables. The pivotal step of meta-analysis exposed
the many inconsistencies among biomarkers that have been proposed to address sim-
ilar biological questions, while highlighting the potential translational value of the bio-
markers in melanoma research. Our meta-analysis procedure demonstrated the utility
of many external data sources pertaining to the same disease, in validating the existing
biomarkers to be of clinical use and in identifying a more robust set of biomarkers. The
analysis also pointed out future directions on the features where more extensive valid-
ations and investigations should be immediately prioritised in the field of melanoma.
This work is also presented in (Jayawardana et al., 2015b).
We extended the method of pre-validation and proposed a novel veritical data in-
tegration framework in Chapter 5. Through our analysis we demonstrated that the
use of multiple types of data, such as clinical and omics data, can be leveraged to im-
prove upon the prediction accuracy of disease prognosis and to identify among those
the dominant sources of prognostic information. Such discoveries hold the potential
in significantly reducing the cost of data generation and to enable the researchers to
focus more specifically on those identified sources. Furthermore, through the incorpor-
ation of platform specific weights we explored methods in data integration extending
the weighted Lasso. Our data integration, combined with the CV procedure we used,
enabled the visualisation of sample level prediction accuracy. Through this, we demon-
strated for the first time that there exist subsets of samples which could benefit from
more dynamic and complex translational models. This inspired the ongoing work by
colleagues (Patrick et al., 2015), to investigate a multi-stage classifier, where different
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combinations of samples benefit from a different data type. Some of the results from
this chapter have been published in (Jayawardana et al., 2015a).
In summary, despite the many challenges encountered, our proposed statistical pro-
cedures demonstrated their validity in real biological data and are able to deliver rev-
elations with translational impact.
A
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135
A.1 survival classes for tcga data 136
a.1 survival classes for tcga data
We considered different criteria to determine the survival groups (GP vs. PP) for the
TCGA cohort used in the analysis of Chapter 4 (introduced in Section 2.2.3: miRNA
data). The final selection was option 7 (12 in poor prognosis group and 11 in good
prognosis group). This selection was guided by the sample sizes in the two survival
groups and was made after discussions with biologists in Professor Mann’s group
(Table A.1).
Table A.1: The different samples sizes for various survival-based splits of the data from
TCGA – This table shows the different criteria considered prior to the final se-
lection of survival groups from data from TCGA. Option 7 was ultimately used
since it provided the best ‘trade-off’ between sample size (including between-class
sample size balance) and relatability to the good and poor prognosis classes of the
Mann miRNA data that was considered in Chapter 4. Abbreviations: ANSR, alive
no sign of relapse; DM, dead melanoma; FU, follow-up.
Poor prognosis group npp Good prognosis group npp
1 Survival time 6 1yr (DM) 8 Survival time > 2yrs (ANSR) 16
2 6 1yr (DM) 8 > 3yrs (ANSR) 11
3 61yr (DM) 8 > 4yrs (ANSR) 5
4 <2yrs (DM) 12 > 2yrs (ANSR) 16
5 <2yrs (Dead, any cause) 14 > 2yrs (Alive, any FU status) 18
6 <2yrs (DM) 12 > 2yrs (Alive) 18
7 <2yrs (DM) 12 > 3yrs (ANSR) 11
8 <2yrs (DM) 12 > 4yrs (ANSR) 5
9 <3yrs (DM) 14 > 4yrs (ANSR) 5
10 <4yrs (DM) 17 > 4yrs (ANSR) 5
a.2 comparison study of the cv procedures
a.2.1 Inclusion frequencies of variables
We considered the variables included at least once in the repeated runs of the CV
procedures. The variable inclusion frequencies of the procedures A–D showed a similar
pattern (Figure A.1) when considering the variables with inclusion frequencies > 0%.
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Figure A.1: Comparison of CV procedures: Gene inclusion frequencies
The ‘FinalCV’ procedure is not compared because the variables selected in each run
was fixed.
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b.1 additional figures from the simulation study
The CV error rates for all ⌧FM (final inclusion frequency threshold: 0.00, 0.05, 0.10, . . . ,
1.00) at each ⌧CV (prediction error threshold: 0.025, 0.05, 0.10, 0.20, . . . , 0.50) considered
are shown in Figure B.1. No clear identifiable pattern can be seen throughout the range
of considered ⌧CV .
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Figure B.1: Prediction error rates. The 5-fold CV error rates for the ⌧CV and ⌧FM (x-
axis) considered in this study.
To select the ⌧FM, the inclusion frequencies of variables for all ⌧CV are considered.
One instance was illustrated in Figure 3.3 in Chapter 3. The remaining instances are
illustrated in Figures B.2-B.7. The ⌧FM threshold was selected based on the separa-
tion between true variables and other variables from the inclusion frequency plots, as
follows:
• When ⌧CV = 0.05, ⌧FM = 0.75
• When ⌧CV = 0.10, ⌧FM = 0.80
• When ⌧CV = 0.20, ⌧FM = 0.85
• When ⌧CV = 0.30, ⌧FM = 0.90
• When ⌧CV = 0.40, ⌧FM = 0.90
• When ⌧CV = 0.50, ⌧FM = 0.90
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Figure B.2: Stability of the variables. The stability measures of the variables when
⌧CV = 0.05. The rows represent the variables and the columns represent
different ⌧FM values. The color indicates the stability, where darkness is
proportional to the inclusion frequency.
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Figure B.3: Stability of the variables. The stability measures of the variables when
⌧CV = 0.10. The rows represent the variables and the columns represent
different ⌧FM values. The color indicates the stability, where darkness is
proportional to the inclusion frequency.
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Figure B.4: Stability of the variables. The stability measures of the variables when
⌧CV = 0.20. The rows represent the variables and the columns represent
different ⌧FM values. The color indicates the stability, where darkness is
proportional to the inclusion frequency.
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Figure B.5: Stability of the variables. The stability measures of the variables when
⌧CV = 0.30. The rows represent the variables and the columns represent
different ⌧FM values. The color indicates the stability, where darkness is
proportional to the inclusion frequency.
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Figure B.6: Stability of the variables. The stability measures of the variables when
⌧CV = 0.40. The rows represent the variables and the columns represent
different ⌧FM values. The color indicates the stability, where darkness is
proportional to the inclusion frequency.
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Figure B.7: Stability of the variables. The stability measures of the variables when
⌧CV = 0.50. The rows represent the variables and the columns represent
different ⌧FM values. The color indicates the stability, where darkness is
proportional to the inclusion frequency.
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c.1 additional information for section 4 .1
c.1.1 Normalization methods: randomRUV
The following R code for randomRUV was used for normalising the Mann miRNA
data.
naiveRandRuv <- function(Y, cIdx, nuCoeff=1e-3, k=m){
## W is the square root of the empirical covariance on the control genes.
svdYc <- svd(Y[, cIdx])
W <- svdYc$u[, 1:k] %*% diag(svdYc$d[1:k])
## Regularization heuristic: nu is a fraction of the largest eigenvalue
of WW'
nu <- nuCoeff*svdYc$d[1]^2
## Naive correction: ridge regression of Y against W
nY <- Y - W %*% solve(t(W)%*%W + nu*diag(k), t(W) %*% Y)
return(nY)
}
c.1.2 Comparison of normalization methods
Mixed model to find the number of DE miRNAs
In the analysis of the Mann data, a linear mixed effects model was used to find the
number of DE miRNAs, to take into account the variability due to probes and rep-
licates for each miRNA (every miRNA in this dataset corresponded to one or more
probes and each probe had one or more technical replicates). The Figure C.1 shows
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that although the expression values of the samples for technical replicates do not show
much variation between them, the values for the different probes show significant
variation between the probes (indicated by the grouping of expression values of each
sample into 1-4 groups in Figure C.1). This illustrates the necessity of accounting for
the variability between the different probes when modelling the miRNA expression
data.
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Figure C.1: The expression values for the 45 samples of miRNA ‘hsa-miR-150’. The
boxplots for the expression values of hsa-miR-150. The x-axis shows the
survival times for the 45 samples (ordered by the survival times) and the
y-axis shows the expression values.
Correlation with qRT-PCR data
The comparison of the normalised Mann miRNA data with the qRT-PCR data using the
Pearson correlation coefficient showed high consistency with the QRUV-normalized
data (using different parameters), where the highest absolute value of the correlation
coefficient was exhibited for the majority of the miRNAs (Table C.1).
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c.2 additional information for section 4 .3
c.2.1 Summary of the melanoma miRNA datasets and the biomarkers used in the meta-
analysis
Table C.2 details the datasets used in Chapter 4, and the information about the pub-
lished and identified biomarkers using these datasets and the survival classes evalu-
ated in each dataset.
c.2.2 Performance of biomarkers relative to random feature sets
Figure C.2 shows the improvement over random signatures (IOR) scores for the val-
idation of random miRNA sets in each validation dataset, ordered by the validation
dataset to facilitate the comparison among signatures within a particular dataset.
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Figure C.2: Improvement over random signature scores. The improvement in predic-
tion error of the signatures relative to the prediction errors of equivalently
sized random miRNA sets, for each of the 100 random miRNA sets gener-
ated, ordered by the validation dataset.
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c.2.3 Intersection of the miRNA prognostic signatures
The analysis of direct overlap among signatures did not allow for the observation of
intersections that may be present prior to the application of the data pre-processing
filters. Therefore, to ascertain any intersections prior to pre-processing the four valid-
ation datasets, we also examined the raw expression data for overlap among miRNAs
appearing in at least one signature (Figure 4.8, Table C.3). For this aspect of the study,
we considered the four main signatures in the four datasets since the 6-miRNA signa-
ture from (Segura et al., 2010) was encompassed by their 18-miRNA signature.
While none of the signature miRNAs were common to all 5 biomarkers (Figure 4.8a),
we observed some overlap at the raw data level. To begin, hsa-miR-514, from the 12-
miRNA signature derived from the Mann expression data, was present in both the
Segura and Caramuta datasets but did not pass our filtering thresholds and was there-
fore ineligible for analysis in our systematic cross-validation setting. An additional
four miRNAs (hsa-miR-142-5p, hsa-miR-150, hsa-miR-155, hsa-miR-142-3p) from that
same signature were present in the Caramuta but removed on filtering. This was the
reason for only 11 and 7 miRNAs from the 12-miRNA signature being available to be
assessed in Segura and Caramuta data respectively in our validation (Table 4.3 and 4.4,
the number of miRNAs available in each case is presented within square brackets).
Similarly of the 18 miRNAs from the signature proposed in (Segura et al., 2010) two
of them (hsa-miR-28-3p and hsa-miR-143*) were excluded on filtering of the Mann
expression data and ten were not present in the data from Caramuta (hsa-miR-142-
5p, hsa-miR-150, hsa-miR-155, hsa-miR-455-3p (0), hsa-miR-145, hsa-miR-497, hsa-miR-
143, hsa-miR-28-3p (0), hsa-miR-28-5p (0), hsa-miR-143*(0), hsa-miR-214). Note that
miRNAs annotated with a ‘(0)’ were not present in the raw data even before any filter-
ing was performed. In analysis of the Caramuta signature (Caramuta et al., 2010) only
one miRNA was removed by filtering (hsa-miR-191, Mann expression data).
Finally, validation of the 15-miRNA signature from TCGA expression data presen-
ted the largest challenge with 10 of the signature miRNAs removed in filtering of the
Mann expression data (hsa-miR-1250-5p, hsa-miR-146a-3p, hsa-miR-155-3p, hsa-miR-
3655, hsa-miR-3679-3p, hsa-miR-411-3p, hsa-miR-452-3p, hsa-miR-541-3p, hsa-miR-767-
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5p, hsa-miR-767-3p). In addition, 5 miRNAs were absent from the filtered Segura data
(hsa-miR-1250-5p (0), hsa-miR-146a-3p, hsa-miR-3655 (0), hsa-miR-3679-3p (0), hsa-
miR-541-3p), and 12 miRNAs were excluded from the expression data from Caramuta
or else not assayed in the first place (hsa-miR-105-5p, hsa-miR-1250-5p(0), hsa-miR-
146a-3p(0), hsa-miR-155-3p(0), hsa-miR-3655(0), hsa-miR-3679-3p (0), hsa-miR-411-3p
(0), hsa-miR-452-3p (0), hsa-miR-541-3p (0), hsa-miR-767-5p, hsa-miR-767-3p). This de-
tailed breakdown highlights the challenge to validation via a meta-analysis caused by
the platform differences.
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d.1 further results from section 5 .3
d.1.1 Use of weights in the median robust method
In Section 5.3 we investigated the effect of using platform dependent weights in the
Lasso feature selection. We observed that when modelling mRNA data, using external
information from other data platforms (protein and miRNA) in the feature selection im-
proved the prediction accuracy. It is of interest to explore whether the weights based
on relevant external information aid to select features with higher predictive accur-
acy in other feature selection methods apart from the Lasso. Inverse correlation based
weights were used in the feature selection when using median robust (MR) method
(MR method explained in Section 5.1.2). The standard procedure can be used here by
replacing each entry in the expression data matrix (xqj, the expression value for the qth
variable and jth sample) by xqj/wq for each variable (q = 1, 2, . . . ,p) and each sample
(j = 1, 2, . . . ,n).
The prediction error rates (Figure D.1) dropped slightly when weights based on pro-
tein information was utilized (mean 5-fold CV error = 23% compared to 24%) and
when weights based on both protein and miRNA platforms were utilized (23%). How-
ever, this result did not hold for the integration of mRNA and miRNA data. Overall
the errors were similar and these weights did not seem to have a significant impact on
MR feature selection method.
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Figure D.1: Effect of incorporating weights in median robust feature selection. The
5-fold CV error rates in data integration setting with median robust feature
selection.MR: No integration, wMR_GP: Integration of mRNA and protein
data, wMR_GM: Integration of mRNA and miRNA data, wMR_GPM: In-
tegration of mRNA, protein and miRNA data.
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